array:24 [
  "pii" => "S000173102300056X"
  "issn" => "00017310"
  "doi" => "10.1016/j.ad.2023.01.004"
  "estado" => "S300"
  "fechaPublicacion" => "2023-05-01"
  "aid" => "3366"
  "copyright" => "AEDV"
  "copyrightAnyo" => "2023"
  "documento" => "article"
  "crossmark" => 1
  "subdocumento" => "pgl"
  "cita" => "Actas Dermosifiliogr. 2023;114:392-401"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:1 [
    "total" => 0
  ]
  "itemSiguiente" => array:18 [
    "pii" => "S0001731023002922"
    "issn" => "00017310"
    "doi" => "10.1016/j.ad.2023.04.013"
    "estado" => "S300"
    "fechaPublicacion" => "2023-05-01"
    "aid" => "3454"
    "copyright" => "AEDV"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "pgl"
    "cita" => "Actas Dermosifiliogr. 2023;114:T392-T401"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:14 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Consensus Document</span>"
      "titulo" => " Common Approach to Metabolic-Associated Fatty Liver Disease in Patients With Psoriasis&#58; Consensus-Based Recommendations From a Multidisciplinary Group of Experts"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:3 [
        0 => "en"
        1 => "en"
        2 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "T392"
          "paginaFinal" => "T401"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Abordaje com&#250;n del paciente con psoriasis y riesgo de esteatosis hep&#225;tica metab&#243;lica&#58; recomendaciones de un grupo de expertos multidisciplinar"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 1
        "multimedia" => array:5 [
          "identificador" => "fig0015"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => false
          "mostrarDisplay" => true
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "fx1.jpeg"
              "Alto" => 301
              "Ancho" => 1333
              "Tamanyo" => 31770
            ]
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "J&#46;M&#46; Carrascosa, E&#46; Vilarrasa, I&#46; Belinch&#243;n, P&#46; Herranz, J&#46; Crespo, F&#46; Guimer&#225;, A&#46; Olveira"
          "autores" => array:8 [
            0 => array:2 [
              "nombre" => "J&#46;M&#46;"
              "apellidos" => "Carrascosa"
            ]
            1 => array:2 [
              "nombre" => "E&#46;"
              "apellidos" => "Vilarrasa"
            ]
            2 => array:2 [
              "nombre" => "I&#46;"
              "apellidos" => "Belinch&#243;n"
            ]
            3 => array:2 [
              "nombre" => "P&#46;"
              "apellidos" => "Herranz"
            ]
            4 => array:2 [
              "nombre" => "J&#46;"
              "apellidos" => "Crespo"
            ]
            5 => array:2 [
              "nombre" => "F&#46;"
              "apellidos" => "Guimer&#225;"
            ]
            6 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Olveira"
            ]
            7 => array:1 [
              "colaborador" => "on behalf of the Working Group for the Common Approach to Psoriasis and MAFLD &#40;GACPE&#41;"
            ]
          ]
        ]
      ]
      "resumen" => array:1 [
        0 => array:3 [
          "titulo" => "Graphical abstract"
          "clase" => "graphical"
          "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall"><elsevierMultimedia ident="fig0015"></elsevierMultimedia></p></span>"
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731023002922?idApp=UINPBA000044"
    "url" => "/00017310/0000011400000005/v2_202306061222/S0001731023002922/v2_202306061222/en/main.assets"
  ]
  "itemAnterior" => array:18 [
    "pii" => "S0001731023003253"
    "issn" => "00017310"
    "doi" => "10.1016/j.ad.2023.04.027"
    "estado" => "S300"
    "fechaPublicacion" => "2023-05-01"
    "aid" => "3475"
    "copyright" => "AEDV"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "fla"
    "cita" => "Actas Dermosifiliogr. 2023;114:T382-T391"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "es" => array:13 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">ORIGINAL</span>"
      "titulo" => " Necesidades cl&#237;nicas no satisfechas y patrones de tratamiento de los pacientes pedi&#225;tricos con psoriasis&#58; estudio de evidencia en el mundo real en Espa&#241;a"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "T382"
          "paginaFinal" => "T391"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Clinical Unmet Needs and Treatment Patterns of Paediatric Psoriasis Patients&#58; A Real-World Evidence Study in Spain"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0015"
          "etiqueta" => "Figura 3"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr3.jpeg"
              "Alto" => 2822
              "Ancho" => 3163
              "Tamanyo" => 486988
            ]
          ]
          "descripcion" => array:1 [
            "es" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Pacientes que recibieron solo terapia t&#243;pica y que ten&#237;an experiencia biol&#243;gica&#44; en general&#44; y por gravedad antes del inicio del tratamiento actual &#40;An&#225;lisis 3&#41;&#46; A&#41; Gr&#225;ficos de barras que muestran la proporci&#243;n de pacientes que solo hab&#237;an recibido terapia t&#243;pica alguna vez&#44; en general&#44; y en pacientes con enfermedad leve y moderada a grave a juicio del m&#233;dico antes del inicio del tratamiento actual &#40;An&#225;lisis 3&#41;&#46; B&#41; Gr&#225;ficos circulares que ilustran la frecuencia de pacientes sin tratamiento biol&#243;gico previo y aquellos que ya lo han recibido&#44; con enfermedad moderada&#44; grave y de moderada a grave&#44; determinada por el m&#233;dico en el momento del inicio del tratamiento actual &#40;An&#225;lisis 3&#41;&#46;</p> <p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">n&#58; n&#250;mero de pacientes con resultado&#59; N&#58; n&#250;mero total de pacientes en el grupo&#59; Pso&#58; psoriasis&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "R&#46; de Lucas, A&#46; Vicente, C&#46; Richardson, J&#46; Lucas, L&#46; Gillespie-Akar, L&#46; G&#243;mez-Labrador, A&#46; Torrelo"
          "autores" => array:7 [
            0 => array:2 [
              "nombre" => "R&#46;"
              "apellidos" => "de Lucas"
            ]
            1 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Vicente"
            ]
            2 => array:2 [
              "nombre" => "C&#46;"
              "apellidos" => "Richardson"
            ]
            3 => array:2 [
              "nombre" => "J&#46;"
              "apellidos" => "Lucas"
            ]
            4 => array:2 [
              "nombre" => "L&#46;"
              "apellidos" => "Gillespie-Akar"
            ]
            5 => array:2 [
              "nombre" => "L&#46;"
              "apellidos" => "G&#243;mez-Labrador"
            ]
            6 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Torrelo"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731023003253?idApp=UINPBA000044"
    "url" => "/00017310/0000011400000005/v2_202306061222/S0001731023003253/v2_202306061222/es/main.assets"
  ]
  "asociados" => array:1 [
    0 => array:18 [
      "pii" => "S0001731023002922"
      "issn" => "00017310"
      "doi" => "10.1016/j.ad.2023.04.013"
      "estado" => "S300"
      "fechaPublicacion" => "2023-05-01"
      "aid" => "3454"
      "copyright" => "AEDV"
      "documento" => "article"
      "crossmark" => 1
      "subdocumento" => "pgl"
      "cita" => "Actas Dermosifiliogr. 2023;114:T392-T401"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:1 [
        "total" => 0
      ]
      "en" => array:14 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Consensus Document</span>"
        "titulo" => " Common Approach to Metabolic-Associated Fatty Liver Disease in Patients With Psoriasis&#58; Consensus-Based Recommendations From a Multidisciplinary Group of Experts"
        "tienePdf" => "en"
        "tieneTextoCompleto" => "en"
        "tieneResumen" => array:3 [
          0 => "en"
          1 => "en"
          2 => "es"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "T392"
            "paginaFinal" => "T401"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "es" => array:1 [
            "titulo" => "Abordaje com&#250;n del paciente con psoriasis y riesgo de esteatosis hep&#225;tica metab&#243;lica&#58; recomendaciones de un grupo de expertos multidisciplinar"
          ]
        ]
        "contieneResumen" => array:2 [
          "en" => true
          "es" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "en" => true
        ]
        "contienePdf" => array:1 [
          "en" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 1
          "multimedia" => array:5 [
            "identificador" => "fig0015"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => false
            "mostrarDisplay" => true
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "fx1.jpeg"
                "Alto" => 301
                "Ancho" => 1333
                "Tamanyo" => 31770
              ]
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "J&#46;M&#46; Carrascosa, E&#46; Vilarrasa, I&#46; Belinch&#243;n, P&#46; Herranz, J&#46; Crespo, F&#46; Guimer&#225;, A&#46; Olveira"
            "autores" => array:8 [
              0 => array:2 [
                "nombre" => "J&#46;M&#46;"
                "apellidos" => "Carrascosa"
              ]
              1 => array:2 [
                "nombre" => "E&#46;"
                "apellidos" => "Vilarrasa"
              ]
              2 => array:2 [
                "nombre" => "I&#46;"
                "apellidos" => "Belinch&#243;n"
              ]
              3 => array:2 [
                "nombre" => "P&#46;"
                "apellidos" => "Herranz"
              ]
              4 => array:2 [
                "nombre" => "J&#46;"
                "apellidos" => "Crespo"
              ]
              5 => array:2 [
                "nombre" => "F&#46;"
                "apellidos" => "Guimer&#225;"
              ]
              6 => array:2 [
                "nombre" => "A&#46;"
                "apellidos" => "Olveira"
              ]
              7 => array:1 [
                "colaborador" => "on behalf of the Working Group for the Common Approach to Psoriasis and MAFLD &#40;GACPE&#41;"
              ]
            ]
          ]
        ]
        "resumen" => array:1 [
          0 => array:3 [
            "titulo" => "Graphical abstract"
            "clase" => "graphical"
            "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall"><elsevierMultimedia ident="fig0015"></elsevierMultimedia></p></span>"
          ]
        ]
      ]
      "idiomaDefecto" => "en"
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731023002922?idApp=UINPBA000044"
      "url" => "/00017310/0000011400000005/v2_202306061222/S0001731023002922/v2_202306061222/en/main.assets"
    ]
  ]
  "es" => array:21 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">DOCUMENTO DE CONSENSO</span>"
    "titulo" => "Abordaje com&#250;n del paciente con psoriasis y riesgo de esteatosis hep&#225;tica metab&#243;lica&#58; recomendaciones de un grupo de expertos multidisciplinar"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "392"
        "paginaFinal" => "401"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "J&#46;M&#46; Carrascosa, E&#46; Vilarrasa, I&#46; Belinch&#243;n, P&#46; Herranz, J&#46; Crespo, F&#46; Guimer&#225;, A&#46; Olveira"
        "autores" => array:8 [
          0 => array:4 [
            "nombre" => "J&#46;M&#46;"
            "apellidos" => "Carrascosa"
            "email" => array:1 [
              0 => "jmcarrascosac@hotmail.com"
            ]
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "E&#46;"
            "apellidos" => "Vilarrasa"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "I&#46;"
            "apellidos" => "Belinch&#243;n"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "P&#46;"
            "apellidos" => "Herranz"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "aff0020"
              ]
            ]
          ]
          4 => array:3 [
            "nombre" => "J&#46;"
            "apellidos" => "Crespo"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">e</span>"
                "identificador" => "aff0025"
              ]
            ]
          ]
          5 => array:3 [
            "nombre" => "F&#46;"
            "apellidos" => "Guimer&#225;"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">f</span>"
                "identificador" => "aff0030"
              ]
            ]
          ]
          6 => array:3 [
            "nombre" => "A&#46;"
            "apellidos" => "Olveira"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">g</span>"
                "identificador" => "aff0035"
              ]
            ]
          ]
          7 => array:2 [
            "colaborador" => "en representaci&#243;n del Grupo de Trabajo para el Abordaje Com&#250;n de la Psoriasis y la EHmet &#40;GACPE&#41;"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#9674;</span>"
                "identificador" => "fn0005"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:7 [
          0 => array:3 [
            "entidad" => "Departamento de Dermatolog&#237;a&#44; Hospital Universitario Germans Trias i Pujol&#44; Universitat Aut&#242;noma de Barcelona&#46; IGTP Badalona&#44; Barcelona&#44; Espa&#241;a"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Departamento de Dermatolog&#237;a&#44; Hospital Santa Creu i Sant Pau&#44; Universitat Aut&#242;noma de Barcelona&#44; Barcelona&#44; Espa&#241;a"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
          2 => array:3 [
            "entidad" => "Departamento de Dermatolog&#237;a&#44; Hospital General Universitario de Alicante&#44; Instituto de Investigaci&#243;n Sanitaria y Biom&#233;dica &#40;ISABIAL&#41;&#44; Universidad Miguel Hern&#225;ndez de Elche&#44; Alicante&#44; Espa&#241;a"
            "etiqueta" => "c"
            "identificador" => "aff0015"
          ]
          3 => array:3 [
            "entidad" => "Departamento de Dermatolog&#237;a&#44; Hospital Universitario La Paz&#44; Madrid&#44; Espa&#241;a"
            "etiqueta" => "d"
            "identificador" => "aff0020"
          ]
          4 => array:3 [
            "entidad" => "Servicio de Gastroenterolog&#237;a y Hepatolog&#237;a&#44; Hospital Universitario Marqu&#233;s de Valdecilla&#46; IDIVAL&#46; Escuela de Medicina&#46; Universidad de Cantabria&#44; Santander&#44; Espa&#241;a"
            "etiqueta" => "e"
            "identificador" => "aff0025"
          ]
          5 => array:3 [
            "entidad" => "Servicio de Dermatolog&#237;a y Patolog&#237;a&#44; Hospital Universitario de Canarias&#44; La Laguna&#44; Espa&#241;a"
            "etiqueta" => "f"
            "identificador" => "aff0030"
          ]
          6 => array:3 [
            "entidad" => "Servicio de Aparato Digestivo&#44; Hospital Universitario La Paz&#44; Madrid&#44; Espa&#241;a"
            "etiqueta" => "g"
            "identificador" => "aff0035"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Autor para correspondencia&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "en" => array:1 [
        "titulo" => "Common Approach to Metabolic-Associated Fatty Liver Disease in Patients With Psoriasis&#58; Consensus-Based Recommendations From a Multidisciplinary Group of Experts"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 1
      "multimedia" => array:5 [
        "identificador" => "fig0015"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "fx1.jpeg"
            "Alto" => 300
            "Ancho" => 1333
            "Tamanyo" => 37221
          ]
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Introducci&#243;n</span><p id="par0005" class="elsevierStylePara elsevierViewall">Aproximadamente 125 millones de personas sufren psoriasis a nivel mundial &#40;1-3&#37;&#41;&#44; m&#225;s de un mill&#243;n en Espa&#241;a &#40;2&#44;69&#37;&#41;<a class="elsevierStyleCrossRefs" href="#bib0470"><span class="elsevierStyleSup">1&#44;2</span></a>&#46; Es una enfermedad inflamatoria sist&#233;mica&#44; con efectos sin&#233;rgicos con otras enfermedades inflamatorias inmunomediadas &#40;IMIDs&#41;<a class="elsevierStyleCrossRefs" href="#bib0475"><span class="elsevierStyleSup">2&#44;3</span></a>&#46; Por este motivo&#44; reconocer el impacto de las comorbilidades asociadas es esencial para un manejo integral<a class="elsevierStyleCrossRef" href="#bib0475"><span class="elsevierStyleSup">2</span></a>&#46;</p><p id="par0010" class="elsevierStylePara elsevierViewall">Entre estas comorbilidades se encuentra la hasta ahora denominada enfermedad hep&#225;tica grasa no alcoh&#243;lica&#59; que en esta revisi&#243;n denominaremos esteatosis hep&#225;tica metab&#243;lica &#40;EHmet&#41;&#44; siguiendo el consenso promovido por la Asociaci&#243;n Espa&#241;ola para el Estudio del H&#237;gado &#40;AEEH&#41;<a class="elsevierStyleCrossRef" href="#bib0485"><span class="elsevierStyleSup">4</span></a>&#46; La EHmet engloba un espectro de lesiones hep&#225;ticas&#44; desde la acumulaci&#243;n de grasa en el h&#237;gado considerada un trastorno metab&#243;lico con escaso potencial evolutivo&#44; hasta la forma inflamatoria o esteatohepatitis&#44; con riesgo de evolucionar a cirrosis y sus complicaciones&#46; En la mayor&#237;a de los casos&#44; es asintom&#225;tica y se asocia con el s&#237;ndrome metab&#243;lico &#40;SM&#41;<a class="elsevierStyleCrossRef" href="#bib0490"><span class="elsevierStyleSup">5</span></a>&#46; De hecho&#44; se reconoce como la manifestaci&#243;n hep&#225;tica del SM y puede aparecer antes que otras manifestaciones<a class="elsevierStyleCrossRefs" href="#bib0495"><span class="elsevierStyleSup">6&#44;7</span></a>&#46; El SM se define como un conjunto de anomal&#237;as metab&#243;licas&#44; entre las que las hep&#225;ticas se consideran fundamentales<a class="elsevierStyleCrossRefs" href="#bib0495"><span class="elsevierStyleSup">6&#44;7</span></a>&#46; La EHmet presenta un amplio espectro cl&#237;nico &#40;<a class="elsevierStyleCrossRef" href="#fig0005">fig&#46; 1</a>&#41;&#44; de naturaleza din&#225;mica&#44; con periodos de progresi&#243;n&#44; regresi&#243;n y estabilidad<a class="elsevierStyleCrossRefs" href="#bib0505"><span class="elsevierStyleSup">8&#44;9</span></a>&#46; La gen&#233;tica y los cambios en el estilo de vida explican parcialmente esta variabilidad&#46; Otros factores causantes de variabilidad de la enfermedad y su respuesta al tratamiento son la edad&#44; la raza&#44; el consumo de alcohol&#44; el sexo y la microbiota<a class="elsevierStyleCrossRef" href="#bib0490"><span class="elsevierStyleSup">5</span></a>&#46;</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0015" class="elsevierStylePara elsevierViewall">La prevalencia de la EHmet aumenta progresiva y paralelamente a la prevalencia del SM&#44; la obesidad y la diabetes mellitus tipo 2 &#40;DM2&#41;<a class="elsevierStyleCrossRefs" href="#bib0505"><span class="elsevierStyleSup">8&#44;10</span></a>&#46; Se estima que la EHmet afecta a 25&#37; de la poblaci&#243;n&#44; llegando a 55&#44;5&#37; en pacientes con DM2&#46; Aunque se desconoce el porcentaje de pacientes con EHmet que desarrollan esteatohepatitis no alcoh&#243;lica &#40;EHNA&#41;&#44; se sabe que supera 10&#37;&#46; La EHNA se diagnostica mediante biopsia en 29&#44;9&#37; de los pacientes con EHmet&#44; pero recientemente esta tasa parece haber aumentado hasta 59&#44;1&#37;<a class="elsevierStyleCrossRef" href="#bib0490"><span class="elsevierStyleSup">5</span></a>&#46;</p><p id="par0020" class="elsevierStylePara elsevierViewall">La EHNA progresa a fibrosis en 40&#44;76&#37; de los pacientes<a class="elsevierStyleCrossRef" href="#bib0505"><span class="elsevierStyleSup">8</span></a>&#46; En Espa&#241;a&#44; se estima que la prevalencia de la EHmet es de 25&#44;8&#37;&#44; y el grado de fibrosis significativa&#44; estimada mediante combinaci&#243;n secuencial de elastometr&#237;a de transici&#243;n &#40;ET&#41; y biopsia hep&#225;tica&#44; es de 2&#44;8&#37;<a class="elsevierStyleCrossRef" href="#bib0515"><span class="elsevierStyleSup">10</span></a>&#46;</p><p id="par0025" class="elsevierStylePara elsevierViewall">El pron&#243;stico del paciente con EHmet viene condicionado por la evoluci&#243;n hacia EHNA&#44; fibrosis y sus comorbilidades&#59; la morbimortalidad hep&#225;tica aumenta fundamentalmente a partir del estadio de fibrosis avanzada<a class="elsevierStyleCrossRefs" href="#bib0515"><span class="elsevierStyleSup">10&#44;11</span></a>&#46; Por ello la EHmet es un importante problema de salud y una causa importante de trasplante hep&#225;tico<a class="elsevierStyleCrossRefs" href="#bib0510"><span class="elsevierStyleSup">9&#44;12</span></a>&#46;</p><p id="par0030" class="elsevierStylePara elsevierViewall">Existen numerosas evidencias de la relaci&#243;n entre psoriasis y EHmet<a class="elsevierStyleCrossRef" href="#bib0540"><span class="elsevierStyleSup">15</span></a>&#46; En general&#44; la prevalencia de EHmet aumenta en pacientes con psoriasis m&#225;s grave<a class="elsevierStyleCrossRefs" href="#bib0545"><span class="elsevierStyleSup">16&#44;17</span></a>&#46; Phan et al&#46; demostraron una prevalencia de EHmet duplicada en pacientes con psoriasis&#44; comparados con no psori&#225;sicos&#44; confirmando datos publicados anteriormente<a class="elsevierStyleCrossRefs" href="#bib0540"><span class="elsevierStyleSup">15&#44;18</span></a>&#46; En Espa&#241;a&#44; 42&#44;3&#37; de los pacientes con psoriasis presentan EHmet<a class="elsevierStyleCrossRef" href="#bib0560"><span class="elsevierStyleSup">19</span></a>&#46; Adem&#225;s&#44; la gravedad de la psoriasis se correlaciona directamente con la de la enfermedad hep&#225;tica<a class="elsevierStyleCrossRef" href="#bib0565"><span class="elsevierStyleSup">20</span></a>&#46; En concordancia&#44; un estudio transversal ha detectado que la fibrosis avanzada es m&#225;s prevalente en pacientes con psoriasis que en controles sanos&#44; siendo la psoriasis un predictor significativo de fibrosis hep&#225;tica avanzada independientemente de otros factores como edad&#44; sexo&#44; &#237;ndice de masa corporal&#44; hipertensi&#243;n y diabetes<a class="elsevierStyleCrossRef" href="#bib0570"><span class="elsevierStyleSup">21</span></a>&#46; De hecho&#44; la psoriasis es un factor de riesgo independiente de EHmet<a class="elsevierStyleCrossRefs" href="#bib0575"><span class="elsevierStyleSup">22&#44;23</span></a>&#46; Asimismo&#44; la hipertensi&#243;n&#44; la hiperglicemia y la obesidad son los principales factores de riesgo de EHmet en pacientes con psoriasis y la asociaci&#243;n entre psoriasis y EHmet es independiente de factores de confusi&#243;n&#44; lo que confirma una fisiopatolog&#237;a com&#250;n que implica v&#237;as inflamatorias y predisposici&#243;n gen&#233;tica<a class="elsevierStyleCrossRef" href="#bib0540"><span class="elsevierStyleSup">15</span></a>&#46; Ambas tienen como etiolog&#237;a com&#250;n una inflamaci&#243;n cr&#243;nica de baja intensidad&#44; que implica adipocinas involucradas en el balance energ&#233;tico y citocinas inflamatorias&#58; interleucina- 17 &#40;IL-17&#41;&#44; factor de necrosis tumoral-&#945; &#40;TNF-&#945;&#41; o interleucina-6 &#40;IL-6&#41;<a class="elsevierStyleCrossRefs" href="#bib0480"><span class="elsevierStyleSup">3&#44;24&#44;25</span></a>&#46;</p><p id="par0035" class="elsevierStylePara elsevierViewall">Estos precedentes permiten sugerir un abordaje precoz de los pacientes con psoriasis realizando un cribado de la EHmet<a class="elsevierStyleCrossRef" href="#bib0595"><span class="elsevierStyleSup">26</span></a>&#46; La AEEH ha publicado recientemente un consenso sobre detecci&#243;n y derivaci&#243;n de enfermedades hep&#225;ticas prevalentes ocultas&#46; Dos conclusiones operativas del consenso fueron&#58; 1&#41; Hacer valoraci&#243;n y seguimiento de una posible enfermedad hep&#225;tica cr&#243;nica en pacientes con enfermedades dermatol&#243;gicas inmunomediadas&#59; y 2&#41; la prevalencia de hepatopat&#237;a cr&#243;nica aumenta en estas patolog&#237;as&#44; tanto por mecanismos inmunol&#243;gicos como inflamatorios&#44; o por hepatotoxicidad<a class="elsevierStyleCrossRef" href="#bib0595"><span class="elsevierStyleSup">26</span></a>&#46;</p><p id="par0040" class="elsevierStylePara elsevierViewall">Para incentivar el manejo multidisciplinar&#44; y con el objetivo de actualizar las recomendaciones de cribado&#44; diagn&#243;stico&#44; monitorizaci&#243;n y criterios de derivaci&#243;n ante la sospecha de EHmet en pacientes con psoriasis&#44; un panel de expertos ha elaborado este documento&#44; bas&#225;ndose en la evidencia cient&#237;fica disponible y en su experiencia en pr&#225;ctica cl&#237;nica real&#46;</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Metodolog&#237;a</span><p id="par0045" class="elsevierStylePara elsevierViewall">Para elaborar este documento siete dermat&#243;logos y cinco hepat&#243;logos&#44; especializados en el manejo de la psoriasis y la EHmet&#44; constituyeron un grupo de trabajo&#46; La metodolog&#237;a utilizada se bas&#243; en el denominado &#171;m&#233;todo formal&#187;<a class="elsevierStyleCrossRefs" href="#bib0600"><span class="elsevierStyleSup">27&#44;28</span></a>&#46; Se empez&#243; evaluando la evidencia cient&#237;fica disponible y cumplimentando varios cuestionarios dise&#241;ados <span class="elsevierStyleItalic">ad hoc</span> para identificar puntos clave sobre identificaci&#243;n&#44; cribado&#44; diagn&#243;stico y manejo de la psoriasis y el riesgo de enfermedad hep&#225;tica&#46; Posteriormente&#44; se analizaron los aspectos cl&#237;nicos de definici&#243;n y manejo del paciente de riesgo en tres reuniones&#46; En la &#250;ltima reuni&#243;n&#44; se desarroll&#243; un algoritmo de manejo del paciente de riesgo y unas recomendaciones de diagn&#243;stico y monitorizaci&#243;n basadas en las principales gu&#237;as de pr&#225;ctica cl&#237;nica &#40;GPC&#41; y en la experiencia en pr&#225;ctica cl&#237;nica real del grupo de expertos&#46;</p><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Identificaci&#243;n de los pacientes con psoriasis y riesgo de enfermedad hep&#225;tica</span><p id="par0050" class="elsevierStylePara elsevierViewall">El panel recomienda cribar los pacientes diagnosticados de psoriasis siguiendo las GPC nacionales<a class="elsevierStyleCrossRefs" href="#bib0610"><span class="elsevierStyleSup">29&#44;30</span></a>&#44; independientemente del tratamiento y el tiempo desde el diagn&#243;stico&#44; siempre que presenten al menos una de las condiciones contempladas como criterios acompa&#241;antes del hallazgo de esteatosis en el diagn&#243;stico de la EHmet<a class="elsevierStyleCrossRef" href="#bib0620"><span class="elsevierStyleSup">31</span></a>&#44; es decir&#44; sobrepeso u obesidad&#44; DM2&#44; y&#47;o evidencias de alteraciones metab&#243;licas&#44; las cuales pueden resumirse as&#237;&#58;<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005"><span class="elsevierStyleLabel">&#8226;</span><p id="par0055" class="elsevierStylePara elsevierViewall">Circunferencia de la cintura &#8805; 102 cm en hombres y &#8805; 88 cm en mujeres&#46;</p></li><li class="elsevierStyleListItem" id="lsti0010"><span class="elsevierStyleLabel">&#8226;</span><p id="par0060" class="elsevierStylePara elsevierViewall">Presi&#243;n arterial &#8805; 130&#47;85 mmHg o tratamiento farmacol&#243;gico espec&#237;fico&#46;</p></li><li class="elsevierStyleListItem" id="lsti0015"><span class="elsevierStyleLabel">&#8226;</span><p id="par0065" class="elsevierStylePara elsevierViewall">Triglic&#233;ridos plasm&#225;ticos &#8805; 150 mg&#47;dL &#40;&#8805; 1&#44;70&#160;mmol&#47;L&#41; o tratamiento farmacol&#243;gico espec&#237;fico&#46;</p></li><li class="elsevierStyleListItem" id="lsti0020"><span class="elsevierStyleLabel">&#8226;</span><p id="par0070" class="elsevierStylePara elsevierViewall">Colesterol de HDL en plasma &#60; 40&#160;mg&#47;dL &#40;&#60; 1&#44;0&#160;mmol&#47;L&#41; para hombres y &#60; 50&#160;mg&#47;dL &#40;&#60; 1&#44;3&#160;mmol&#47;L&#41; para mujeres&#44; o tratamiento farmacol&#243;gico espec&#237;fico&#46;</p></li><li class="elsevierStyleListItem" id="lsti0025"><span class="elsevierStyleLabel">&#8226;</span><p id="par0075" class="elsevierStylePara elsevierViewall">Prediabetes &#40;niveles de glucosa en ayunas&#58; 100 a 125&#160;mg&#47;dL &#91;5&#44;6 a 6&#44;9&#160;mmol&#47;L&#93;&#44; o dos horas tras sobrecarga oral&#58; 140 a 199&#160;mg&#47;dL &#91;7&#44;8 a 11&#44;0&#160;mmol&#47;L&#93; o HbA1c&#58; 5&#44;7 a 6&#44;4&#37; &#91;39 a 47&#160;mmol&#47;mol&#93;&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0030"><span class="elsevierStyleLabel">&#8226;</span><p id="par0080" class="elsevierStylePara elsevierViewall">HOMA-IR &#40;modelo homeost&#225;tico para evaluar la resistencia a la insulina&#41; &#8805; 2&#44;5&#46;</p></li><li class="elsevierStyleListItem" id="lsti0035"><span class="elsevierStyleLabel">&#8226;</span><p id="par0085" class="elsevierStylePara elsevierViewall">Nivel de prote&#237;na C reactiva de alta sensibilidad en plasma &#62; 2&#160;mg&#47;L&#46;</p></li></ul></p><p id="par0090" class="elsevierStylePara elsevierViewall">Ante un paciente con psoriasis y al menos un factor de riesgo de SM&#44; se debe valorar el riesgo o presencia de enfermedad hep&#225;tica&#46; Al ser una enfermedad silenciosa&#44; las GPC nacionales e internacionales aconsejan la identificaci&#243;n precoz del riesgo de estadios progresivos de EHmet&#44; desde la esteatosis a estadios avanzados como la fibrosis&#44; utilizando m&#233;todos no invasivos como el FIB-4<a class="elsevierStyleCrossRefs" href="#bib0515"><span class="elsevierStyleSup">10&#44;30&#44;31</span></a>&#46; Se descarta usar valores aislados de transaminasas como m&#233;todo &#250;nico para el diagn&#243;stico precoz de la EHmet&#44; ya que pueden ser normales incluso con fibrosis avanzada<a class="elsevierStyleCrossRef" href="#bib0625"><span class="elsevierStyleSup">32</span></a>&#46;</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Recomendaciones de cribado de la EHmet</span><p id="par0095" class="elsevierStylePara elsevierViewall">Tras identificar un paciente de riesgo&#44; se inicia la primera etapa del algoritmo de cribado y seguimiento recomendado &#40;<a class="elsevierStyleCrossRef" href="#fig0010">fig&#46; 2</a>&#41;&#46;</p><elsevierMultimedia ident="fig0010"></elsevierMultimedia><p id="par0100" class="elsevierStylePara elsevierViewall">No existe un consenso sobre estrategias de diagn&#243;stico y puntos de corte de herramientas no invasivas &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">tabla 1</a>&#41; empleadas en lugar de la biopsia hep&#225;tica &#40;prueba de referencia<a class="elsevierStyleCrossRef" href="#bib0630"><span class="elsevierStyleSup">33</span></a>&#44; pero con complicaciones&#41;<a class="elsevierStyleCrossRefs" href="#bib0515"><span class="elsevierStyleSup">10&#44;22&#44;31</span></a>&#46; Las GPC recomiendan combinar &#237;ndices serol&#243;gicos y la ET&#44; que reduce aproximadamente en 50-60&#37; la necesidad de biopsia y ofrece un diagn&#243;stico preciso<a class="elsevierStyleCrossRef" href="#bib0635"><span class="elsevierStyleSup">34</span></a>&#44; empleando &#237;ndices serol&#243;gicos de fibrosis como primera herramienta de cribado y&#44; en caso de riesgo elevado&#44; la ET&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0105" class="elsevierStylePara elsevierViewall">La <a class="elsevierStyleCrossRef" href="#tbl0005">tabla 1</a> enumera diversas herramientas no invasivas de cribado de la fibrosis hep&#225;tica&#46; Se consider&#243; que el marcador serol&#243;gico fibrosis-4 &#40;FIB-4&#41; es la herramienta m&#225;s adecuada para iniciar el cribado en dermatolog&#237;a&#44; ya que se ha validado externamente para el cribado de fibrosis en h&#237;gado graso de pacientes con psoriasis&#44; es de f&#225;cil petici&#243;n y manejo y est&#225; recomendado por las GPC<a class="elsevierStyleCrossRefs" href="#bib0515"><span class="elsevierStyleSup">10&#44;22&#44;31</span></a>&#46; El FIB-4 utiliza el recuento plaquetario&#44; la edad y los valores de aspartato aminotransferasa &#40;AST&#41; y alanina aminotransferasa &#40;ALT&#41;&#59; ofrece un alto valor predictivo negativo &#40;VPN&#41; para el diagn&#243;stico de fibrosis avanzada &#40;F3-F4&#41;&#44; permitiendo evitar la biopsia hep&#225;tica<a class="elsevierStyleCrossRefs" href="#bib0640"><span class="elsevierStyleSup">35&#44;36</span></a>&#46; Valores del FIB-4 inferiores a 1&#44;30 excluyen la fibrosis avanzada con un VPN de 85&#37;&#59; valores superiores a 2&#44;67 indican fibrosis avanzada con un VPP de 79&#37;<a class="elsevierStyleCrossRef" href="#bib0650"><span class="elsevierStyleSup">37</span></a>&#46; No obstante&#44; hay que tener en cuenta el riesgo de falso positivo asociado al VPP&#44; la probabilidad relativamente elevada &#40;1&#47;3&#41; de obtener valores intermedios &#40;1&#44;30-2&#44;67&#41; y el efecto de la edad en la exactitud del pron&#243;stico &#40;se propone un valor umbral de FIB-4 &#61; 2 en mayores de 65 a&#241;os&#41;<a class="elsevierStyleCrossRef" href="#bib0655"><span class="elsevierStyleSup">38</span></a>&#46;</p><p id="par0110" class="elsevierStylePara elsevierViewall">No debe olvidarse que la precisi&#243;n del FIB-4 depende de la edad&#58; no es aplicable en menores de 35 a&#241;os y requiere valores de corte m&#225;s ajustados para incrementar su especificidad en mayores de 65<a class="elsevierStyleCrossRef" href="#bib0660"><span class="elsevierStyleSup">39</span></a>&#46; El <span class="elsevierStyleItalic">Hepamet Fibrosis Score</span> &#40;HFS&#41; es un panel serol&#243;gico m&#225;s espec&#237;fico &#40;con valores predictivos mayores que el FIB-4&#41; y preciso&#44; con menor incertidumbre diagn&#243;stica y la &#250;nica limitaci&#243;n de incluir el &#237;ndice HOMA&#44; que no suele obtenerse de rutina<a class="elsevierStyleCrossRef" href="#bib0665"><span class="elsevierStyleSup">40</span></a>&#46;</p><p id="par0115" class="elsevierStylePara elsevierViewall">Cuando el &#237;ndice utilizado sugiera riesgo bajo&#44; se recomienda seguimiento bianual por dermatolog&#237;a con reevaluaci&#243;n del &#237;ndice de riesgo<a class="elsevierStyleCrossRef" href="#bib0620"><span class="elsevierStyleSup">31</span></a>&#46; Con riesgo medio&#47;alto&#44; se recomienda la ET<a class="elsevierStyleCrossRefs" href="#bib0620"><span class="elsevierStyleSup">31&#44;38&#44;48</span></a>&#46; Esta t&#233;cnica ha demostrado ser efectiva para monitorizar peri&#243;dicamente la gravedad de la enfermedad y diagnostica con elevada precisi&#243;n los estadios avanzados de fibrosis &#40;F3-F4&#41; en correlaci&#243;n con las caracter&#237;sticas cl&#237;nicas del paciente<a class="elsevierStyleCrossRefs" href="#bib0710"><span class="elsevierStyleSup">49&#44;50</span></a> y sin a&#241;adir riesgos&#44; al ser una prueba inocua&#46; No obstante&#44; se debe tener en cuenta que&#44; independientemente de la ET&#44; un FIB-4 elevado indica riesgo aumentado&#59; por lo tanto&#44; la decisi&#243;n depender&#225; de la accesibilidad y utilidad de la ET &#40;c&#243;mo influir&#225; el resultado&#41;&#46; Asimismo&#44; se recomienda derivar para ET a pacientes con FIB-4 intermedio&#44; por su elevada incertidumbre&#46;</p><p id="par0120" class="elsevierStylePara elsevierViewall">Wong et al&#46; demostraron que el valor de ET &#61; 7&#44;9 kPa presenta la mayor precisi&#243;n &#40;sensibilidad 91&#37;&#44; especificidad 75&#37; y VPP 97&#37;&#41; para el diagn&#243;stico de fibrosis avanzada y cirrosis en pacientes con EHmet<a class="elsevierStyleCrossRef" href="#bib0720"><span class="elsevierStyleSup">51</span></a>&#46; Por ello&#44; el punto de corte recomendado en pacientes de riesgo elevado es 8 kPa&#46; Con FIB-4 elevado y ET &#8804; 8 kPa&#44; se reevaluar&#225; anualmente el FIB-4 y&#47;o se solicitar&#225; una nueva ET seg&#250;n disponibilidad&#46;</p><p id="par0125" class="elsevierStylePara elsevierViewall">Si se confirma una ET &#62;8 kPa&#44; con riesgo de fibrosis avanzada &#40;F3-F4&#41;&#44; el paciente se derivar&#225; al Servicio de Aparato Digestivo&#44; en donde se considerar&#225; el manejo m&#225;s adecuado &#40;<a class="elsevierStyleCrossRef" href="#fig0010">fig&#46; 2</a>&#41;&#46; Si la ET no estuviera disponible&#44; los pacientes con FIB-4 elevado deben derivarse a un especialista de digestivo&#46;</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Tratamientos actuales para la psoriasis e impacto sobre la EHmet</span><p id="par0130" class="elsevierStylePara elsevierViewall">Las recomendaciones del panel de expertos se centran en pautas generales a considerar en supuestos cl&#237;nicos frecuentes adaptables&#44; seg&#250;n criterio del especialista&#46;</p><p id="par0135" class="elsevierStylePara elsevierViewall">Las recomendaciones de dieta y ejercicio de las GPC son el pilar del tratamiento de la EHmet<a class="elsevierStyleCrossRef" href="#bib0620"><span class="elsevierStyleSup">31</span></a>&#46; Reducciones de peso &#8805; 10&#37; pueden resolver la EHNA y reducir la fibrosis al menos un estadio&#46; P&#233;rdidas de peso menores &#40;5-10&#37;&#41; pueden mejorar algunos componentes de la EHmet&#46; La dieta mediterr&#225;nea&#44; aun sin p&#233;rdida de peso&#44; reduce el contenido graso del h&#237;gado<a class="elsevierStyleCrossRef" href="#bib0725"><span class="elsevierStyleSup">52</span></a>&#46;</p><p id="par0140" class="elsevierStylePara elsevierViewall">Actualmente se est&#225;n desarrollando f&#225;rmacos para el tratamiento de la EHmet&#46; En la <a class="elsevierStyleCrossRef" href="#tbl0010">tabla 2</a> se enumeran algunos ensayos cl&#237;nicos de su eficacia y seguridad&#46;</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><p id="par0145" class="elsevierStylePara elsevierViewall">En pacientes con ET 6-8 kPa&#44; independientemente del FIB-4&#44; sin enfermedad hep&#225;tica grave&#44; se deben valorar los factores de SM&#44; evaluando el grado de enfermedad metab&#243;lica para estimar el riesgo de progresi&#243;n hacia fibrosis avanzada o cirrosis<a class="elsevierStyleCrossRef" href="#bib0500"><span class="elsevierStyleSup">7</span></a>&#46; As&#237;&#44; se determinar&#225; la monitorizaci&#243;n y pruebas complementarias a realizar con respecto a las recomendaciones en estos perfiles &#40;seguimiento anual y repetici&#243;n de FIB-4&#41;&#46;</p><p id="par0150" class="elsevierStylePara elsevierViewall">Los pacientes con psoriasis y hepatopat&#237;a tienen riesgo aumentado de hepatotoxicidad inducida por f&#225;rmacos &#40;<a class="elsevierStyleCrossRef" href="#tbl0015">tabla 3</a>&#41;<a class="elsevierStyleCrossRef" href="#bib0810"><span class="elsevierStyleSup">68</span></a>&#46; Metotrexato &#40;MTX&#41; es el f&#225;rmaco sist&#233;mico convencional m&#225;s utilizado en psoriasis moderada-grave debido a su coste-efectividad y larga trayectoria cl&#237;nica&#44; pero es hepatot&#243;xico y puede favorecer la fibrosis<a class="elsevierStyleCrossRefs" href="#bib0815"><span class="elsevierStyleSup">69&#8211;71</span></a>&#46;</p><elsevierMultimedia ident="tbl0015"></elsevierMultimedia><p id="par0155" class="elsevierStylePara elsevierViewall">Un reciente estudio espa&#241;ol en pacientes con psoriasis moderada-grave tratados con MTX demostr&#243; correlaci&#243;n entre la duraci&#243;n del tratamiento y el riesgo de fibrosis hep&#225;tica&#58; la proporci&#243;n de pacientes con riesgo de fibrosis avanzada &#40;FIB-4 &#62; 1&#44;3&#41; aument&#243; desde 18&#44;2&#37;&#44; con MTX administrado durante 16-24 semanas&#44; hasta 27&#44;3&#37; y 32&#44;3&#37;&#44; cuando el tratamiento dur&#243; 52-104 semanas y &#62; 104 semanas&#44; respectivamente<a class="elsevierStyleCrossRef" href="#bib0830"><span class="elsevierStyleSup">72</span></a>&#46; Shetty et al<span class="elsevierStyleItalic">&#46;</span> recomiendan adaptar la intensidad y frecuencia de monitorizaci&#243;n dependiendo de los factores de riesgo individuales&#44; y enfatizan el mayor riesgo de da&#241;o hep&#225;tico por MTX en pacientes con EHNA o EHNA-fibrosis<a class="elsevierStyleCrossRef" href="#bib0825"><span class="elsevierStyleSup">71</span></a>&#46;</p><p id="par0160" class="elsevierStylePara elsevierViewall">Se recomienda monitorizar el da&#241;o hep&#225;tico de pacientes con psoriasis tratados con esteat&#243;genos<a class="elsevierStyleCrossRef" href="#bib0810"><span class="elsevierStyleSup">68</span></a>&#46; Una reciente GPC considera que la amiodarona&#44; el metotrexato&#44; el tamoxifeno y los agentes quimioterap&#233;uticos 5-fluoracilo e irinotec&#225;n son factores de riesgo de EHmet y se deben mantener o retirar en funci&#243;n de sus beneficios potenciales frente al riesgo de progresi&#243;n de la enfermedad hep&#225;tica &#40;recomendaci&#243;n de grado B basada en la extrapolaci&#243;n de estudios de nivel 1 de evidencia&#41;<a class="elsevierStyleCrossRef" href="#bib0915"><span class="elsevierStyleSup">89</span></a>&#46;</p><p id="par0165" class="elsevierStylePara elsevierViewall">Se aconseja realizar ET a pacientes con FIB-4 bajo y tratamiento hepatot&#243;xico<a class="elsevierStyleCrossRefs" href="#bib0820"><span class="elsevierStyleSup">70&#44;89&#44;90</span></a>&#46; Ante pacientes con psoriasis moderada-grave&#44; tratamiento hepatot&#243;xico y ET &#8804; 8 kPa &#40;procedente del brazo FIB-4 alto o reevaluado con FIB-4 bajo debido al tratamiento&#41;&#44; se valorar&#225; continuar el tratamiento con f&#225;rmacos hepatot&#243;xicos seg&#250;n el balance riesgo-beneficio individualizado&#44; teniendo en cuenta las recomendaciones del hepat&#243;logo&#46; Se desaconsejan los f&#225;rmacos hepatot&#243;xicos en pacientes con FIB-4 alto y&#47;o ET &#62; 8 kPa&#44; debido al riesgo de fibrosis avanzada &#40;F3-F4&#41; &#40;<a class="elsevierStyleCrossRef" href="#tbl0020">tabla 4</a>&#41;&#46;</p><elsevierMultimedia ident="tbl0020"></elsevierMultimedia></span></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Discusi&#243;n</span><p id="par0170" class="elsevierStylePara elsevierViewall">La definici&#243;n consensuada entre dermat&#243;logos y hepat&#243;logos de criterios sencillos basados en la evidencia para identificar&#44; diagnosticar y monitorizar individuos de riesgo resulta fundamental para el manejo eficiente de la EHmet&#46; Las recomendaciones generales deber&#225;n adaptarse a las peculiaridades&#44; necesidades y posibilidades organizativas y asistenciales de los distintos centros y profesionales&#46;</p><p id="par0175" class="elsevierStylePara elsevierViewall">Debe considerarse la interacci&#243;n entre los tratamientos de la psoriasis y la EHmet&#44; teniendo en cuenta tanto la prevalencia de la patolog&#237;a hep&#225;tica como el impacto potencial y diverso de los f&#225;rmacos&#46; Es necesario ponderar el balance entre riesgo y beneficio del uso continuado de tratamientos con potencial hepatot&#243;xico en pacientes con riesgo de fibrosis hep&#225;tica&#44; realizando una evaluaci&#243;n y seguimiento individualizados&#46;</p><p id="par0180" class="elsevierStylePara elsevierViewall">De todos los tratamientos investigados&#44; el riesgo de desarrollar y&#47;o empeorar la EHmet solo aumenta con el MTX&#46; La fototerapia y algunos tratamientos convencionales de nueva generaci&#243;n no han demostrado hepatotoxicidad en pacientes con esteatosis hep&#225;tica&#46; Por su parte&#44; aunque la mayor&#237;a de las terapias biol&#243;gicas presenta un balance riesgo-beneficio favorable en pacientes con esteatosis hep&#225;tica y grados variables de fibrosis&#44; su potencial hepatot&#243;xico es diverso &#40;<a class="elsevierStyleCrossRef" href="#tbl0015">tabla 3</a>&#41;&#46;</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Conclusiones</span><p id="par0185" class="elsevierStylePara elsevierViewall">Ante la prevalencia de la EHmet en pacientes con psoriasis y la interrelaci&#243;n entre ambas patolog&#237;as recomendamos el despistaje de enfermedad hep&#225;tica en pacientes con psoriasis y alg&#250;n componente de EHmet&#44; independientemente del grado de alteraci&#243;n de la bioqu&#237;mica hep&#225;tica&#46; El despistaje ser&#225; sistem&#225;tico&#44; como parte del proceso asistencial de la psoriasis en las consultas o unidades asistenciales de dermatolog&#237;a&#46; La estrategia recomendada de mayor valor es la aplicaci&#243;n combinada del &#237;ndice serol&#243;gico FIB-4 y la ET y la derivaci&#243;n del paciente a hepatolog&#237;a cuando se detecte riesgo significativo de fibrosis avanzada&#46;</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Financiaci&#243;n</span><p id="par0190" class="elsevierStylePara elsevierViewall">Las reuniones del panel de expertos fueron financiadas por Novartis Farmac&#233;utica S&#46;A&#46;</p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Conflictos de intereses</span><p id="par0195" class="elsevierStylePara elsevierViewall">Novartis ha facilitado la celebraci&#243;n de las reuniones para los integrantes del grupo&#44; pero ninguno de sus empleados ha participado en el desarrollo y elaboraci&#243;n del material cient&#237;fico&#44; las discusiones o el texto escrito&#46;</p><p id="par0200" class="elsevierStylePara elsevierViewall">Antonio Olveira ha participado como investigador&#44; ponente o consultor en proyectos patrocinados por&#58; Abbvie&#44; Alexion&#44; BMS&#44; Janssen&#44; MSD&#44; Gilead&#44; Novartis&#46;</p><p id="par0205" class="elsevierStylePara elsevierViewall">Isabel Belinch&#243;n ha sido consultora y&#47;u oradora y&#47;o particip&#243; en ensayos cl&#237;nicos patrocinados por compa&#241;&#237;as que fabrican medicamentos utilizados para el tratamiento de la psoriasis&#44; incluyendo Janssen Pharmaceuticals Inc&#46;&#44; Almirall SA&#44; Lilly&#44; Abbvie&#44; Novartis&#44; Celgene&#44; Biogen&#44; Amgen&#44; LEO Pharma&#44; Pfizer-Wyeth&#44; MSD y UCB&#46;</p><p id="par0210" class="elsevierStylePara elsevierViewall">Pedro Herranz ha participado como investigador&#44; ponente o consultor en proyectos patrocinados por&#58; Abbvie&#44; Almirall&#44; Amgen&#44; Celgene&#44; LEO Pharma&#44; Lilly&#44; Novartis&#44; Pfizer&#44; Sandoz&#44; Sanofi&#44; UCB&#46;</p><p id="par0215" class="elsevierStylePara elsevierViewall">Javier Crespo ha participado como investigador&#44; ponente o consultor en proyectos patrocinados por&#58; Abbvie&#44; Alexion&#44; BMS&#44; Amgen&#44; Celgene&#44; Gilead&#44; Janssen&#44; MSD&#46;</p><p id="par0220" class="elsevierStylePara elsevierViewall">Eva Vilarrasa ha percibido honorarios de consultor&#237;a&#47;orador de y&#47;o particip&#243; en ensayos cl&#237;nicos patrocinados por Abbvie&#44; Almirall&#44; Amgen&#44; Bayer&#44; Boehringer Ingelheim&#44; Celgene&#44; Gebro&#44; Isdin&#44; Janssen&#44; LEO Pharma&#44; Lilly&#44; Merck-Serono&#44; MSD&#44; Novartis&#44; Pfizer&#44; Roche&#44; Sandoz&#44; Sanofi y UCB&#46;</p><p id="par0225" class="elsevierStylePara elsevierViewall">Salvador Benlloch P&#233;rez ha participado como investigador&#44; ponente&#44; o consultor en proyectos y ensayos cl&#237;nicos patrocinados por Novartis&#44; Novo Nordisk&#44; Gilead&#46;</p><p id="par0230" class="elsevierStylePara elsevierViewall">Jorge Alonso Su&#225;rez P&#233;rez ha participado como miembro de &#171;<span class="elsevierStyleItalic">steering committee</span>&#187; y&#47;o invitado como ponente por Novartis&#44; LEO Pharma&#44; Abbvie&#44; Lilly&#44; Janssen&#44; UCB&#44; Amgen y Almirall&#46;</p><p id="par0235" class="elsevierStylePara elsevierViewall">Jos&#233; Manuel Carrascosa ha participado como IP&#47;SI y&#47;o asesor o miembro del comit&#233; directivo y&#47;o ponente invitado de Novartis&#44; LEO Pharma&#44; Abbvie&#44; Lilly&#44; Janssen&#44; UCB&#44; Sandoz&#44; Mylan&#44; Amgen&#44; Almirall&#44; Bristol-Myers-Squibb y Boehringer Ingelheim&#46;</p><p id="par0240" class="elsevierStylePara elsevierViewall">Javier Ampuero declara no tener conflictos de inter&#233;s&#46;</p><p id="par0245" class="elsevierStylePara elsevierViewall">Francisco Guimer&#225; declara no tener conflictos de inter&#233;s&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:12 [
        0 => array:3 [
          "identificador" => "xres1908352"
          "titulo" => "Graphical abstract"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0005"
            ]
          ]
        ]
        1 => array:3 [
          "identificador" => "xres1908350"
          "titulo" => "Resumen"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0010"
            ]
          ]
        ]
        2 => array:2 [
          "identificador" => "xpalclavsec1648578"
          "titulo" => "Palabras clave"
        ]
        3 => array:3 [
          "identificador" => "xres1908351"
          "titulo" => "Abstract"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0015"
            ]
          ]
        ]
        4 => array:2 [
          "identificador" => "xpalclavsec1648577"
          "titulo" => "Keywords"
        ]
        5 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Introducci&#243;n"
        ]
        6 => array:3 [
          "identificador" => "sec0010"
          "titulo" => "Metodolog&#237;a"
          "secciones" => array:3 [
            0 => array:2 [
              "identificador" => "sec0015"
              "titulo" => "Identificaci&#243;n de los pacientes con psoriasis y riesgo de enfermedad hep&#225;tica"
            ]
            1 => array:2 [
              "identificador" => "sec0020"
              "titulo" => "Recomendaciones de cribado de la EHmet"
            ]
            2 => array:2 [
              "identificador" => "sec0025"
              "titulo" => "Tratamientos actuales para la psoriasis e impacto sobre la EHmet"
            ]
          ]
        ]
        7 => array:2 [
          "identificador" => "sec0030"
          "titulo" => "Discusi&#243;n"
        ]
        8 => array:2 [
          "identificador" => "sec0035"
          "titulo" => "Conclusiones"
        ]
        9 => array:2 [
          "identificador" => "sec0040"
          "titulo" => "Financiaci&#243;n"
        ]
        10 => array:2 [
          "identificador" => "sec0045"
          "titulo" => "Conflictos de intereses"
        ]
        11 => array:1 [
          "titulo" => "Bibliograf&#237;a"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2022-11-10"
    "fechaAceptado" => "2023-01-17"
    "PalabrasClave" => array:2 [
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec1648578"
          "palabras" => array:4 [
            0 => "Psoriasis"
            1 => "Esteatosis hep&#225;tica metab&#243;lica"
            2 => "EHmet"
            3 => "Hepatotoxicidad"
          ]
        ]
      ]
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec1648577"
          "palabras" => array:4 [
            0 => "Psoriasis"
            1 => "Metabolic-associated fatty liver disease"
            2 => "MAFLD"
            3 => "Hepatotoxicity"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "es" => array:2 [
        "titulo" => "Resumen"
        "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">En los &#250;ltimos a&#241;os se est&#225;n haciendo notables esfuerzos para entender la relaci&#243;n existente entre la psoriasis y la esteatosis hep&#225;tica metab&#243;lica &#40;EHmet&#41;&#46; No solo se presenta este trastorno en pacientes psori&#225;sicos con una mayor prevalencia&#44; sino que adem&#225;s se acompa&#241;a de una mayor gravedad&#46; Con este precedente&#44; se evidencia la necesidad de establecer un protocolo de abordaje precoz de la enfermedad hep&#225;tica en los pacientes con psoriasis&#46; Asimismo&#44; es de especial relevancia la evaluaci&#243;n de riesgo y beneficio en referencia al uso de tratamientos con potencial hepatot&#243;xico&#46; En el presente manuscrito se exponen las recomendaciones de un panel de expertos en dermatolog&#237;a y hepatolog&#237;a para el cribado&#44; diagn&#243;stico&#44; monitorizaci&#243;n y criterios de derivaci&#243;n en pacientes con psoriasis&#44; en caso de sospecha de esteatosis hep&#225;tica metab&#243;lica&#46;</p></span>"
      ]
      "en" => array:2 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abst0015" class="elsevierStyleSection elsevierViewall"><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Recent years have seen concerted efforts to understand the relation between psoriasis and metabolic-associated fatty liver disease &#40;MAFLD&#41;&#46; Not only is MALFD diagnosed more often in patients with psoriasis&#44; but its clinical course is also more aggressive&#46; A common approach is therefore needed to enable early detection of liver disease coincident with psoriasis&#46; Especially important is an analysis of risks and benefits of potentially hepatotoxic treatments&#46; This consensus paper presents the recommendations of a group of experts in dermatology and hepatology regarding screening for MALFD as well as criteria for monitoring patients and referring them to hepatologists when liver disease is suspected&#46;</p></span>"
      ]
    ]
    "NotaPie" => array:1 [
      0 => array:3 [
        "etiqueta" => "&#9674;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0025">Todos los componentes del Grupo de Trabajo para el Abordaje Com&#250;n de la Psoriasis y la EHmet &#40;GACPE&#41; est&#225;n relacionados en el <a class="elsevierStyleCrossRef" href="#sec0050">anexo</a>&#46;</p>"
        "identificador" => "fn0005"
      ]
    ]
    "apendice" => array:1 [
      0 => array:1 [
        "seccion" => array:1 [
          0 => array:5 [
            "apendice" => "<p id="par0250" class="elsevierStylePara elsevierViewall">El Grupo de Trabajo para el Abordaje Com&#250;n de la Psoriasis y la EHmet &#40;GACPE&#41; est&#225; constituido por siete dermat&#243;logos y cinco hepat&#243;logos&#44; especializados en el manejo de la psoriasis y la EHmet&#58;</p>"
            "etiqueta" => "Anexo"
            "titulo" => "Grupo de Trabajo para el Abordaje Com&#250;n de la Psoriasis y la EHmet &#40;GACPE&#41;&#58;"
            "identificador" => "sec0050"
            "apendiceSeccion" => array:2 [
              0 => array:3 [
                "apendice" => "<p id="par0260" class="elsevierStylePara elsevierViewall">Jorge Alonso Su&#225;rez-P&#233;rez&#46; Departamento de Dermatolog&#237;a&#44; Hospital Universitario Virgen de la Victoria&#44; M&#225;laga&#44; Espa&#241;a&#46;</p> <p id="par0265" class="elsevierStylePara elsevierViewall">Susana Armesto Alonso&#46; Departamento de Dermatolog&#237;a&#44; Hospital Universitario Marqu&#233;s de Valdecilla&#44; Santander&#44; Espa&#241;a&#46;</p> <p id="par0270" class="elsevierStylePara elsevierViewall">Isabel Belinch&#243;n Romero&#46; Departamento de Dermatolog&#237;a&#44; Hospital General Universitario de Alicante&#44; Instituto de Investigaci&#243;n Sanitaria y Biom&#233;dica &#40;ISABIAL&#41;&#44; Universidad Miguel Hern&#225;ndez de Elche&#44; Alicante&#44; Espa&#241;a&#46;</p> <p id="par0275" class="elsevierStylePara elsevierViewall">Jos&#233; Manuel Carrascosa Carrillo&#46; Departamento de Dermatolog&#237;a&#46; Hospital Universitario Germans Trias i Pujol&#46; Universitat Aut&#242;noma de Barcelona&#46; IGTP Badalona&#44; Espa&#241;a&#46;</p> <p id="par0280" class="elsevierStylePara elsevierViewall">Francisco Guimer&#225; Mart&#237;n-Neda&#46; Servicio de Dermatolog&#237;a y Patolog&#237;a&#44; Hospital Universitario de Canarias&#44; La Laguna&#44; Espa&#241;a&#46;</p> <p id="par0285" class="elsevierStylePara elsevierViewall">Pedro Herranz Pinto&#46; Departamento de Dermatolog&#237;a&#44; Hospital Universitario La Paz&#44; Madrid&#44; Espa&#241;a&#46;</p> <p id="par0290" class="elsevierStylePara elsevierViewall">Eva Vilarrasa Rull&#46; Departamento de Dermatolog&#237;a&#44; Hospital Santa Creu i Sant Pau&#44; Universitat Aut&#242;noma de Barcelona&#44; Barcelona&#44; Espa&#241;a&#46;</p>"
                "titulo" => "Dermat&#243;logos"
                "identificador" => "sec0055"
              ]
              1 => array:3 [
                "apendice" => "<p id="par0300" class="elsevierStylePara elsevierViewall">Javier Ampuero Herrojo&#46; Departamento de Enfermedades Digestivas&#44; Hospital Universitario Virgen del Roc&#237;o&#46; Laboratorio 213&#44; Instituto de Biomedicina de Sevilla &#40;IBIS&#41;&#46; Departamento de Medicina&#44; Universidad de Sevilla&#46; Centro Biom&#233;dico en Red de Enfermedades Hep&#225;ticas y Digestivas &#40;CIBERehd&#41;&#46; Sevilla&#44; Espa&#241;a&#46;</p> <p id="par0305" class="elsevierStylePara elsevierViewall">Salvador Benlloch P&#233;rez&#46; Servicio de Enfermedades Digestivas&#44; Hospital Arnau de Vilanova&#46; Valencia&#46; Centro Biom&#233;dico en Red de Enfermedades Hep&#225;ticas y Digestivas &#40;CIBERehd&#41;&#46; Valencia&#44; Espa&#241;a&#46;</p> <p id="par0310" class="elsevierStylePara elsevierViewall">Javier Crespo Garc&#237;a&#46; Servicio de Gastroenterolog&#237;a y Hepatolog&#237;a&#46; Hospital Universitario Marqu&#233;s de Valdecilla&#46; IDIVAL&#46; Escuela de Medicina&#46; Universidad de Cantabria&#46; Santander&#44; Espa&#241;a&#46;</p> <p id="par0315" class="elsevierStylePara elsevierViewall">Antonio Olveira Mart&#237;n&#46; Servicio de Aparato Digestivo&#44; Hospital Universitario La Paz&#44; Madrid&#44; Espa&#241;a&#46;</p>"
                "titulo" => "Hepat&#243;logos"
                "identificador" => "sec0060"
              ]
            ]
          ]
        ]
      ]
    ]
    "multimedia" => array:7 [
      0 => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figura 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 655
            "Ancho" => 2925
            "Tamanyo" => 121640
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Progresi&#243;n de la EHmet&#46; Desde la esteatosis hep&#225;tica &#40;estable&#44; con escaso riesgo de progresi&#243;n&#44; caracterizada por la acumulaci&#243;n de grasa intracelular en el hepatocito&#41;&#44; pasando por la evoluci&#243;n a esteatohepatitis no alcoh&#243;lica &#40;EHNA&#41; &#40;cuando la infiltraci&#243;n de grasa va acompa&#241;ada de cambios inflamatorios y da&#241;o celular&#41;&#44; y el desarrollo de fibrosis hep&#225;tica &#40;dep&#243;sito de col&#225;geno en forma de septos fibrosos que provocan una alteraci&#243;n arquitectural y disfunci&#243;n progresiva del hepatocito&#41;&#46; La fibrosis predispone al desarrollo de cirrosis &#40;septos fibr&#243;ticos y n&#243;dulos de regeneraci&#243;n&#41; y carcinoma hepatocelular &#40;CHC&#41; y&#47;o fallo hep&#225;tico<a class="elsevierStyleCrossRefs" href="#bib0495"><span class="elsevierStyleSup">6&#44;8&#44;10&#44;12&#8211;14</span></a>&#46;</p>"
        ]
      ]
      1 => array:7 [
        "identificador" => "fig0010"
        "etiqueta" => "Figura 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr2.jpeg"
            "Alto" => 1365
            "Ancho" => 2933
            "Tamanyo" => 218408
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Algoritmo de cribado del paciente de riesgo de EHmet&#46; Se debe tener en cuenta que en funci&#243;n de la realidad asistencial de cada hospital y la disponibilidad de elastometr&#237;a de transici&#243;n &#40;ET&#41;&#44; la ET se puede solicitar desde el Servicio de Dermatolog&#237;a o se debe derivar el paciente al Servicio de Aparato Digestivo&#46;</p> <p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">&#42;Se aconseja realizar ET para evaluar el riesgo de fibrosis a pacientes con FIB-4 bajo y con tratamiento hepatot&#243;xico&#46;</p>"
        ]
      ]
      2 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Tabla 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">AH&#58; &#225;cido hialur&#243;nico&#59; ALT&#58; alanina aminotransferasa&#59; APRI&#58; <span class="elsevierStyleItalic">AST to platelet ratio index</span>&#59; AST&#58; aspartato aminotransferasa&#59; DM&#58; diabetes mellitus&#59; ELF&#58; <span class="elsevierStyleItalic">enhanced liver fibrosis</span>&#59; FLI&#58; <span class="elsevierStyleItalic">fatty liver index</span>&#59; GGT&#58; gamma-glutamil transferasa&#59; HFS&#58; <span class="elsevierStyleItalic">Hepamet fibrosis score</span>&#59; HSI&#58; <span class="elsevierStyleItalic">hepatic steatosis index</span>&#59; IMC&#58; &#237;ndice de masa corporal&#59; NAFLD-FS&#58; <span class="elsevierStyleItalic">non-alcoholic fatty liver disease fibrosis score</span>&#59; PIIINP&#58; p&#233;ptido amino-terminal del procol&#225;geno III&#59; TIMP-1&#58; inhibidor tisular de la metaloproteinasa 1 de la matriz&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&#205;ndice&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Estadio&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Par&#225;metros&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " colspan="4" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Riesgo de fibrosis avanzada seg&#250;n valores de corte</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">HSI<a class="elsevierStyleCrossRef" href="#bib0670"><span class="elsevierStyleSup">41</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Esteatosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ALT&#47;AST&#44; IMC&#44; sexo&#44; diabetes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="4" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#60; 30&#58; bajo&#62; 36&#58; alto</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">FLI<a class="elsevierStyleCrossRef" href="#bib0675"><span class="elsevierStyleSup">42</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Esteatosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Per&#237;metro abdominal&#44; IMC&#44; triglic&#233;ridos&#44; GGT&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="4" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#60; 30&#58; bajo30-59&#58; intermedio&#8805; 60&#58; alto</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">NAFLD-FS <a class="elsevierStyleCrossRef" href="#bib0680"><span class="elsevierStyleSup">43</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Fibrosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hiperglucemia en ayunas&#47;DM&#44; edad&#44; IMC&#44; ALT&#44; AST&#44; plaquetas&#44; alb&#250;mina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="4" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#60; -1&#46;455&#58; F0-F2&#44; bajo-1&#46;455-0&#44;675&#58; indeterminado&#62; 0&#44;675&#58; F3-F4&#44; alto</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#205;ndice FIB-4<a class="elsevierStyleCrossRef" href="#bib0685"><span class="elsevierStyleSup">44</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Fibrosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Edad&#44; ALT&#44; AST&#44; plaquetas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="4" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#60; 1&#44;30&#58; F0-F2&#44; bajo&#62; 2&#44;67&#58; F3-F4&#44; alto</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">HFS<a class="elsevierStyleCrossRef" href="#bib0665"><span class="elsevierStyleSup">40</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Fibrosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Sexo&#44; edad&#44; DM&#44; glucosa&#44; insulina&#44; HOMA &#40;No DM&#41;&#44; AST&#44; alb&#250;mina&#44; plaquetas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Valor HFS&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">F2-F4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">F3-F4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">F4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#60; 0&#44;12&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">23&#44;6&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">8&#44;1&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#44;9&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#44;12-0&#44;47&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">57&#44;1&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">33&#44;7&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7&#44;4&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#62; 0&#44;47&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">86&#44;4&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">76&#44;3&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">35&#44;5&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">APRI<a class="elsevierStyleCrossRef" href="#bib0690"><span class="elsevierStyleSup">45</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Fibrosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">AST&#44; plaquetas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="4" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">F0-F2&#58; &#60; 0&#44;5&#59; 72&#44;7&#37;F3-F4&#58; &#62; 1&#44;5&#59; 54&#44;2&#37;</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#205;ndice BARD<a class="elsevierStyleCrossRef" href="#bib0695"><span class="elsevierStyleSup">46</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Fibrosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ALT&#44; AST&#44; DM&#44; IMC&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="4" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0-1&#58; bajo2-4&#58; alto</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#205;ndice ELF<a class="elsevierStyleCrossRef" href="#bib0700"><span class="elsevierStyleSup">47</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Fibrosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">AH&#44; PIIINP&#44; TIMP-1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="4" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#60; 7&#44;7&#58; nulo o bajo&#8805; 7&#44;7-9&#44;7&#58; moderado&#8805; 9&#44;8 alto</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3185341.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">&#205;ndices para el diagn&#243;stico no invasivo de la EHmet</p>"
        ]
      ]
      3 => array:8 [
        "identificador" => "tbl0010"
        "etiqueta" => "Tabla 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at2"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">ACC&#58; acetil-coenzima A carboxilasa&#59; ASK1&#58; cinasa reguladora de la se&#241;al de apoptosis 1&#59; CCR2&#47;5&#58; correceptor de quimiocinas 2&#47;5&#59; FGF21&#58; factor de crecimiento de fibroblastos 21&#59; FXR&#58; receptor X farnesoide&#59; GLP1&#58; p&#233;ptido similar al glucag&#243;n 1&#59; HSP47 siRNA&#58; &#225;cido ribonucleico peque&#241;o de interferencia de la prote&#237;na de choque t&#233;rmico 47&#59; PPAR&#945;&#47;&#948;&#58; receptores activados por proliferadores peroxisomales &#945;&#47;&#948;&#59; SCD&#58; estearoil-coenzima A desaturasa&#59; SGLT2&#58; cotransportador de sodio-glucosa tipo 2&#59; TLR4&#58; receptor tipo toll 4&#59; TR&#946;&#58; receptor &#946; de hormona tiroidea&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Diana&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">F&#225;rmaco&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Acci&#243;n&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Fase&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Ref&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Diabetes&#44; resistencia a la insulina</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Semaglutida&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">An&#225;logo del receptor GLP1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">II&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0735"><span class="elsevierStyleSup">54</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Canagliflozina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Inhibidor SGLT2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">piloto&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0740"><span class="elsevierStyleSup">55</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">BMS-986036&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">FGF21 recombinante&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">II&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0745"><span class="elsevierStyleSup">56</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Dislipemia</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Aramcol&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Inhibidor SCD&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">III&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0750"><span class="elsevierStyleSup">57</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Firsocostat &#40;GS-0976&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Inhibidor ACC&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">II&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0755"><span class="elsevierStyleSup">58</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Receptor nuclear</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#193;cido obetic&#243;lico&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Agonista FXR&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">III&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0760"><span class="elsevierStyleSup">59</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Elafibranor&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Agonista PPAR&#945;&#47;&#948;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">III&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0765"><span class="elsevierStyleSup">60</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Resmetirom &#40;MGL-3196&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Agonista TR&#946;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">III&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0770"><span class="elsevierStyleSup">61</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Apoptosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Emricasan&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Inhibidor caspasas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">II&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0775"><span class="elsevierStyleSup">62</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="5" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Inflamaci&#243;n&#44; fibrosis</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Selonsertib&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Inhibidor ASK1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">III&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0780"><span class="elsevierStyleSup">63</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Cenicriviroc&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Antagonista CCR2&#47;5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">III&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0785"><span class="elsevierStyleSup">64</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">GR-MD-02&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Inhibidor de galectina-3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">I&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0790"><span class="elsevierStyleSup">65</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">JKB-121&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Antagonista TLR4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">II&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0795"><span class="elsevierStyleSup">66</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ND-LO2-s0201&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">HSP47 siRNA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">II&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0805"><span class="elsevierStyleSup">67</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3185344.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Ensayos cl&#237;nicos de tratamientos para la EHmet &#40;adaptado de<a class="elsevierStyleCrossRef" href="#bib0730"><span class="elsevierStyleSup">53</span></a>&#41;</p>"
        ]
      ]
      4 => array:8 [
        "identificador" => "tbl0015"
        "etiqueta" => "Tabla 3"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at3"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">NA&#58; no aplicable &#40;no existen estudios al respecto&#41;&#59; BILt&#58; bilirrubina total&#46;</p><p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">El grupo de inhibidores de TNF incluye etanercept&#44; adalimumab e infliximab&#46; El grupo de anti-IL17A incluye brodalumab&#44; ixekizumab y secukinumab&#46; El grupo de anti-IL23 incluye tildrakizumab&#44; guselkumab&#44; risankizumab&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">F&#225;rmaco&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Toxicidad&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Tipo de da&#241;o&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">En insuficiencia hep&#225;tica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Riesgo incrementado de da&#241;o hep&#225;tico&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Metotrexato<a class="elsevierStyleCrossRefs" href="#bib0815"><span class="elsevierStyleSup">69&#8211;73</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#43;&#43;&#43;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Da&#241;o oxidativo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Uso con precauci&#243;nContraindicado si BILt &#62; 5 mg&#47;dL&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">EHmet&#47;obesidad&#44; leflunomida&#44; alcohol&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Acitretina<a class="elsevierStyleCrossRefs" href="#bib0855"><span class="elsevierStyleSup">74&#44;75</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#43;&#43;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Disfunci&#243;n mitocondrial&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Contraindicado&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hipertransaminemia de 15-30&#37;<a class="elsevierStyleCrossRef" href="#bib0860"><span class="elsevierStyleSup">75</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Inhibidores TNF<a class="elsevierStyleCrossRefs" href="#bib0865"><span class="elsevierStyleSup">76&#8211;78</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#43;&#43;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Fallo hep&#225;tico&#44; hepatitis no infecciosa&#44; insuficiencia hep&#225;tica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Aumento de riesgo de da&#241;o hep&#225;tico con adalimumab<a class="elsevierStyleCrossRef" href="#bib0880"><span class="elsevierStyleSup">79</span></a> y hepatitis autoinmune con infliximab<a class="elsevierStyleCrossRef" href="#bib0875"><span class="elsevierStyleSup">78</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ab IL-12&#47;23<a class="elsevierStyleCrossRef" href="#bib0880"><span class="elsevierStyleSup">79</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#43;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">N&#47;A&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ab IL-23<a class="elsevierStyleCrossRefs" href="#bib0925"><span class="elsevierStyleSup">80&#8211;82</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#43;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Aumento de las transaminasas<a class="elsevierStyleCrossRef" href="#tblfn0025">&#42;</a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ab IL-17<a class="elsevierStyleCrossRefs" href="#bib0890"><span class="elsevierStyleSup">83&#8211;85</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Posible efecto protector de la inhibici&#243;n de IL-17A en modelos animales<a class="elsevierStyleCrossRef" href="#bib0935"><span class="elsevierStyleSup">86</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Apremilast<a class="elsevierStyleCrossRef" href="#bib0940"><span class="elsevierStyleSup">87</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ciclosporina<a class="elsevierStyleCrossRef" href="#bib0945"><span class="elsevierStyleSup">88</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Rara&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Da&#241;o oxidativo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">SeguroRequiere reducci&#243;n de dosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Obesidad&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3185342.png"
              ]
            ]
          ]
          "notaPie" => array:1 [
            0 => array:3 [
              "identificador" => "tblfn0025"
              "etiqueta" => "&#42;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Solo guselkumab&#44; en estudios de artritis psori&#225;sica&#44; seg&#250;n ficha t&#233;cnica&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">F&#225;rmacos empleados en el tratamiento de la psoriasis y su impacto hep&#225;tico &#40;adaptada de<a class="elsevierStyleCrossRefs" href="#bib0590"><span class="elsevierStyleSup">25&#44;69&#8211;88</span></a>&#41;</p>"
        ]
      ]
      5 => array:8 [
        "identificador" => "tbl0020"
        "etiqueta" => "Tabla 4"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at4"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Escalas de gravedad de la psoriasis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">BSA<a class="elsevierStyleCrossRef" href="#tblfn0010">&#42;</a> 10&#37; o PASI<a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">&#42;&#42;</span></a> &#62; 10 o DLQI<a class="elsevierStyleCrossRef" href="#tblfn0020"><span class="elsevierStyleSup">&#42;&#42;&#42;</span></a> &#62; 10&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Localizaci&#243;n&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#193;reas expuestas &#40;regi&#243;n facial y dorso de manos&#41;&#44; palmas&#44; plantas&#44; genitales&#44; cuero cabelludo&#44; u&#241;as y placas recalcitrantes&#44; con impacto funcional o psicol&#243;gico para el paciente&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Fracaso de terapias previas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No controlable con tratamiento t&#243;pico o fototerapia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3185343.png"
              ]
            ]
          ]
          "notaPie" => array:3 [
            0 => array:3 [
              "identificador" => "tblfn0010"
              "etiqueta" => "&#42;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0010">La determinaci&#243;n de la superficie corporal afectada&#44; <span class="elsevierStyleItalic">body surface area</span> &#40;BSA&#41;&#44; es una de las escalas de medida m&#225;s empleadas en la evaluaci&#243;n de la gravedad de la psoriasis<a class="elsevierStyleCrossRef" href="#bib0950"><span class="elsevierStyleSup">91</span></a>&#46; El &#237;ndice BSA se calcula a partir de la media aritm&#233;tica de la superficie de la piel afectada ponderada seg&#250;n el &#225;rea total que ocupa cada parte del cuerpo evaluada&#58; la cabeza representa 10&#37;&#44; las extremidades superiores 20&#37;&#44; el tronco 30&#37; y las extremidades inferiores 40&#37; de la superficie corporal total<a class="elsevierStyleCrossRef" href="#bib0955"><span class="elsevierStyleSup">92</span></a>&#46;</p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0015"
              "etiqueta" => "&#42;&#42;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0015">El <span class="elsevierStyleItalic">Psoriasis Area Severity Index</span> &#40;PASI&#41; es la escala de medida m&#225;s utilizada para la valoraci&#243;n de la gravedad de la psoriasis y la toma de decisi&#243;n para la indicaci&#243;n de tratamiento&#46; Este &#237;ndice combina la valoraci&#243;n de cada lesi&#243;n de psoriasis del 0 al 4 &#40;0 &#61; ninguno&#44; 1 &#61; leve&#44; 2 &#61; moderado&#44; 3 &#61; marcado&#44; 4 &#61; muy marcado&#41; con base en tres par&#225;metros&#58; eritema&#44; infiltraci&#243;n y descamaci&#243;n&#44; en cuatro partes del cuerpo&#58; cabeza&#44; tronco&#44; extremidades superiores y extremidades inferiores<a class="elsevierStyleCrossRefs" href="#bib0955"><span class="elsevierStyleSup">92&#44;93</span></a>&#46;</p>"
            ]
            2 => array:3 [
              "identificador" => "tblfn0020"
              "etiqueta" => "&#42;&#42;&#42;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0020">El <span class="elsevierStyleItalic">Dermatology Life Quality Index</span> &#40;DLQI&#41; se compone de 10 preguntas con cuatro respuestas &#40;0 &#61; nada&#44; 1 &#61; un poco&#44; 2 &#61; mucho&#44; 3 &#61; much&#237;simo&#41; y se calcula sumando la puntuaci&#243;n de cada pregunta&#46; A mayor puntuaci&#243;n&#44; mayor es el deterioro de la calidad de vida<a class="elsevierStyleCrossRef" href="#bib0965"><span class="elsevierStyleSup">94</span></a>&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">Definici&#243;n de la psoriasis &#171;moderada a grave&#187; candidata a terapia sist&#233;mica propuesta por el Grupo de Psoriasis &#40;GPS&#41; de la Academia Espa&#241;ola de Dermatolog&#237;a y Venereolog&#237;a &#40;AEDV&#41;<a class="elsevierStyleCrossRef" href="#bib0610"><span class="elsevierStyleSup">29</span></a></p>"
        ]
      ]
      6 => array:5 [
        "identificador" => "fig0015"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "fx1.jpeg"
            "Alto" => 300
            "Ancho" => 1333
            "Tamanyo" => 37221
          ]
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "Bibliograf&#237;a"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:94 [
            0 => array:3 [
              "identificador" => "bib0470"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "&#91;Prevalence of ten Immune-mediated inflammatory diseases &#40;IMID&#41; in Spain&#93;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Rev Esp Salud Publica&#46;"
                        "fecha" => "2019"
                        "volumen" => "93"
                        "paginaInicial" => "e201903013"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0475"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Psoriasis and comorbid diseases"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2016.07.064"
                      "Revista" => array:7 [
                        "tituloSerie" => "J Am Acad Dermatol&#46;"
                        "fecha" => "2017"
                        "volumen" => "76"
                        "paginaInicial" => "377"
                        "paginaFinal" => "390"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S0140673613624228"
                          "estado" => "S300"
                          "issn" => "01406736"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0480"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Relationship between non-alcoholic fatty liver disease and psoriasis&#58; A novel Hepato-Dermal axis&#63;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [ …4]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3390/ijms17020217"
                      "Revista" => array:5 [
                        "tituloSerie" => "Int J Mol Sci&#46;"
                        "fecha" => "2016"
                        "volumen" => "17"
                        "paginaInicial" => "217"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0485"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Looking for a new name for non-alcoholic fatty liver disease in Spanish&#58; esteatosis hep&#225;tica metab&#243;lica &#40;EHmet&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Rev Esp Enferm Dig&#46;"
                        "fecha" => "2021"
                        "volumen" => "113"
                        "paginaInicial" => "161"
                        "paginaFinal" => "163"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0490"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Non-alcoholic fatty liver disease&#58; Metabolic&#44; genetic&#44; epigenetic and environmental risk factors"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [ …4]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3390/ijerph18105227"
                      "Revista" => array:6 [
                        "tituloSerie" => "Int J Environ Res Public Health&#46;"
                        "fecha" => "2021"
                        "volumen" => "18"
                        "paginaInicial" => "5227"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S0090825809007240"
                          "estado" => "S300"
                          "issn" => "00908258"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0495"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Non-alcoholic fatty liver disease&#58; A sign of systemic disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.metabol.2017.04.011"
                      "Revista" => array:6 [
                        "tituloSerie" => "Metabolism&#46;"
                        "fecha" => "2017"
                        "volumen" => "72"
                        "paginaInicial" => "94"
                        "paginaFinal" => "108"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0500"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The Metabolic Syndrome and Its Influence on Nonalcoholic Steatohepatitis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.cld.2015.10.002"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Liver Dis&#46;"
                        "fecha" => "2016"
                        "volumen" => "20"
                        "paginaInicial" => "225"
                        "paginaFinal" => "243"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0505"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Global epidemiology of nonalcoholic fatty liver disease&#8212;Meta-analytic assessment of prevalence&#44; incidence&#44; and outcomes"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Hepatology&#46;"
                        "fecha" => "2016"
                        "volumen" => "64"
                        "paginaInicial" => "73"
                        "paginaFinal" => "84"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0510"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis&#58; Implications for Liver Transplantation"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [ …4]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1097/TP.0000000000002484"
                      "Revista" => array:6 [
                        "tituloSerie" => "Transplantation&#46;"
                        "fecha" => "2019"
                        "volumen" => "103"
                        "paginaInicial" => "22"
                        "paginaFinal" => "27"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0515"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Consensus document Management of non-alcoholic fatty liver disease &#40;NAFLD&#41;&#46; Clinical practice guideline"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.gastrohep.2017.12.003"
                      "Revista" => array:7 [
                        "tituloSerie" => "Gastroenterol Hepatol&#46;"
                        "fecha" => "2018"
                        "volumen" => "41"
                        "paginaInicial" => "328"
                        "paginaFinal" => "349"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S0140673618324875"
                          "estado" => "S300"
                          "issn" => "01406736"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0520"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/hep.30251"
                      "Revista" => array:6 [
                        "tituloSerie" => "Hepatology&#46;"
                        "fecha" => "2019"
                        "volumen" => "69"
                        "paginaInicial" => "2672"
                        "paginaFinal" => "2682"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0525"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Burden of liver diseases in the world"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [ …4]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jhep.2018.09.014"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Hepatol&#46;"
                        "fecha" => "2019"
                        "volumen" => "70"
                        "paginaInicial" => "151"
                        "paginaFinal" => "171"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0530"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Fourth&#44; the progression of liver disease in NASH is not linear and can be manifested by periods of progression&#44; regression and stability"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [ …1]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:4 [
                        "tituloSerie" => "Nature&#46;"
                        "fecha" => "2017"
                        "volumen" => "550"
                        "paginaInicial" => "S102"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0535"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1053/j.gastro.2014.11.039"
                      "Revista" => array:6 [
                        "tituloSerie" => "Gastroenterology&#46;"
                        "fecha" => "2015"
                        "volumen" => "148"
                        "paginaInicial" => "547"
                        "paginaFinal" => "555"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0540"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Relationship between psoriasis and non-alcoholic fatty liver disease &#8211; Updated systematic review and adjusted meta-analysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [ …4]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/ajd.13015"
                      "Revista" => array:6 [
                        "tituloSerie" => "Australas J Dermatol&#46;"
                        "fecha" => "2019"
                        "volumen" => "60"
                        "paginaInicial" => "e352"
                        "paginaFinal" => "e355"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0545"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [ …4]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "J Hepatol&#46;"
                        "fecha" => "2009"
                        "volumen" => "51"
                        "paginaInicial" => "758"
                        "paginaFinal" => "764"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0550"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The increased prevalence of non-alcoholic fatty liver disease in psoriatic patients&#58; A study from South India"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1440-0960.2012.00905.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "Australas J Dermatol&#46;"
                        "fecha" => "2012"
                        "volumen" => "53"
                        "paginaInicial" => "190"
                        "paginaFinal" => "197"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0555"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Risk of non-alcoholic fatty liver disease in patients with psoriasis&#58; A systematic review and meta-analysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Eur Acad Dermatology Venereol&#46;"
                        "fecha" => "2015"
                        "volumen" => "29"
                        "paginaInicial" => "656"
                        "paginaFinal" => "662"
                        "itemHostRev" => array:3 [
                          "pii" => "S1470204516306271"
                          "estado" => "S300"
                          "issn" => "14702045"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0560"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Non-alcoholic fatty liver disease is associated with bacterial translocation and a higher inflammation response in psoriatic patients"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1038/s41598-020-79139-8"
                      "Revista" => array:6 [
                        "tituloSerie" => "Sci Rep&#46;"
                        "fecha" => "2021"
                        "volumen" => "11"
                        "paginaInicial" => "1"
                        "paginaFinal" => "12"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib0565"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Psoriasis and fatty liver&#58; A harmful synergy"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Rev Esp Enfermedades Dig&#46;"
                        "fecha" => "2019"
                        "volumen" => "111"
                        "paginaInicial" => "314"
                        "paginaFinal" => "319"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib0570"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Eur Acad Dermatol Venereol&#46;"
                        "fecha" => "2016"
                        "volumen" => "30"
                        "paginaInicial" => "282"
                        "paginaFinal" => "287"
                        "itemHostRev" => array:3 [
                          "pii" => "S1470204517304692"
                          "estado" => "S300"
                          "issn" => "14702045"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib0575"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The diagnosis and management of nonalcoholic fatty liver disease&#58; Practice guidance from the American Association for the Study of Liver Diseases"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/hep.29367"
                      "Revista" => array:7 [
                        "tituloSerie" => "Hepatology&#46;"
                        "fecha" => "2018"
                        "volumen" => "67"
                        "paginaInicial" => "328"
                        "paginaFinal" => "357"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S0360301619340659"
                          "estado" => "S300"
                          "issn" => "03603016"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib0580"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Increased prevalence of advanced liver fibrosis in patients with psoriasis&#58; A cross-sectional analysis from the rotterdam study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Acta Derm Venereol&#46;"
                        "fecha" => "2016"
                        "volumen" => "96"
                        "paginaInicial" => "213"
                        "paginaFinal" => "217"
                        "itemHostRev" => array:3 [
                          "pii" => "S0090825809004636"
                          "estado" => "S300"
                          "issn" => "00908258"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib0585"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Nonalcoholic fatty liver disease in patients with psoriasis&#58; a consequence of systemic inflammatory burden&#63;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/bjd.16239"
                      "Revista" => array:7 [
                        "tituloSerie" => "Br J Dermatol&#46;"
                        "fecha" => "2018"
                        "volumen" => "179"
                        "paginaInicial" => "16"
                        "paginaFinal" => "29"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S0140673617324406"
                          "estado" => "S300"
                          "issn" => "01406736"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib0590"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Liver Illness and Psoriatic Patients"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [ …5]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Biomed Res Int&#46;"
                        "fecha" => "2018"
                        "volumen" => "2018"
                        "paginaInicial" => "1"
                        "paginaFinal" => "12"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib0595"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Consenso sobre M&#233;todos de Detecci&#243;n y Derivaci&#243;n de Enfermedades Hep&#225;ticas Prevalentes Ocultas&#46; Consenso AEEH"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:5 [ …5]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:2 [
                        "tituloSerie" => "Gastroenterol Hepatol&#46;"
                        "fecha" => "2022"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            26 => array:3 [
              "identificador" => "bib0600"
              "etiqueta" => "27"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "M&#233;todos de consenso Uso adecuado de la evidencia en la toma de decisiones&#46; &#171;M&#233;todo RAND&#47;UCLA&#187;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Rehabilitaci&#243;n"
                        "fecha" => "2001"
                        "volumen" => "35"
                        "paginaInicial" => "388"
                        "paginaFinal" => "392"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            27 => array:3 [
              "identificador" => "bib0605"
              "etiqueta" => "28"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Research methods for formal consensus development"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.7748/nr.22.6.35.e1342"
                      "Revista" => array:6 [
                        "tituloSerie" => "Nurse Res&#46;"
                        "fecha" => "2015"
                        "volumen" => "22"
                        "paginaInicial" => "35"
                        "paginaFinal" => "40"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            28 => array:3 [
              "identificador" => "bib0610"
              "etiqueta" => "29"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Practical update of the Recommendations Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology &#40;GPS&#41; on the Treatment of Psoriasis with Biologic Therapy Part 1&#46; Concepts and General Management of Psoriasis with Biologic Therapy"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ad.2021.10.003"
                      "Revista" => array:6 [
                        "tituloSerie" => "Actas Dermosifiliogr&#46;"
                        "fecha" => "2022"
                        "volumen" => "113"
                        "paginaInicial" => "261"
                        "paginaFinal" => "277"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            29 => array:3 [
              "identificador" => "bib0615"
              "etiqueta" => "30"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Practical Update of the Guidelines Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology &#40;GPs&#41; on the Treatment of Psoriasis With Biologic Agents&#58; Part 2 - Management of Special Populations Patients With Comorbid Conditions&#44; and Risk"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ad.2022.01.024"
                      "Revista" => array:6 [
                        "tituloSerie" => "Actas Dermosifiliogr&#46;"
                        "fecha" => "2022"
                        "volumen" => "113"
                        "paginaInicial" => "583"
                        "paginaFinal" => "609"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            30 => array:3 [
              "identificador" => "bib0620"
              "etiqueta" => "31"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Valoraci&#243;n bioqu&#237;mica en la enfermedad hep&#225;tica grasa asociada a la disfunci&#243;n metab&#243;lica"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Adv Lab Med&#46;"
                        "fecha" => "2021"
                        "volumen" => "2"
                        "paginaInicial" => "209"
                        "paginaFinal" => "219"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            31 => array:3 [
              "identificador" => "bib0625"
              "etiqueta" => "32"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "colaboracion" => "European Association for the Study of the Liver &#40;EASL&#41;&#46; European Association for the Study of Diabetes &#40;EASD&#41;&#46; European Association for the Study of Obesity &#40;EASO&#41;"
                          "etal" => false
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "J Hepatol&#46;"
                        "fecha" => "2016"
                        "volumen" => "64"
                        "paginaInicial" => "1388"
                        "paginaFinal" => "1402"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            32 => array:3 [
              "identificador" => "bib0630"
              "etiqueta" => "33"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1053/jhep.2003.50229"
                      "Revista" => array:6 [
                        "tituloSerie" => "Hepatology&#46;"
                        "fecha" => "2003"
                        "volumen" => "37"
                        "paginaInicial" => "1286"
                        "paginaFinal" => "1292"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            33 => array:3 [
              "identificador" => "bib0635"
              "etiqueta" => "34"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Utilidad pr&#225;ctica de los &#237;ndices no invasivos en la esteatosis hep&#225;tica metab&#243;lica"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.endinu.2021.08.001"
                      "Revista" => array:5 [
                        "tituloSerie" => "Endocrinol Diabetes Nutr&#46;"
                        "fecha" => "2022"
                        "volumen" => "69"
                        "paginaInicial" => "418"
                        "paginaFinal" => "425"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            34 => array:3 [
              "identificador" => "bib0640"
              "etiqueta" => "35"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Current guidelines for the management of non-alcoholic fatty liver disease&#58; A systematic review with comparative analysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3748/wjg.v24.i30.3361"
                      "Revista" => array:6 [
                        "tituloSerie" => "World J Gastroenterol&#46;"
                        "fecha" => "2018"
                        "volumen" => "24"
                        "paginaInicial" => "3361"
                        "paginaFinal" => "3373"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            35 => array:3 [
              "identificador" => "bib0645"
              "etiqueta" => "36"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Development of a simple noninvasive index to predict significant fibrosis in patients with HIV&#47;HCV coinfection"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/hep.21178"
                      "Revista" => array:6 [
                        "tituloSerie" => "Hepatology&#46;"
                        "fecha" => "2006"
                        "volumen" => "43"
                        "paginaInicial" => "1317"
                        "paginaFinal" => "1325"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            36 => array:3 [
              "identificador" => "bib0650"
              "etiqueta" => "37"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [ …5]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/gut.2010.216077"
                      "Revista" => array:6 [
                        "tituloSerie" => "Gut&#46;"
                        "fecha" => "2010"
                        "volumen" => "59"
                        "paginaInicial" => "1265"
                        "paginaFinal" => "1269"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            37 => array:3 [
              "identificador" => "bib0655"
              "etiqueta" => "38"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/apt.14219"
                      "Revista" => array:6 [
                        "tituloSerie" => "Aliment Pharmacol Ther&#46;"
                        "fecha" => "2017"
                        "volumen" => "46"
                        "paginaInicial" => "617"
                        "paginaFinal" => "627"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            38 => array:3 [
              "identificador" => "bib0660"
              "etiqueta" => "39"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis &#8211; 2021 update"
                      "autores" => array:1 [
                        0 => array:2 [
                          "colaboracion" => "European Association for the Study of the Liver&#46; Clinical Practice Guideline Panel&#46; EASL Governing Board representative"
                          "etal" => false
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jhep.2021.05.025"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Hepatol&#46;"
                        "fecha" => "2021"
                        "volumen" => "75"
                        "paginaInicial" => "659"
                        "paginaFinal" => "689"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            39 => array:3 [
              "identificador" => "bib0665"
              "etiqueta" => "40"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1038/ajg.2016.453"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Gastroenterol&#46;"
                        "fecha" => "2017"
                        "volumen" => "112"
                        "paginaInicial" => "740"
                        "paginaFinal" => "751"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            40 => array:3 [
              "identificador" => "bib0670"
              "etiqueta" => "41"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Development and Validation of Hepamet Fibrosis Scoring System&#8211;A Simple Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Clin Gastroenterol Hepatol&#46;"
                        "fecha" => "2020"
                        "volumen" => "18"
                        "paginaInicial" => "216"
                        "paginaFinal" => "225&#46;e5"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            41 => array:3 [
              "identificador" => "bib0675"
              "etiqueta" => "42"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Hepatic steatosis index&#58; a simple screening tool reflecting nonalcoholic fatty liver disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.dld.2009.08.002"
                      "Revista" => array:6 [
                        "tituloSerie" => "Dig Liver Dis&#46;"
                        "fecha" => "2010"
                        "volumen" => "42"
                        "paginaInicial" => "503"
                        "paginaFinal" => "508"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            42 => array:3 [
              "identificador" => "bib0680"
              "etiqueta" => "43"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The Fatty Liver Index&#58; a simple and accurate predictor of hepatic steatosis in the general population"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1186/1471-230X-6-33"
                      "Revista" => array:5 [
                        "tituloSerie" => "BMC Gastroenterol&#46;"
                        "fecha" => "2006"
                        "volumen" => "6"
                        "paginaInicial" => "33"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            43 => array:3 [
              "identificador" => "bib0685"
              "etiqueta" => "44"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The NAFLD fibrosis score&#58; a noninvasive system that identifies liver fibrosis in patients with NAFLD"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/hep.21496"
                      "Revista" => array:6 [
                        "tituloSerie" => "Hepatology&#46;"
                        "fecha" => "2007"
                        "volumen" => "45"
                        "paginaInicial" => "846"
                        "paginaFinal" => "854"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            44 => array:3 [
              "identificador" => "bib0690"
              "etiqueta" => "45"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1186/1471-230X-12-2"
                      "Revista" => array:5 [
                        "tituloSerie" => "BMC Gastroenterol&#46;"
                        "fecha" => "2012"
                        "volumen" => "12"
                        "paginaInicial" => "2"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            45 => array:3 [
              "identificador" => "bib0695"
              "etiqueta" => "46"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "AST to Platelet Ratio Index and fibrosis 4 calculator scores for non-invasive assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [ …4]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.dld.2017.05.002"
                      "Revista" => array:6 [
                        "tituloSerie" => "Dig Liver Dis&#46;"
                        "fecha" => "2017"
                        "volumen" => "49"
                        "paginaInicial" => "1133"
                        "paginaFinal" => "1138"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            46 => array:3 [
              "identificador" => "bib0700"
              "etiqueta" => "47"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [ …5]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/gut.2007.146019"
                      "Revista" => array:6 [
                        "tituloSerie" => "Gut&#46;"
                        "fecha" => "2008"
                        "volumen" => "57"
                        "paginaInicial" => "1441"
                        "paginaFinal" => "1447"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            47 => array:3 [
              "identificador" => "bib0705"
              "etiqueta" => "48"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Noninvasive markers of fibrosis in nonalcoholic fatty liver disease&#58; Validating the European Liver Fibrosis Panel and exploring simple markers"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/hep.21984"
                      "Revista" => array:6 [
                        "tituloSerie" => "Hepatology&#46;"
                        "fecha" => "2008"
                        "volumen" => "47"
                        "paginaInicial" => "455"
                        "paginaFinal" => "460"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            48 => array:3 [
              "identificador" => "bib0710"
              "etiqueta" => "49"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Transient elastography&#58; A new noninvasive method for assessment of hepatic fibrosis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ultrasmedbio.2003.07.001"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ultrasound Med Biol&#46;"
                        "fecha" => "2003"
                        "volumen" => "29"
                        "paginaInicial" => "1705"
                        "paginaFinal" => "1713"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            49 => array:3 [
              "identificador" => "bib0715"
              "etiqueta" => "50"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Liver elastography&#58; what it is&#44; how it is done&#44; and how it is interpreted"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.rx.2017.11.002"
                      "Revista" => array:6 [
                        "tituloSerie" => "Radiologia&#46;"
                        "fecha" => "2018"
                        "volumen" => "60"
                        "paginaInicial" => "183"
                        "paginaFinal" => "189"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            50 => array:3 [
              "identificador" => "bib0720"
              "etiqueta" => "51"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/hep.23312"
                      "Revista" => array:6 [
                        "tituloSerie" => "Hepatology&#46;"
                        "fecha" => "2010"
                        "volumen" => "51"
                        "paginaInicial" => "454"
                        "paginaFinal" => "462"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            51 => array:3 [
              "identificador" => "bib0725"
              "etiqueta" => "52"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of NAFLD with diet physical activity and exercise"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jhep.2017.05.016"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Hepatol&#46;"
                        "fecha" => "2017"
                        "volumen" => "67"
                        "paginaInicial" => "829"
                        "paginaFinal" => "846"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            52 => array:3 [
              "identificador" => "bib0730"
              "etiqueta" => "53"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Current status&#44; problems&#44; and perspectives of non-alcoholic fatty liver disease research"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3748/wjg.v25.i2.163"
                      "Revista" => array:7 [
                        "tituloSerie" => "World J Gastroenterol&#46;"
                        "fecha" => "2019"
                        "volumen" => "25"
                        "paginaInicial" => "163"
                        "paginaFinal" => "177"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S0090825820339676"
                          "estado" => "S300"
                          "issn" => "00908258"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            53 => array:3 [
              "identificador" => "bib0735"
              "etiqueta" => "54"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med&#46;"
                        "fecha" => "2021"
                        "volumen" => "384"
                        "paginaInicial" => "1113"
                        "paginaFinal" => "1124"
                        "itemHostRev" => array:3 [
                          "pii" => "S0360301620341146"
                          "estado" => "S300"
                          "issn" => "03603016"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            54 => array:3 [
              "identificador" => "bib0740"
              "etiqueta" => "55"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus&#58; Preliminary prospective study based on serial liver biopsies"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/hep4.1019"
                      "Revista" => array:6 [
                        "tituloSerie" => "Hepatol Commun&#46;"
                        "fecha" => "2017"
                        "volumen" => "1"
                        "paginaInicial" => "46"
                        "paginaFinal" => "52"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            55 => array:3 [
              "identificador" => "bib0745"
              "etiqueta" => "56"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Pegbelfermin &#40;BMS-986036&#41;&#44; a PEGylated fibroblast growth factor 21 analogue&#44; in patients with non-alcoholic steatohepatitis&#58; a randomised&#44; double-blind&#44; placebo-controlled&#44; phase 2<span class="elsevierStyleHsp" style=""></span>a trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(18)31785-9"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet&#46;"
                        "fecha" => "2019"
                        "volumen" => "392"
                        "paginaInicial" => "2705"
                        "paginaFinal" => "2717"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            56 => array:3 [
              "identificador" => "bib0750"
              "etiqueta" => "57"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "ClinicalTrials&#46;gov&#46; A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH &#40;ARMOR&#41; &#91;consultado 1 Jul 2022&#93;&#46; Disponible en&#58; <a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT04104321">https&#58;&#47;&#47;clinicaltrials&#46;gov&#47;ct2&#47;show&#47;NCT04104321</a>&#46;"
                ]
              ]
            ]
            57 => array:3 [
              "identificador" => "bib0755"
              "etiqueta" => "58"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "GS-0976 &#40;Firsocostat&#41;&#58; an investigational liver-directed acetyl-CoA carboxylase &#40;ACC&#41; inhibitor for the treatment of non-alcoholic steatohepatitis &#40;NASH&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [ …5]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1080/13543784.2020.1668374"
                      "Revista" => array:6 [
                        "tituloSerie" => "Expert Opin Investig Drugs&#46;"
                        "fecha" => "2020"
                        "volumen" => "29"
                        "paginaInicial" => "135"
                        "paginaFinal" => "141"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            58 => array:3 [
              "identificador" => "bib0760"
              "etiqueta" => "59"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic&#44; non-alcoholic steatohepatitis &#40;FLINT&#41;&#58; a multicentre&#44; randomised&#44; placebo-controlled trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(14)61933-4"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet&#46;"
                        "fecha" => "2015"
                        "volumen" => "385"
                        "paginaInicial" => "956"
                        "paginaFinal" => "965"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            59 => array:3 [
              "identificador" => "bib0765"
              "etiqueta" => "60"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Elafibranor&#44; an Agonist of the Peroxisome Proliferator-Activated Receptor-alpha and -delta&#44; Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1053/j.gastro.2016.01.038"
                      "Revista" => array:6 [
                        "tituloSerie" => "Gastroenterology&#46;"
                        "fecha" => "2016"
                        "volumen" => "150"
                        "paginaInicial" => "1147"
                        "paginaFinal" => "1159&#46;e5"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            60 => array:3 [
              "identificador" => "bib0770"
              "etiqueta" => "61"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Hepatol Commun&#46;"
                        "fecha" => "2021"
                        "volumen" => "5"
                        "paginaInicial" => "573"
                        "paginaFinal" => "588"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            61 => array:3 [
              "identificador" => "bib0775"
              "etiqueta" => "62"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The pan-caspase inhibitor Emricasan &#40;IDN-6556&#41; decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Liver Int&#46;"
                        "fecha" => "2015"
                        "volumen" => "35"
                        "paginaInicial" => "953"
                        "paginaFinal" => "966"
                        "itemHostRev" => array:3 [
                          "pii" => "S0360301619339665"
                          "estado" => "S300"
                          "issn" => "03603016"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            62 => array:3 [
              "identificador" => "bib0780"
              "etiqueta" => "63"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "NASH&#58; Novel therapeutic strategies targeting ASK1 in NASH"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1038/nrgastro.2017.42"
                      "Revista" => array:6 [
                        "tituloSerie" => "Nat Rev Gastroenterol Hepatol&#46;"
                        "fecha" => "2017"
                        "volumen" => "14"
                        "paginaInicial" => "329"
                        "paginaFinal" => "330"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            63 => array:3 [
              "identificador" => "bib0785"
              "etiqueta" => "64"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A randomized&#44; placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/hep.29477"
                      "Revista" => array:7 [
                        "tituloSerie" => "Hepatology&#46;"
                        "fecha" => "2018"
                        "volumen" => "67"
                        "paginaInicial" => "1754"
                        "paginaFinal" => "1767"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S147020451630626X"
                          "estado" => "S300"
                          "issn" => "14702045"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            64 => array:3 [
              "identificador" => "bib0790"
              "etiqueta" => "65"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Randomised clinical study&#58; GR-MD-02&#44; a galectin-3 inhibitor&#44; vs&#46; placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/apt.13816"
                      "Revista" => array:6 [
                        "tituloSerie" => "Aliment Pharmacol Ther&#46;"
                        "fecha" => "2016"
                        "volumen" => "44"
                        "paginaInicial" => "1183"
                        "paginaFinal" => "1198"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            65 => array:3 [
              "identificador" => "bib0795"
              "etiqueta" => "66"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "JKB-121 in patients with nonalcoholic steatohepatitis&#58; A phase 2 double blind randomized placebo control study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "J Hepatol&#46;"
                        "fecha" => "2018"
                        "volumen" => "68"
                        "paginaInicial" => "S103"
                        "itemHostRev" => array:3 [
                          "pii" => "S2352302620303604"
                          "estado" => "S300"
                          "issn" => "23523026"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            66 => array:3 [
              "identificador" => "bib0805"
              "etiqueta" => "67"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "ClinicalTrials&#46;gov&#46; JUNIPER&#58; A Phase 2 Study to Evaluate the Safety&#44; Biological Activity&#44; and PK of ND-L02-s0201 in Subjects With IPF &#91;consultado 1 Jul 2022&#93;&#46; Disponible en&#58; <a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03538301">https&#58;&#47;&#47;clinicaltrials&#46;gov&#47;ct2&#47;show&#47;NCT03538301</a>&#46;"
                ]
              ]
            ]
            67 => array:3 [
              "identificador" => "bib0810"
              "etiqueta" => "68"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Systemic psoriasis therapies and comorbid disease in patients with psoriasis&#58; A review of potential risks and benefits"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [ …4]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Aesthet Dermatol&#46;"
                        "fecha" => "2019"
                        "volumen" => "12"
                        "paginaInicial" => "46"
                        "paginaFinal" => "54"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            68 => array:3 [
              "identificador" => "bib0815"
              "etiqueta" => "69"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Methotrexate and liver fibrosis in people with psoriasis&#58; A systematic review of observational studies"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Br J Dermatol&#46;"
                        "fecha" => "2014"
                        "volumen" => "171"
                        "paginaInicial" => "17"
                        "paginaFinal" => "29"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            69 => array:3 [
              "identificador" => "bib0820"
              "etiqueta" => "70"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "NICE&#46; Psoriasis&#58; assessment and management &#40;CG153&#41;&#46; Clinical Guideline 84&#44; no pagination&#44; 2015&#46;"
                ]
              ]
            ]
            70 => array:3 [
              "identificador" => "bib0825"
              "etiqueta" => "71"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Methotrexate Hepatotoxicity and the Impact of Nonalcoholic Fatty Liver Disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [ …4]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.amjms.2017.03.014"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Med Sci&#46;"
                        "fecha" => "2017"
                        "volumen" => "354"
                        "paginaInicial" => "172"
                        "paginaFinal" => "181"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            71 => array:3 [
              "identificador" => "bib0830"
              "etiqueta" => "72"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Unmet needs in patients with moderate-to-severe plaque psoriasis treated with methotrexate in real world practice&#58; FirST study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1080/09546634.2020.1801977"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Dermatolog Treat&#46;"
                        "fecha" => "2022"
                        "volumen" => "33"
                        "paginaInicial" => "1329"
                        "paginaFinal" => "1338"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            72 => array:3 [
              "identificador" => "bib0850"
              "etiqueta" => "73"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Agencia Espa&#241;ola de Medicamentos y Productos Sanitarios&#46; Ficha T&#233;cnica de Metotrexato&#46;"
                ]
              ]
            ]
            73 => array:3 [
              "identificador" => "bib0855"
              "etiqueta" => "74"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Ficha t&#233;cnica de Acitretina&#46; Agencia Europea de Medicamentos&#44; 2020&#46;"
                ]
              ]
            ]
            74 => array:3 [
              "identificador" => "bib0860"
              "etiqueta" => "75"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Acitretin affects bioenergetics of liver mitochondria and promotes mitochondrial permeability transition&#58; potential mechanisms of hepatotoxicity"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.tox.2013.01.020"
                      "Revista" => array:6 [
                        "tituloSerie" => "Toxicology&#46;"
                        "fecha" => "2013"
                        "volumen" => "306"
                        "paginaInicial" => "93"
                        "paginaFinal" => "100"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            75 => array:3 [
              "identificador" => "bib0865"
              "etiqueta" => "76"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Ficha t&#233;cnica de Humira&#46; Agencia Europea de Medicamentos&#44; 2009&#46;"
                ]
              ]
            ]
            76 => array:3 [
              "identificador" => "bib0870"
              "etiqueta" => "77"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Ficha t&#233;cnica de Cimzia&#46; Agencia Europea de Medicamentos&#44; 2019&#46;"
                ]
              ]
            ]
            77 => array:3 [
              "identificador" => "bib0875"
              "etiqueta" => "78"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Ficha t&#233;cnica de Remicade&#46; Agencia Europea de Medicamentos&#44; 2014&#46;"
                ]
              ]
            ]
            78 => array:3 [
              "identificador" => "bib0880"
              "etiqueta" => "79"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Agencia Espa&#241;ola de Medicamentos y Productos Sanitarios&#46; Ficha T&#233;cnica de Ustekinumab&#44; Stelara&#174;&#44; 2013&#46;"
                ]
              ]
            ]
            79 => array:3 [
              "identificador" => "bib0925"
              "etiqueta" => "80"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:1 [
                      "autores" => array:1 [
                        0 => array:2 [
                          "colaboracion" => "European Medicines Agency Tremfya &#40;Guselkumab&#41;&#58; summary of product characteristics"
                          "etal" => false
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:4 [
                        "tituloSerie" => "Agencia Eur Medicam&#46;"
                        "fecha" => "2019"
                        "paginaInicial" => "1"
                        "paginaFinal" => "71"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            80 => array:3 [
              "identificador" => "bib0930"
              "etiqueta" => "81"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Ficha t&#233;cnica de Skyrizi&#46; Agencia Europea de Medicamentos&#44; 2014&#46;"
                ]
              ]
            ]
            81 => array:3 [
              "identificador" => "bib0885"
              "etiqueta" => "82"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Ficha t&#233;cnica de Tremfya&#46; Agencia Europea de Medicamentos&#44; 2009&#46;"
                ]
              ]
            ]
            82 => array:3 [
              "identificador" => "bib0890"
              "etiqueta" => "83"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Ficha t&#233;cnica de Cosentyx&#46; Agencia Europea de Medicamentos&#44; 2019&#46;"
                ]
              ]
            ]
            83 => array:3 [
              "identificador" => "bib0895"
              "etiqueta" => "84"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Ficha t&#233;cnica de Kyntheum&#46; Agencia Europea de Medicamentos&#44; 2014&#46;"
                ]
              ]
            ]
            84 => array:3 [
              "identificador" => "bib0900"
              "etiqueta" => "85"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Ficha t&#233;cnica de Taltz&#46; Agencia Europea de Medicamentos&#44; 2019&#46; doi&#58;10&#46;2307&#47;j&#46;ctvdf0dxq&#46;12&#46;"
                ]
              ]
            ]
            85 => array:3 [
              "identificador" => "bib0935"
              "etiqueta" => "86"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Metabolic Inflammation-Associated IL-17A Causes Non-alcoholic Steatohepatitis and Hepatocellular Carcinoma"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ccell.2016.05.020"
                      "Revista" => array:6 [
                        "tituloSerie" => "Cancer Cell&#46;"
                        "fecha" => "2016"
                        "volumen" => "30"
                        "paginaInicial" => "161"
                        "paginaFinal" => "175"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            86 => array:3 [
              "identificador" => "bib0940"
              "etiqueta" => "87"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Agencia Espa&#241;ola de Medicamentos y Productos Sanitarios&#46; Ficha T&#233;cnica de Apremilast&#46;"
                ]
              ]
            ]
            87 => array:3 [
              "identificador" => "bib0945"
              "etiqueta" => "88"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Agencia Espa&#241;ola de Medicamentos y Productos Sanitarios&#46; Ficha T&#233;cnica Ciclosporina&#44; 2020&#46;"
                ]
              ]
            ]
            88 => array:3 [
              "identificador" => "bib0915"
              "etiqueta" => "89"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "EASL Clinical Practice Guidelines&#58; Drug-induced liver injury"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jhep.2019.02.014"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Hepatol&#46;"
                        "fecha" => "2019"
                        "volumen" => "70"
                        "paginaInicial" => "1222"
                        "paginaFinal" => "1261"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            89 => array:3 [
              "identificador" => "bib0920"
              "etiqueta" => "90"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Drug use and toxicity in psoriatic disease&#58; Focus on methotrexate"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Rheumatol&#46;"
                        "fecha" => "2008"
                        "volumen" => "35"
                        "paginaInicial" => "1454"
                        "paginaFinal" => "1457"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            90 => array:3 [
              "identificador" => "bib0950"
              "etiqueta" => "91"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Validaci&#243;n del m&#233;todo de cuantificaci&#243;n del &#225;rea corporal afectada por la psoriasis mediante l&#225;piz &#243;ptico"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ad.2019.07.002"
                      "Revista" => array:6 [
                        "tituloSerie" => "Actas Dermosifiliogr&#46;"
                        "fecha" => "2020"
                        "volumen" => "111"
                        "paginaInicial" => "143"
                        "paginaFinal" => "148"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            91 => array:3 [
              "identificador" => "bib0955"
              "etiqueta" => "92"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A comparison between BSA&#44; PASI"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "PLASI and SAPASI as measures of disease severity and improvement by therapy in patients with psoriasis&#46;"
                        "fecha" => "2008"
                        "paginaInicial" => "1019"
                        "paginaFinal" => "1023"
                        "itemHostRev" => array:3 [
                          "pii" => "S0090825820338087"
                           …2
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            92 => array:3 [
              "identificador" => "bib0960"
              "etiqueta" => "93"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Assessing Psoriasis Severity and Outcomes for Clinical Trials and Routine Clinical Practice"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.det.2014.09.005"
                      "Revista" => array:6 [
                        "tituloSerie" => "Dermatol Clin&#46;"
                        "fecha" => "2015"
                        "volumen" => "33"
                        "paginaInicial" => "57"
                        "paginaFinal" => "71"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            93 => array:3 [
              "identificador" => "bib0965"
              "etiqueta" => "94"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Adaptaci&#243;n transcultural al espa&#241;ol del cuestionario Dermatology Life Quality Index &#40;DLQI&#41;&#58; El &#205;ndice de Calidad de Vida en Dermatolog&#237;a &#124; Actas Dermo-Sifiliogr&#225;ficas &#91;consultado 1 Jul 2022&#93;&#46; Disponible en&#58; <a target="_blank" href="https://www.actasdermo.org/es-adaptacion-transcultural-al-espanol-del-articulo-13003408">https&#58;&#47;&#47;www&#46;actasdermo&#46;org&#47;es-adaptacion-transcultural-al-espanol-del-articulo-13003408</a>&#46;"
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "es"
  "url" => "/00017310/0000011400000005/v2_202306061222/S000173102300056X/v2_202306061222/es/main.assets"
  "Apartado" => array:4 [
    "identificador" => "6238"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Documento de consenso"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/00017310/0000011400000005/v2_202306061222/S000173102300056X/v2_202306061222/es/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S000173102300056X?idApp=UINPBA000044"
]
Compartir
Información de la revista

Estadísticas

Siga este enlace para acceder al texto completo del artículo

DOCUMENTO DE CONSENSO
Abordaje común del paciente con psoriasis y riesgo de esteatosis hepática metabólica: recomendaciones de un grupo de expertos multidisciplinar
Common Approach to Metabolic-Associated Fatty Liver Disease in Patients With Psoriasis: Consensus-Based Recommendations From a Multidisciplinary Group of Experts
J.M. Carrascosaa,
Autor para correspondencia
jmcarrascosac@hotmail.com

Autor para correspondencia.
, E. Vilarrasab, I. Belinchónc, P. Herranzd, J. Crespoe, F. Guimeráf, A. Olveirag, en representación del Grupo de Trabajo para el Abordaje Común de la Psoriasis y la EHmet (GACPE)
a Departamento de Dermatología, Hospital Universitario Germans Trias i Pujol, Universitat Autònoma de Barcelona. IGTP Badalona, Barcelona, España
b Departamento de Dermatología, Hospital Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, España
c Departamento de Dermatología, Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria y Biomédica (ISABIAL), Universidad Miguel Hernández de Elche, Alicante, España
d Departamento de Dermatología, Hospital Universitario La Paz, Madrid, España
e Servicio de Gastroenterología y Hepatología, Hospital Universitario Marqués de Valdecilla. IDIVAL. Escuela de Medicina. Universidad de Cantabria, Santander, España
f Servicio de Dermatología y Patología, Hospital Universitario de Canarias, La Laguna, España
g Servicio de Aparato Digestivo, Hospital Universitario La Paz, Madrid, España
Leído
5265
Veces
se ha leído el artículo
1524
Total PDF
3741
Total HTML
Compartir estadísticas
 array:24 [
  "pii" => "S000173102300056X"
  "issn" => "00017310"
  "doi" => "10.1016/j.ad.2023.01.004"
  "estado" => "S300"
  "fechaPublicacion" => "2023-05-01"
  "aid" => "3366"
  "copyright" => "AEDV"
  "copyrightAnyo" => "2023"
  "documento" => "article"
  "crossmark" => 1
  "subdocumento" => "pgl"
  "cita" => "Actas Dermosifiliogr. 2023;114:392-401"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:1 [
    "total" => 0
  ]
  "itemSiguiente" => array:18 [
    "pii" => "S0001731023002922"
    "issn" => "00017310"
    "doi" => "10.1016/j.ad.2023.04.013"
    "estado" => "S300"
    "fechaPublicacion" => "2023-05-01"
    "aid" => "3454"
    "copyright" => "AEDV"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "pgl"
    "cita" => "Actas Dermosifiliogr. 2023;114:T392-T401"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:14 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Consensus Document</span>"
      "titulo" => " Common Approach to Metabolic-Associated Fatty Liver Disease in Patients With Psoriasis&#58; Consensus-Based Recommendations From a Multidisciplinary Group of Experts"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:3 [
        0 => "en"
        1 => "en"
        2 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "T392"
          "paginaFinal" => "T401"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Abordaje com&#250;n del paciente con psoriasis y riesgo de esteatosis hep&#225;tica metab&#243;lica&#58; recomendaciones de un grupo de expertos multidisciplinar"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 1
        "multimedia" => array:5 [
          "identificador" => "fig0015"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => false
          "mostrarDisplay" => true
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "fx1.jpeg"
              "Alto" => 301
              "Ancho" => 1333
              "Tamanyo" => 31770
            ]
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "J&#46;M&#46; Carrascosa, E&#46; Vilarrasa, I&#46; Belinch&#243;n, P&#46; Herranz, J&#46; Crespo, F&#46; Guimer&#225;, A&#46; Olveira"
          "autores" => array:8 [
            0 => array:2 [
              "nombre" => "J&#46;M&#46;"
              "apellidos" => "Carrascosa"
            ]
            1 => array:2 [
              "nombre" => "E&#46;"
              "apellidos" => "Vilarrasa"
            ]
            2 => array:2 [
              "nombre" => "I&#46;"
              "apellidos" => "Belinch&#243;n"
            ]
            3 => array:2 [
              "nombre" => "P&#46;"
              "apellidos" => "Herranz"
            ]
            4 => array:2 [
              "nombre" => "J&#46;"
              "apellidos" => "Crespo"
            ]
            5 => array:2 [
              "nombre" => "F&#46;"
              "apellidos" => "Guimer&#225;"
            ]
            6 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Olveira"
            ]
            7 => array:1 [
              "colaborador" => "on behalf of the Working Group for the Common Approach to Psoriasis and MAFLD &#40;GACPE&#41;"
            ]
          ]
        ]
      ]
      "resumen" => array:1 [
        0 => array:3 [
          "titulo" => "Graphical abstract"
          "clase" => "graphical"
          "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall"><elsevierMultimedia ident="fig0015"></elsevierMultimedia></p></span>"
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731023002922?idApp=UINPBA000044"
    "url" => "/00017310/0000011400000005/v2_202306061222/S0001731023002922/v2_202306061222/en/main.assets"
  ]
  "itemAnterior" => array:18 [
    "pii" => "S0001731023003253"
    "issn" => "00017310"
    "doi" => "10.1016/j.ad.2023.04.027"
    "estado" => "S300"
    "fechaPublicacion" => "2023-05-01"
    "aid" => "3475"
    "copyright" => "AEDV"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "fla"
    "cita" => "Actas Dermosifiliogr. 2023;114:T382-T391"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "es" => array:13 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">ORIGINAL</span>"
      "titulo" => " Necesidades cl&#237;nicas no satisfechas y patrones de tratamiento de los pacientes pedi&#225;tricos con psoriasis&#58; estudio de evidencia en el mundo real en Espa&#241;a"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "T382"
          "paginaFinal" => "T391"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Clinical Unmet Needs and Treatment Patterns of Paediatric Psoriasis Patients&#58; A Real-World Evidence Study in Spain"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0015"
          "etiqueta" => "Figura 3"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr3.jpeg"
              "Alto" => 2822
              "Ancho" => 3163
              "Tamanyo" => 486988
            ]
          ]
          "descripcion" => array:1 [
            "es" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Pacientes que recibieron solo terapia t&#243;pica y que ten&#237;an experiencia biol&#243;gica&#44; en general&#44; y por gravedad antes del inicio del tratamiento actual &#40;An&#225;lisis 3&#41;&#46; A&#41; Gr&#225;ficos de barras que muestran la proporci&#243;n de pacientes que solo hab&#237;an recibido terapia t&#243;pica alguna vez&#44; en general&#44; y en pacientes con enfermedad leve y moderada a grave a juicio del m&#233;dico antes del inicio del tratamiento actual &#40;An&#225;lisis 3&#41;&#46; B&#41; Gr&#225;ficos circulares que ilustran la frecuencia de pacientes sin tratamiento biol&#243;gico previo y aquellos que ya lo han recibido&#44; con enfermedad moderada&#44; grave y de moderada a grave&#44; determinada por el m&#233;dico en el momento del inicio del tratamiento actual &#40;An&#225;lisis 3&#41;&#46;</p> <p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">n&#58; n&#250;mero de pacientes con resultado&#59; N&#58; n&#250;mero total de pacientes en el grupo&#59; Pso&#58; psoriasis&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "R&#46; de Lucas, A&#46; Vicente, C&#46; Richardson, J&#46; Lucas, L&#46; Gillespie-Akar, L&#46; G&#243;mez-Labrador, A&#46; Torrelo"
          "autores" => array:7 [
            0 => array:2 [
              "nombre" => "R&#46;"
              "apellidos" => "de Lucas"
            ]
            1 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Vicente"
            ]
            2 => array:2 [
              "nombre" => "C&#46;"
              "apellidos" => "Richardson"
            ]
            3 => array:2 [
              "nombre" => "J&#46;"
              "apellidos" => "Lucas"
            ]
            4 => array:2 [
              "nombre" => "L&#46;"
              "apellidos" => "Gillespie-Akar"
            ]
            5 => array:2 [
              "nombre" => "L&#46;"
              "apellidos" => "G&#243;mez-Labrador"
            ]
            6 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Torrelo"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731023003253?idApp=UINPBA000044"
    "url" => "/00017310/0000011400000005/v2_202306061222/S0001731023003253/v2_202306061222/es/main.assets"
  ]
  "asociados" => array:1 [
    0 => array:18 [
      "pii" => "S0001731023002922"
      "issn" => "00017310"
      "doi" => "10.1016/j.ad.2023.04.013"
      "estado" => "S300"
      "fechaPublicacion" => "2023-05-01"
      "aid" => "3454"
      "copyright" => "AEDV"
      "documento" => "article"
      "crossmark" => 1
      "subdocumento" => "pgl"
      "cita" => "Actas Dermosifiliogr. 2023;114:T392-T401"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:1 [
        "total" => 0
      ]
      "en" => array:14 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Consensus Document</span>"
        "titulo" => " Common Approach to Metabolic-Associated Fatty Liver Disease in Patients With Psoriasis&#58; Consensus-Based Recommendations From a Multidisciplinary Group of Experts"
        "tienePdf" => "en"
        "tieneTextoCompleto" => "en"
        "tieneResumen" => array:3 [
          0 => "en"
          1 => "en"
          2 => "es"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "T392"
            "paginaFinal" => "T401"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "es" => array:1 [
            "titulo" => "Abordaje com&#250;n del paciente con psoriasis y riesgo de esteatosis hep&#225;tica metab&#243;lica&#58; recomendaciones de un grupo de expertos multidisciplinar"
          ]
        ]
        "contieneResumen" => array:2 [
          "en" => true
          "es" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "en" => true
        ]
        "contienePdf" => array:1 [
          "en" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 1
          "multimedia" => array:5 [
            "identificador" => "fig0015"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => false
            "mostrarDisplay" => true
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "fx1.jpeg"
                "Alto" => 301
                "Ancho" => 1333
                "Tamanyo" => 31770
              ]
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "J&#46;M&#46; Carrascosa, E&#46; Vilarrasa, I&#46; Belinch&#243;n, P&#46; Herranz, J&#46; Crespo, F&#46; Guimer&#225;, A&#46; Olveira"
            "autores" => array:8 [
              0 => array:2 [
                "nombre" => "J&#46;M&#46;"
                "apellidos" => "Carrascosa"
              ]
              1 => array:2 [
                "nombre" => "E&#46;"
                "apellidos" => "Vilarrasa"
              ]
              2 => array:2 [
                "nombre" => "I&#46;"
                "apellidos" => "Belinch&#243;n"
              ]
              3 => array:2 [
                "nombre" => "P&#46;"
                "apellidos" => "Herranz"
              ]
              4 => array:2 [
                "nombre" => "J&#46;"
                "apellidos" => "Crespo"
              ]
              5 => array:2 [
                "nombre" => "F&#46;"
                "apellidos" => "Guimer&#225;"
              ]
              6 => array:2 [
                "nombre" => "A&#46;"
                "apellidos" => "Olveira"
              ]
              7 => array:1 [
                "colaborador" => "on behalf of the Working Group for the Common Approach to Psoriasis and MAFLD &#40;GACPE&#41;"
              ]
            ]
          ]
        ]
        "resumen" => array:1 [
          0 => array:3 [
            "titulo" => "Graphical abstract"
            "clase" => "graphical"
            "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall"><elsevierMultimedia ident="fig0015"></elsevierMultimedia></p></span>"
          ]
        ]
      ]
      "idiomaDefecto" => "en"
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731023002922?idApp=UINPBA000044"
      "url" => "/00017310/0000011400000005/v2_202306061222/S0001731023002922/v2_202306061222/en/main.assets"
    ]
  ]
  "es" => array:21 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">DOCUMENTO DE CONSENSO</span>"
    "titulo" => "Abordaje com&#250;n del paciente con psoriasis y riesgo de esteatosis hep&#225;tica metab&#243;lica&#58; recomendaciones de un grupo de expertos multidisciplinar"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "392"
        "paginaFinal" => "401"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "J&#46;M&#46; Carrascosa, E&#46; Vilarrasa, I&#46; Belinch&#243;n, P&#46; Herranz, J&#46; Crespo, F&#46; Guimer&#225;, A&#46; Olveira"
        "autores" => array:8 [
          0 => array:4 [
            "nombre" => "J&#46;M&#46;"
            "apellidos" => "Carrascosa"
            "email" => array:1 [
              0 => "jmcarrascosac@hotmail.com"
            ]
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "E&#46;"
            "apellidos" => "Vilarrasa"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "I&#46;"
            "apellidos" => "Belinch&#243;n"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "P&#46;"
            "apellidos" => "Herranz"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "aff0020"
              ]
            ]
          ]
          4 => array:3 [
            "nombre" => "J&#46;"
            "apellidos" => "Crespo"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">e</span>"
                "identificador" => "aff0025"
              ]
            ]
          ]
          5 => array:3 [
            "nombre" => "F&#46;"
            "apellidos" => "Guimer&#225;"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">f</span>"
                "identificador" => "aff0030"
              ]
            ]
          ]
          6 => array:3 [
            "nombre" => "A&#46;"
            "apellidos" => "Olveira"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">g</span>"
                "identificador" => "aff0035"
              ]
            ]
          ]
          7 => array:2 [
            "colaborador" => "en representaci&#243;n del Grupo de Trabajo para el Abordaje Com&#250;n de la Psoriasis y la EHmet &#40;GACPE&#41;"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#9674;</span>"
                "identificador" => "fn0005"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:7 [
          0 => array:3 [
            "entidad" => "Departamento de Dermatolog&#237;a&#44; Hospital Universitario Germans Trias i Pujol&#44; Universitat Aut&#242;noma de Barcelona&#46; IGTP Badalona&#44; Barcelona&#44; Espa&#241;a"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Departamento de Dermatolog&#237;a&#44; Hospital Santa Creu i Sant Pau&#44; Universitat Aut&#242;noma de Barcelona&#44; Barcelona&#44; Espa&#241;a"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
          2 => array:3 [
            "entidad" => "Departamento de Dermatolog&#237;a&#44; Hospital General Universitario de Alicante&#44; Instituto de Investigaci&#243;n Sanitaria y Biom&#233;dica &#40;ISABIAL&#41;&#44; Universidad Miguel Hern&#225;ndez de Elche&#44; Alicante&#44; Espa&#241;a"
            "etiqueta" => "c"
            "identificador" => "aff0015"
          ]
          3 => array:3 [
            "entidad" => "Departamento de Dermatolog&#237;a&#44; Hospital Universitario La Paz&#44; Madrid&#44; Espa&#241;a"
            "etiqueta" => "d"
            "identificador" => "aff0020"
          ]
          4 => array:3 [
            "entidad" => "Servicio de Gastroenterolog&#237;a y Hepatolog&#237;a&#44; Hospital Universitario Marqu&#233;s de Valdecilla&#46; IDIVAL&#46; Escuela de Medicina&#46; Universidad de Cantabria&#44; Santander&#44; Espa&#241;a"
            "etiqueta" => "e"
            "identificador" => "aff0025"
          ]
          5 => array:3 [
            "entidad" => "Servicio de Dermatolog&#237;a y Patolog&#237;a&#44; Hospital Universitario de Canarias&#44; La Laguna&#44; Espa&#241;a"
            "etiqueta" => "f"
            "identificador" => "aff0030"
          ]
          6 => array:3 [
            "entidad" => "Servicio de Aparato Digestivo&#44; Hospital Universitario La Paz&#44; Madrid&#44; Espa&#241;a"
            "etiqueta" => "g"
            "identificador" => "aff0035"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Autor para correspondencia&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "en" => array:1 [
        "titulo" => "Common Approach to Metabolic-Associated Fatty Liver Disease in Patients With Psoriasis&#58; Consensus-Based Recommendations From a Multidisciplinary Group of Experts"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 1
      "multimedia" => array:5 [
        "identificador" => "fig0015"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "fx1.jpeg"
            "Alto" => 300
            "Ancho" => 1333
            "Tamanyo" => 37221
          ]
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Introducci&#243;n</span><p id="par0005" class="elsevierStylePara elsevierViewall">Aproximadamente 125 millones de personas sufren psoriasis a nivel mundial &#40;1-3&#37;&#41;&#44; m&#225;s de un mill&#243;n en Espa&#241;a &#40;2&#44;69&#37;&#41;<a class="elsevierStyleCrossRefs" href="#bib0470"><span class="elsevierStyleSup">1&#44;2</span></a>&#46; Es una enfermedad inflamatoria sist&#233;mica&#44; con efectos sin&#233;rgicos con otras enfermedades inflamatorias inmunomediadas &#40;IMIDs&#41;<a class="elsevierStyleCrossRefs" href="#bib0475"><span class="elsevierStyleSup">2&#44;3</span></a>&#46; Por este motivo&#44; reconocer el impacto de las comorbilidades asociadas es esencial para un manejo integral<a class="elsevierStyleCrossRef" href="#bib0475"><span class="elsevierStyleSup">2</span></a>&#46;</p><p id="par0010" class="elsevierStylePara elsevierViewall">Entre estas comorbilidades se encuentra la hasta ahora denominada enfermedad hep&#225;tica grasa no alcoh&#243;lica&#59; que en esta revisi&#243;n denominaremos esteatosis hep&#225;tica metab&#243;lica &#40;EHmet&#41;&#44; siguiendo el consenso promovido por la Asociaci&#243;n Espa&#241;ola para el Estudio del H&#237;gado &#40;AEEH&#41;<a class="elsevierStyleCrossRef" href="#bib0485"><span class="elsevierStyleSup">4</span></a>&#46; La EHmet engloba un espectro de lesiones hep&#225;ticas&#44; desde la acumulaci&#243;n de grasa en el h&#237;gado considerada un trastorno metab&#243;lico con escaso potencial evolutivo&#44; hasta la forma inflamatoria o esteatohepatitis&#44; con riesgo de evolucionar a cirrosis y sus complicaciones&#46; En la mayor&#237;a de los casos&#44; es asintom&#225;tica y se asocia con el s&#237;ndrome metab&#243;lico &#40;SM&#41;<a class="elsevierStyleCrossRef" href="#bib0490"><span class="elsevierStyleSup">5</span></a>&#46; De hecho&#44; se reconoce como la manifestaci&#243;n hep&#225;tica del SM y puede aparecer antes que otras manifestaciones<a class="elsevierStyleCrossRefs" href="#bib0495"><span class="elsevierStyleSup">6&#44;7</span></a>&#46; El SM se define como un conjunto de anomal&#237;as metab&#243;licas&#44; entre las que las hep&#225;ticas se consideran fundamentales<a class="elsevierStyleCrossRefs" href="#bib0495"><span class="elsevierStyleSup">6&#44;7</span></a>&#46; La EHmet presenta un amplio espectro cl&#237;nico &#40;<a class="elsevierStyleCrossRef" href="#fig0005">fig&#46; 1</a>&#41;&#44; de naturaleza din&#225;mica&#44; con periodos de progresi&#243;n&#44; regresi&#243;n y estabilidad<a class="elsevierStyleCrossRefs" href="#bib0505"><span class="elsevierStyleSup">8&#44;9</span></a>&#46; La gen&#233;tica y los cambios en el estilo de vida explican parcialmente esta variabilidad&#46; Otros factores causantes de variabilidad de la enfermedad y su respuesta al tratamiento son la edad&#44; la raza&#44; el consumo de alcohol&#44; el sexo y la microbiota<a class="elsevierStyleCrossRef" href="#bib0490"><span class="elsevierStyleSup">5</span></a>&#46;</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0015" class="elsevierStylePara elsevierViewall">La prevalencia de la EHmet aumenta progresiva y paralelamente a la prevalencia del SM&#44; la obesidad y la diabetes mellitus tipo 2 &#40;DM2&#41;<a class="elsevierStyleCrossRefs" href="#bib0505"><span class="elsevierStyleSup">8&#44;10</span></a>&#46; Se estima que la EHmet afecta a 25&#37; de la poblaci&#243;n&#44; llegando a 55&#44;5&#37; en pacientes con DM2&#46; Aunque se desconoce el porcentaje de pacientes con EHmet que desarrollan esteatohepatitis no alcoh&#243;lica &#40;EHNA&#41;&#44; se sabe que supera 10&#37;&#46; La EHNA se diagnostica mediante biopsia en 29&#44;9&#37; de los pacientes con EHmet&#44; pero recientemente esta tasa parece haber aumentado hasta 59&#44;1&#37;<a class="elsevierStyleCrossRef" href="#bib0490"><span class="elsevierStyleSup">5</span></a>&#46;</p><p id="par0020" class="elsevierStylePara elsevierViewall">La EHNA progresa a fibrosis en 40&#44;76&#37; de los pacientes<a class="elsevierStyleCrossRef" href="#bib0505"><span class="elsevierStyleSup">8</span></a>&#46; En Espa&#241;a&#44; se estima que la prevalencia de la EHmet es de 25&#44;8&#37;&#44; y el grado de fibrosis significativa&#44; estimada mediante combinaci&#243;n secuencial de elastometr&#237;a de transici&#243;n &#40;ET&#41; y biopsia hep&#225;tica&#44; es de 2&#44;8&#37;<a class="elsevierStyleCrossRef" href="#bib0515"><span class="elsevierStyleSup">10</span></a>&#46;</p><p id="par0025" class="elsevierStylePara elsevierViewall">El pron&#243;stico del paciente con EHmet viene condicionado por la evoluci&#243;n hacia EHNA&#44; fibrosis y sus comorbilidades&#59; la morbimortalidad hep&#225;tica aumenta fundamentalmente a partir del estadio de fibrosis avanzada<a class="elsevierStyleCrossRefs" href="#bib0515"><span class="elsevierStyleSup">10&#44;11</span></a>&#46; Por ello la EHmet es un importante problema de salud y una causa importante de trasplante hep&#225;tico<a class="elsevierStyleCrossRefs" href="#bib0510"><span class="elsevierStyleSup">9&#44;12</span></a>&#46;</p><p id="par0030" class="elsevierStylePara elsevierViewall">Existen numerosas evidencias de la relaci&#243;n entre psoriasis y EHmet<a class="elsevierStyleCrossRef" href="#bib0540"><span class="elsevierStyleSup">15</span></a>&#46; En general&#44; la prevalencia de EHmet aumenta en pacientes con psoriasis m&#225;s grave<a class="elsevierStyleCrossRefs" href="#bib0545"><span class="elsevierStyleSup">16&#44;17</span></a>&#46; Phan et al&#46; demostraron una prevalencia de EHmet duplicada en pacientes con psoriasis&#44; comparados con no psori&#225;sicos&#44; confirmando datos publicados anteriormente<a class="elsevierStyleCrossRefs" href="#bib0540"><span class="elsevierStyleSup">15&#44;18</span></a>&#46; En Espa&#241;a&#44; 42&#44;3&#37; de los pacientes con psoriasis presentan EHmet<a class="elsevierStyleCrossRef" href="#bib0560"><span class="elsevierStyleSup">19</span></a>&#46; Adem&#225;s&#44; la gravedad de la psoriasis se correlaciona directamente con la de la enfermedad hep&#225;tica<a class="elsevierStyleCrossRef" href="#bib0565"><span class="elsevierStyleSup">20</span></a>&#46; En concordancia&#44; un estudio transversal ha detectado que la fibrosis avanzada es m&#225;s prevalente en pacientes con psoriasis que en controles sanos&#44; siendo la psoriasis un predictor significativo de fibrosis hep&#225;tica avanzada independientemente de otros factores como edad&#44; sexo&#44; &#237;ndice de masa corporal&#44; hipertensi&#243;n y diabetes<a class="elsevierStyleCrossRef" href="#bib0570"><span class="elsevierStyleSup">21</span></a>&#46; De hecho&#44; la psoriasis es un factor de riesgo independiente de EHmet<a class="elsevierStyleCrossRefs" href="#bib0575"><span class="elsevierStyleSup">22&#44;23</span></a>&#46; Asimismo&#44; la hipertensi&#243;n&#44; la hiperglicemia y la obesidad son los principales factores de riesgo de EHmet en pacientes con psoriasis y la asociaci&#243;n entre psoriasis y EHmet es independiente de factores de confusi&#243;n&#44; lo que confirma una fisiopatolog&#237;a com&#250;n que implica v&#237;as inflamatorias y predisposici&#243;n gen&#233;tica<a class="elsevierStyleCrossRef" href="#bib0540"><span class="elsevierStyleSup">15</span></a>&#46; Ambas tienen como etiolog&#237;a com&#250;n una inflamaci&#243;n cr&#243;nica de baja intensidad&#44; que implica adipocinas involucradas en el balance energ&#233;tico y citocinas inflamatorias&#58; interleucina- 17 &#40;IL-17&#41;&#44; factor de necrosis tumoral-&#945; &#40;TNF-&#945;&#41; o interleucina-6 &#40;IL-6&#41;<a class="elsevierStyleCrossRefs" href="#bib0480"><span class="elsevierStyleSup">3&#44;24&#44;25</span></a>&#46;</p><p id="par0035" class="elsevierStylePara elsevierViewall">Estos precedentes permiten sugerir un abordaje precoz de los pacientes con psoriasis realizando un cribado de la EHmet<a class="elsevierStyleCrossRef" href="#bib0595"><span class="elsevierStyleSup">26</span></a>&#46; La AEEH ha publicado recientemente un consenso sobre detecci&#243;n y derivaci&#243;n de enfermedades hep&#225;ticas prevalentes ocultas&#46; Dos conclusiones operativas del consenso fueron&#58; 1&#41; Hacer valoraci&#243;n y seguimiento de una posible enfermedad hep&#225;tica cr&#243;nica en pacientes con enfermedades dermatol&#243;gicas inmunomediadas&#59; y 2&#41; la prevalencia de hepatopat&#237;a cr&#243;nica aumenta en estas patolog&#237;as&#44; tanto por mecanismos inmunol&#243;gicos como inflamatorios&#44; o por hepatotoxicidad<a class="elsevierStyleCrossRef" href="#bib0595"><span class="elsevierStyleSup">26</span></a>&#46;</p><p id="par0040" class="elsevierStylePara elsevierViewall">Para incentivar el manejo multidisciplinar&#44; y con el objetivo de actualizar las recomendaciones de cribado&#44; diagn&#243;stico&#44; monitorizaci&#243;n y criterios de derivaci&#243;n ante la sospecha de EHmet en pacientes con psoriasis&#44; un panel de expertos ha elaborado este documento&#44; bas&#225;ndose en la evidencia cient&#237;fica disponible y en su experiencia en pr&#225;ctica cl&#237;nica real&#46;</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Metodolog&#237;a</span><p id="par0045" class="elsevierStylePara elsevierViewall">Para elaborar este documento siete dermat&#243;logos y cinco hepat&#243;logos&#44; especializados en el manejo de la psoriasis y la EHmet&#44; constituyeron un grupo de trabajo&#46; La metodolog&#237;a utilizada se bas&#243; en el denominado &#171;m&#233;todo formal&#187;<a class="elsevierStyleCrossRefs" href="#bib0600"><span class="elsevierStyleSup">27&#44;28</span></a>&#46; Se empez&#243; evaluando la evidencia cient&#237;fica disponible y cumplimentando varios cuestionarios dise&#241;ados <span class="elsevierStyleItalic">ad hoc</span> para identificar puntos clave sobre identificaci&#243;n&#44; cribado&#44; diagn&#243;stico y manejo de la psoriasis y el riesgo de enfermedad hep&#225;tica&#46; Posteriormente&#44; se analizaron los aspectos cl&#237;nicos de definici&#243;n y manejo del paciente de riesgo en tres reuniones&#46; En la &#250;ltima reuni&#243;n&#44; se desarroll&#243; un algoritmo de manejo del paciente de riesgo y unas recomendaciones de diagn&#243;stico y monitorizaci&#243;n basadas en las principales gu&#237;as de pr&#225;ctica cl&#237;nica &#40;GPC&#41; y en la experiencia en pr&#225;ctica cl&#237;nica real del grupo de expertos&#46;</p><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Identificaci&#243;n de los pacientes con psoriasis y riesgo de enfermedad hep&#225;tica</span><p id="par0050" class="elsevierStylePara elsevierViewall">El panel recomienda cribar los pacientes diagnosticados de psoriasis siguiendo las GPC nacionales<a class="elsevierStyleCrossRefs" href="#bib0610"><span class="elsevierStyleSup">29&#44;30</span></a>&#44; independientemente del tratamiento y el tiempo desde el diagn&#243;stico&#44; siempre que presenten al menos una de las condiciones contempladas como criterios acompa&#241;antes del hallazgo de esteatosis en el diagn&#243;stico de la EHmet<a class="elsevierStyleCrossRef" href="#bib0620"><span class="elsevierStyleSup">31</span></a>&#44; es decir&#44; sobrepeso u obesidad&#44; DM2&#44; y&#47;o evidencias de alteraciones metab&#243;licas&#44; las cuales pueden resumirse as&#237;&#58;<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005"><span class="elsevierStyleLabel">&#8226;</span><p id="par0055" class="elsevierStylePara elsevierViewall">Circunferencia de la cintura &#8805; 102 cm en hombres y &#8805; 88 cm en mujeres&#46;</p></li><li class="elsevierStyleListItem" id="lsti0010"><span class="elsevierStyleLabel">&#8226;</span><p id="par0060" class="elsevierStylePara elsevierViewall">Presi&#243;n arterial &#8805; 130&#47;85 mmHg o tratamiento farmacol&#243;gico espec&#237;fico&#46;</p></li><li class="elsevierStyleListItem" id="lsti0015"><span class="elsevierStyleLabel">&#8226;</span><p id="par0065" class="elsevierStylePara elsevierViewall">Triglic&#233;ridos plasm&#225;ticos &#8805; 150 mg&#47;dL &#40;&#8805; 1&#44;70&#160;mmol&#47;L&#41; o tratamiento farmacol&#243;gico espec&#237;fico&#46;</p></li><li class="elsevierStyleListItem" id="lsti0020"><span class="elsevierStyleLabel">&#8226;</span><p id="par0070" class="elsevierStylePara elsevierViewall">Colesterol de HDL en plasma &#60; 40&#160;mg&#47;dL &#40;&#60; 1&#44;0&#160;mmol&#47;L&#41; para hombres y &#60; 50&#160;mg&#47;dL &#40;&#60; 1&#44;3&#160;mmol&#47;L&#41; para mujeres&#44; o tratamiento farmacol&#243;gico espec&#237;fico&#46;</p></li><li class="elsevierStyleListItem" id="lsti0025"><span class="elsevierStyleLabel">&#8226;</span><p id="par0075" class="elsevierStylePara elsevierViewall">Prediabetes &#40;niveles de glucosa en ayunas&#58; 100 a 125&#160;mg&#47;dL &#91;5&#44;6 a 6&#44;9&#160;mmol&#47;L&#93;&#44; o dos horas tras sobrecarga oral&#58; 140 a 199&#160;mg&#47;dL &#91;7&#44;8 a 11&#44;0&#160;mmol&#47;L&#93; o HbA1c&#58; 5&#44;7 a 6&#44;4&#37; &#91;39 a 47&#160;mmol&#47;mol&#93;&#41;&#46;</p></li><li class="elsevierStyleListItem" id="lsti0030"><span class="elsevierStyleLabel">&#8226;</span><p id="par0080" class="elsevierStylePara elsevierViewall">HOMA-IR &#40;modelo homeost&#225;tico para evaluar la resistencia a la insulina&#41; &#8805; 2&#44;5&#46;</p></li><li class="elsevierStyleListItem" id="lsti0035"><span class="elsevierStyleLabel">&#8226;</span><p id="par0085" class="elsevierStylePara elsevierViewall">Nivel de prote&#237;na C reactiva de alta sensibilidad en plasma &#62; 2&#160;mg&#47;L&#46;</p></li></ul></p><p id="par0090" class="elsevierStylePara elsevierViewall">Ante un paciente con psoriasis y al menos un factor de riesgo de SM&#44; se debe valorar el riesgo o presencia de enfermedad hep&#225;tica&#46; Al ser una enfermedad silenciosa&#44; las GPC nacionales e internacionales aconsejan la identificaci&#243;n precoz del riesgo de estadios progresivos de EHmet&#44; desde la esteatosis a estadios avanzados como la fibrosis&#44; utilizando m&#233;todos no invasivos como el FIB-4<a class="elsevierStyleCrossRefs" href="#bib0515"><span class="elsevierStyleSup">10&#44;30&#44;31</span></a>&#46; Se descarta usar valores aislados de transaminasas como m&#233;todo &#250;nico para el diagn&#243;stico precoz de la EHmet&#44; ya que pueden ser normales incluso con fibrosis avanzada<a class="elsevierStyleCrossRef" href="#bib0625"><span class="elsevierStyleSup">32</span></a>&#46;</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Recomendaciones de cribado de la EHmet</span><p id="par0095" class="elsevierStylePara elsevierViewall">Tras identificar un paciente de riesgo&#44; se inicia la primera etapa del algoritmo de cribado y seguimiento recomendado &#40;<a class="elsevierStyleCrossRef" href="#fig0010">fig&#46; 2</a>&#41;&#46;</p><elsevierMultimedia ident="fig0010"></elsevierMultimedia><p id="par0100" class="elsevierStylePara elsevierViewall">No existe un consenso sobre estrategias de diagn&#243;stico y puntos de corte de herramientas no invasivas &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">tabla 1</a>&#41; empleadas en lugar de la biopsia hep&#225;tica &#40;prueba de referencia<a class="elsevierStyleCrossRef" href="#bib0630"><span class="elsevierStyleSup">33</span></a>&#44; pero con complicaciones&#41;<a class="elsevierStyleCrossRefs" href="#bib0515"><span class="elsevierStyleSup">10&#44;22&#44;31</span></a>&#46; Las GPC recomiendan combinar &#237;ndices serol&#243;gicos y la ET&#44; que reduce aproximadamente en 50-60&#37; la necesidad de biopsia y ofrece un diagn&#243;stico preciso<a class="elsevierStyleCrossRef" href="#bib0635"><span class="elsevierStyleSup">34</span></a>&#44; empleando &#237;ndices serol&#243;gicos de fibrosis como primera herramienta de cribado y&#44; en caso de riesgo elevado&#44; la ET&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0105" class="elsevierStylePara elsevierViewall">La <a class="elsevierStyleCrossRef" href="#tbl0005">tabla 1</a> enumera diversas herramientas no invasivas de cribado de la fibrosis hep&#225;tica&#46; Se consider&#243; que el marcador serol&#243;gico fibrosis-4 &#40;FIB-4&#41; es la herramienta m&#225;s adecuada para iniciar el cribado en dermatolog&#237;a&#44; ya que se ha validado externamente para el cribado de fibrosis en h&#237;gado graso de pacientes con psoriasis&#44; es de f&#225;cil petici&#243;n y manejo y est&#225; recomendado por las GPC<a class="elsevierStyleCrossRefs" href="#bib0515"><span class="elsevierStyleSup">10&#44;22&#44;31</span></a>&#46; El FIB-4 utiliza el recuento plaquetario&#44; la edad y los valores de aspartato aminotransferasa &#40;AST&#41; y alanina aminotransferasa &#40;ALT&#41;&#59; ofrece un alto valor predictivo negativo &#40;VPN&#41; para el diagn&#243;stico de fibrosis avanzada &#40;F3-F4&#41;&#44; permitiendo evitar la biopsia hep&#225;tica<a class="elsevierStyleCrossRefs" href="#bib0640"><span class="elsevierStyleSup">35&#44;36</span></a>&#46; Valores del FIB-4 inferiores a 1&#44;30 excluyen la fibrosis avanzada con un VPN de 85&#37;&#59; valores superiores a 2&#44;67 indican fibrosis avanzada con un VPP de 79&#37;<a class="elsevierStyleCrossRef" href="#bib0650"><span class="elsevierStyleSup">37</span></a>&#46; No obstante&#44; hay que tener en cuenta el riesgo de falso positivo asociado al VPP&#44; la probabilidad relativamente elevada &#40;1&#47;3&#41; de obtener valores intermedios &#40;1&#44;30-2&#44;67&#41; y el efecto de la edad en la exactitud del pron&#243;stico &#40;se propone un valor umbral de FIB-4 &#61; 2 en mayores de 65 a&#241;os&#41;<a class="elsevierStyleCrossRef" href="#bib0655"><span class="elsevierStyleSup">38</span></a>&#46;</p><p id="par0110" class="elsevierStylePara elsevierViewall">No debe olvidarse que la precisi&#243;n del FIB-4 depende de la edad&#58; no es aplicable en menores de 35 a&#241;os y requiere valores de corte m&#225;s ajustados para incrementar su especificidad en mayores de 65<a class="elsevierStyleCrossRef" href="#bib0660"><span class="elsevierStyleSup">39</span></a>&#46; El <span class="elsevierStyleItalic">Hepamet Fibrosis Score</span> &#40;HFS&#41; es un panel serol&#243;gico m&#225;s espec&#237;fico &#40;con valores predictivos mayores que el FIB-4&#41; y preciso&#44; con menor incertidumbre diagn&#243;stica y la &#250;nica limitaci&#243;n de incluir el &#237;ndice HOMA&#44; que no suele obtenerse de rutina<a class="elsevierStyleCrossRef" href="#bib0665"><span class="elsevierStyleSup">40</span></a>&#46;</p><p id="par0115" class="elsevierStylePara elsevierViewall">Cuando el &#237;ndice utilizado sugiera riesgo bajo&#44; se recomienda seguimiento bianual por dermatolog&#237;a con reevaluaci&#243;n del &#237;ndice de riesgo<a class="elsevierStyleCrossRef" href="#bib0620"><span class="elsevierStyleSup">31</span></a>&#46; Con riesgo medio&#47;alto&#44; se recomienda la ET<a class="elsevierStyleCrossRefs" href="#bib0620"><span class="elsevierStyleSup">31&#44;38&#44;48</span></a>&#46; Esta t&#233;cnica ha demostrado ser efectiva para monitorizar peri&#243;dicamente la gravedad de la enfermedad y diagnostica con elevada precisi&#243;n los estadios avanzados de fibrosis &#40;F3-F4&#41; en correlaci&#243;n con las caracter&#237;sticas cl&#237;nicas del paciente<a class="elsevierStyleCrossRefs" href="#bib0710"><span class="elsevierStyleSup">49&#44;50</span></a> y sin a&#241;adir riesgos&#44; al ser una prueba inocua&#46; No obstante&#44; se debe tener en cuenta que&#44; independientemente de la ET&#44; un FIB-4 elevado indica riesgo aumentado&#59; por lo tanto&#44; la decisi&#243;n depender&#225; de la accesibilidad y utilidad de la ET &#40;c&#243;mo influir&#225; el resultado&#41;&#46; Asimismo&#44; se recomienda derivar para ET a pacientes con FIB-4 intermedio&#44; por su elevada incertidumbre&#46;</p><p id="par0120" class="elsevierStylePara elsevierViewall">Wong et al&#46; demostraron que el valor de ET &#61; 7&#44;9 kPa presenta la mayor precisi&#243;n &#40;sensibilidad 91&#37;&#44; especificidad 75&#37; y VPP 97&#37;&#41; para el diagn&#243;stico de fibrosis avanzada y cirrosis en pacientes con EHmet<a class="elsevierStyleCrossRef" href="#bib0720"><span class="elsevierStyleSup">51</span></a>&#46; Por ello&#44; el punto de corte recomendado en pacientes de riesgo elevado es 8 kPa&#46; Con FIB-4 elevado y ET &#8804; 8 kPa&#44; se reevaluar&#225; anualmente el FIB-4 y&#47;o se solicitar&#225; una nueva ET seg&#250;n disponibilidad&#46;</p><p id="par0125" class="elsevierStylePara elsevierViewall">Si se confirma una ET &#62;8 kPa&#44; con riesgo de fibrosis avanzada &#40;F3-F4&#41;&#44; el paciente se derivar&#225; al Servicio de Aparato Digestivo&#44; en donde se considerar&#225; el manejo m&#225;s adecuado &#40;<a class="elsevierStyleCrossRef" href="#fig0010">fig&#46; 2</a>&#41;&#46; Si la ET no estuviera disponible&#44; los pacientes con FIB-4 elevado deben derivarse a un especialista de digestivo&#46;</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Tratamientos actuales para la psoriasis e impacto sobre la EHmet</span><p id="par0130" class="elsevierStylePara elsevierViewall">Las recomendaciones del panel de expertos se centran en pautas generales a considerar en supuestos cl&#237;nicos frecuentes adaptables&#44; seg&#250;n criterio del especialista&#46;</p><p id="par0135" class="elsevierStylePara elsevierViewall">Las recomendaciones de dieta y ejercicio de las GPC son el pilar del tratamiento de la EHmet<a class="elsevierStyleCrossRef" href="#bib0620"><span class="elsevierStyleSup">31</span></a>&#46; Reducciones de peso &#8805; 10&#37; pueden resolver la EHNA y reducir la fibrosis al menos un estadio&#46; P&#233;rdidas de peso menores &#40;5-10&#37;&#41; pueden mejorar algunos componentes de la EHmet&#46; La dieta mediterr&#225;nea&#44; aun sin p&#233;rdida de peso&#44; reduce el contenido graso del h&#237;gado<a class="elsevierStyleCrossRef" href="#bib0725"><span class="elsevierStyleSup">52</span></a>&#46;</p><p id="par0140" class="elsevierStylePara elsevierViewall">Actualmente se est&#225;n desarrollando f&#225;rmacos para el tratamiento de la EHmet&#46; En la <a class="elsevierStyleCrossRef" href="#tbl0010">tabla 2</a> se enumeran algunos ensayos cl&#237;nicos de su eficacia y seguridad&#46;</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><p id="par0145" class="elsevierStylePara elsevierViewall">En pacientes con ET 6-8 kPa&#44; independientemente del FIB-4&#44; sin enfermedad hep&#225;tica grave&#44; se deben valorar los factores de SM&#44; evaluando el grado de enfermedad metab&#243;lica para estimar el riesgo de progresi&#243;n hacia fibrosis avanzada o cirrosis<a class="elsevierStyleCrossRef" href="#bib0500"><span class="elsevierStyleSup">7</span></a>&#46; As&#237;&#44; se determinar&#225; la monitorizaci&#243;n y pruebas complementarias a realizar con respecto a las recomendaciones en estos perfiles &#40;seguimiento anual y repetici&#243;n de FIB-4&#41;&#46;</p><p id="par0150" class="elsevierStylePara elsevierViewall">Los pacientes con psoriasis y hepatopat&#237;a tienen riesgo aumentado de hepatotoxicidad inducida por f&#225;rmacos &#40;<a class="elsevierStyleCrossRef" href="#tbl0015">tabla 3</a>&#41;<a class="elsevierStyleCrossRef" href="#bib0810"><span class="elsevierStyleSup">68</span></a>&#46; Metotrexato &#40;MTX&#41; es el f&#225;rmaco sist&#233;mico convencional m&#225;s utilizado en psoriasis moderada-grave debido a su coste-efectividad y larga trayectoria cl&#237;nica&#44; pero es hepatot&#243;xico y puede favorecer la fibrosis<a class="elsevierStyleCrossRefs" href="#bib0815"><span class="elsevierStyleSup">69&#8211;71</span></a>&#46;</p><elsevierMultimedia ident="tbl0015"></elsevierMultimedia><p id="par0155" class="elsevierStylePara elsevierViewall">Un reciente estudio espa&#241;ol en pacientes con psoriasis moderada-grave tratados con MTX demostr&#243; correlaci&#243;n entre la duraci&#243;n del tratamiento y el riesgo de fibrosis hep&#225;tica&#58; la proporci&#243;n de pacientes con riesgo de fibrosis avanzada &#40;FIB-4 &#62; 1&#44;3&#41; aument&#243; desde 18&#44;2&#37;&#44; con MTX administrado durante 16-24 semanas&#44; hasta 27&#44;3&#37; y 32&#44;3&#37;&#44; cuando el tratamiento dur&#243; 52-104 semanas y &#62; 104 semanas&#44; respectivamente<a class="elsevierStyleCrossRef" href="#bib0830"><span class="elsevierStyleSup">72</span></a>&#46; Shetty et al<span class="elsevierStyleItalic">&#46;</span> recomiendan adaptar la intensidad y frecuencia de monitorizaci&#243;n dependiendo de los factores de riesgo individuales&#44; y enfatizan el mayor riesgo de da&#241;o hep&#225;tico por MTX en pacientes con EHNA o EHNA-fibrosis<a class="elsevierStyleCrossRef" href="#bib0825"><span class="elsevierStyleSup">71</span></a>&#46;</p><p id="par0160" class="elsevierStylePara elsevierViewall">Se recomienda monitorizar el da&#241;o hep&#225;tico de pacientes con psoriasis tratados con esteat&#243;genos<a class="elsevierStyleCrossRef" href="#bib0810"><span class="elsevierStyleSup">68</span></a>&#46; Una reciente GPC considera que la amiodarona&#44; el metotrexato&#44; el tamoxifeno y los agentes quimioterap&#233;uticos 5-fluoracilo e irinotec&#225;n son factores de riesgo de EHmet y se deben mantener o retirar en funci&#243;n de sus beneficios potenciales frente al riesgo de progresi&#243;n de la enfermedad hep&#225;tica &#40;recomendaci&#243;n de grado B basada en la extrapolaci&#243;n de estudios de nivel 1 de evidencia&#41;<a class="elsevierStyleCrossRef" href="#bib0915"><span class="elsevierStyleSup">89</span></a>&#46;</p><p id="par0165" class="elsevierStylePara elsevierViewall">Se aconseja realizar ET a pacientes con FIB-4 bajo y tratamiento hepatot&#243;xico<a class="elsevierStyleCrossRefs" href="#bib0820"><span class="elsevierStyleSup">70&#44;89&#44;90</span></a>&#46; Ante pacientes con psoriasis moderada-grave&#44; tratamiento hepatot&#243;xico y ET &#8804; 8 kPa &#40;procedente del brazo FIB-4 alto o reevaluado con FIB-4 bajo debido al tratamiento&#41;&#44; se valorar&#225; continuar el tratamiento con f&#225;rmacos hepatot&#243;xicos seg&#250;n el balance riesgo-beneficio individualizado&#44; teniendo en cuenta las recomendaciones del hepat&#243;logo&#46; Se desaconsejan los f&#225;rmacos hepatot&#243;xicos en pacientes con FIB-4 alto y&#47;o ET &#62; 8 kPa&#44; debido al riesgo de fibrosis avanzada &#40;F3-F4&#41; &#40;<a class="elsevierStyleCrossRef" href="#tbl0020">tabla 4</a>&#41;&#46;</p><elsevierMultimedia ident="tbl0020"></elsevierMultimedia></span></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Discusi&#243;n</span><p id="par0170" class="elsevierStylePara elsevierViewall">La definici&#243;n consensuada entre dermat&#243;logos y hepat&#243;logos de criterios sencillos basados en la evidencia para identificar&#44; diagnosticar y monitorizar individuos de riesgo resulta fundamental para el manejo eficiente de la EHmet&#46; Las recomendaciones generales deber&#225;n adaptarse a las peculiaridades&#44; necesidades y posibilidades organizativas y asistenciales de los distintos centros y profesionales&#46;</p><p id="par0175" class="elsevierStylePara elsevierViewall">Debe considerarse la interacci&#243;n entre los tratamientos de la psoriasis y la EHmet&#44; teniendo en cuenta tanto la prevalencia de la patolog&#237;a hep&#225;tica como el impacto potencial y diverso de los f&#225;rmacos&#46; Es necesario ponderar el balance entre riesgo y beneficio del uso continuado de tratamientos con potencial hepatot&#243;xico en pacientes con riesgo de fibrosis hep&#225;tica&#44; realizando una evaluaci&#243;n y seguimiento individualizados&#46;</p><p id="par0180" class="elsevierStylePara elsevierViewall">De todos los tratamientos investigados&#44; el riesgo de desarrollar y&#47;o empeorar la EHmet solo aumenta con el MTX&#46; La fototerapia y algunos tratamientos convencionales de nueva generaci&#243;n no han demostrado hepatotoxicidad en pacientes con esteatosis hep&#225;tica&#46; Por su parte&#44; aunque la mayor&#237;a de las terapias biol&#243;gicas presenta un balance riesgo-beneficio favorable en pacientes con esteatosis hep&#225;tica y grados variables de fibrosis&#44; su potencial hepatot&#243;xico es diverso &#40;<a class="elsevierStyleCrossRef" href="#tbl0015">tabla 3</a>&#41;&#46;</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Conclusiones</span><p id="par0185" class="elsevierStylePara elsevierViewall">Ante la prevalencia de la EHmet en pacientes con psoriasis y la interrelaci&#243;n entre ambas patolog&#237;as recomendamos el despistaje de enfermedad hep&#225;tica en pacientes con psoriasis y alg&#250;n componente de EHmet&#44; independientemente del grado de alteraci&#243;n de la bioqu&#237;mica hep&#225;tica&#46; El despistaje ser&#225; sistem&#225;tico&#44; como parte del proceso asistencial de la psoriasis en las consultas o unidades asistenciales de dermatolog&#237;a&#46; La estrategia recomendada de mayor valor es la aplicaci&#243;n combinada del &#237;ndice serol&#243;gico FIB-4 y la ET y la derivaci&#243;n del paciente a hepatolog&#237;a cuando se detecte riesgo significativo de fibrosis avanzada&#46;</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Financiaci&#243;n</span><p id="par0190" class="elsevierStylePara elsevierViewall">Las reuniones del panel de expertos fueron financiadas por Novartis Farmac&#233;utica S&#46;A&#46;</p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Conflictos de intereses</span><p id="par0195" class="elsevierStylePara elsevierViewall">Novartis ha facilitado la celebraci&#243;n de las reuniones para los integrantes del grupo&#44; pero ninguno de sus empleados ha participado en el desarrollo y elaboraci&#243;n del material cient&#237;fico&#44; las discusiones o el texto escrito&#46;</p><p id="par0200" class="elsevierStylePara elsevierViewall">Antonio Olveira ha participado como investigador&#44; ponente o consultor en proyectos patrocinados por&#58; Abbvie&#44; Alexion&#44; BMS&#44; Janssen&#44; MSD&#44; Gilead&#44; Novartis&#46;</p><p id="par0205" class="elsevierStylePara elsevierViewall">Isabel Belinch&#243;n ha sido consultora y&#47;u oradora y&#47;o particip&#243; en ensayos cl&#237;nicos patrocinados por compa&#241;&#237;as que fabrican medicamentos utilizados para el tratamiento de la psoriasis&#44; incluyendo Janssen Pharmaceuticals Inc&#46;&#44; Almirall SA&#44; Lilly&#44; Abbvie&#44; Novartis&#44; Celgene&#44; Biogen&#44; Amgen&#44; LEO Pharma&#44; Pfizer-Wyeth&#44; MSD y UCB&#46;</p><p id="par0210" class="elsevierStylePara elsevierViewall">Pedro Herranz ha participado como investigador&#44; ponente o consultor en proyectos patrocinados por&#58; Abbvie&#44; Almirall&#44; Amgen&#44; Celgene&#44; LEO Pharma&#44; Lilly&#44; Novartis&#44; Pfizer&#44; Sandoz&#44; Sanofi&#44; UCB&#46;</p><p id="par0215" class="elsevierStylePara elsevierViewall">Javier Crespo ha participado como investigador&#44; ponente o consultor en proyectos patrocinados por&#58; Abbvie&#44; Alexion&#44; BMS&#44; Amgen&#44; Celgene&#44; Gilead&#44; Janssen&#44; MSD&#46;</p><p id="par0220" class="elsevierStylePara elsevierViewall">Eva Vilarrasa ha percibido honorarios de consultor&#237;a&#47;orador de y&#47;o particip&#243; en ensayos cl&#237;nicos patrocinados por Abbvie&#44; Almirall&#44; Amgen&#44; Bayer&#44; Boehringer Ingelheim&#44; Celgene&#44; Gebro&#44; Isdin&#44; Janssen&#44; LEO Pharma&#44; Lilly&#44; Merck-Serono&#44; MSD&#44; Novartis&#44; Pfizer&#44; Roche&#44; Sandoz&#44; Sanofi y UCB&#46;</p><p id="par0225" class="elsevierStylePara elsevierViewall">Salvador Benlloch P&#233;rez ha participado como investigador&#44; ponente&#44; o consultor en proyectos y ensayos cl&#237;nicos patrocinados por Novartis&#44; Novo Nordisk&#44; Gilead&#46;</p><p id="par0230" class="elsevierStylePara elsevierViewall">Jorge Alonso Su&#225;rez P&#233;rez ha participado como miembro de &#171;<span class="elsevierStyleItalic">steering committee</span>&#187; y&#47;o invitado como ponente por Novartis&#44; LEO Pharma&#44; Abbvie&#44; Lilly&#44; Janssen&#44; UCB&#44; Amgen y Almirall&#46;</p><p id="par0235" class="elsevierStylePara elsevierViewall">Jos&#233; Manuel Carrascosa ha participado como IP&#47;SI y&#47;o asesor o miembro del comit&#233; directivo y&#47;o ponente invitado de Novartis&#44; LEO Pharma&#44; Abbvie&#44; Lilly&#44; Janssen&#44; UCB&#44; Sandoz&#44; Mylan&#44; Amgen&#44; Almirall&#44; Bristol-Myers-Squibb y Boehringer Ingelheim&#46;</p><p id="par0240" class="elsevierStylePara elsevierViewall">Javier Ampuero declara no tener conflictos de inter&#233;s&#46;</p><p id="par0245" class="elsevierStylePara elsevierViewall">Francisco Guimer&#225; declara no tener conflictos de inter&#233;s&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:12 [
        0 => array:3 [
          "identificador" => "xres1908352"
          "titulo" => "Graphical abstract"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0005"
            ]
          ]
        ]
        1 => array:3 [
          "identificador" => "xres1908350"
          "titulo" => "Resumen"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0010"
            ]
          ]
        ]
        2 => array:2 [
          "identificador" => "xpalclavsec1648578"
          "titulo" => "Palabras clave"
        ]
        3 => array:3 [
          "identificador" => "xres1908351"
          "titulo" => "Abstract"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0015"
            ]
          ]
        ]
        4 => array:2 [
          "identificador" => "xpalclavsec1648577"
          "titulo" => "Keywords"
        ]
        5 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Introducci&#243;n"
        ]
        6 => array:3 [
          "identificador" => "sec0010"
          "titulo" => "Metodolog&#237;a"
          "secciones" => array:3 [
            0 => array:2 [
              "identificador" => "sec0015"
              "titulo" => "Identificaci&#243;n de los pacientes con psoriasis y riesgo de enfermedad hep&#225;tica"
            ]
            1 => array:2 [
              "identificador" => "sec0020"
              "titulo" => "Recomendaciones de cribado de la EHmet"
            ]
            2 => array:2 [
              "identificador" => "sec0025"
              "titulo" => "Tratamientos actuales para la psoriasis e impacto sobre la EHmet"
            ]
          ]
        ]
        7 => array:2 [
          "identificador" => "sec0030"
          "titulo" => "Discusi&#243;n"
        ]
        8 => array:2 [
          "identificador" => "sec0035"
          "titulo" => "Conclusiones"
        ]
        9 => array:2 [
          "identificador" => "sec0040"
          "titulo" => "Financiaci&#243;n"
        ]
        10 => array:2 [
          "identificador" => "sec0045"
          "titulo" => "Conflictos de intereses"
        ]
        11 => array:1 [
          "titulo" => "Bibliograf&#237;a"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2022-11-10"
    "fechaAceptado" => "2023-01-17"
    "PalabrasClave" => array:2 [
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec1648578"
          "palabras" => array:4 [
            0 => "Psoriasis"
            1 => "Esteatosis hep&#225;tica metab&#243;lica"
            2 => "EHmet"
            3 => "Hepatotoxicidad"
          ]
        ]
      ]
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec1648577"
          "palabras" => array:4 [
            0 => "Psoriasis"
            1 => "Metabolic-associated fatty liver disease"
            2 => "MAFLD"
            3 => "Hepatotoxicity"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "es" => array:2 [
        "titulo" => "Resumen"
        "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">En los &#250;ltimos a&#241;os se est&#225;n haciendo notables esfuerzos para entender la relaci&#243;n existente entre la psoriasis y la esteatosis hep&#225;tica metab&#243;lica &#40;EHmet&#41;&#46; No solo se presenta este trastorno en pacientes psori&#225;sicos con una mayor prevalencia&#44; sino que adem&#225;s se acompa&#241;a de una mayor gravedad&#46; Con este precedente&#44; se evidencia la necesidad de establecer un protocolo de abordaje precoz de la enfermedad hep&#225;tica en los pacientes con psoriasis&#46; Asimismo&#44; es de especial relevancia la evaluaci&#243;n de riesgo y beneficio en referencia al uso de tratamientos con potencial hepatot&#243;xico&#46; En el presente manuscrito se exponen las recomendaciones de un panel de expertos en dermatolog&#237;a y hepatolog&#237;a para el cribado&#44; diagn&#243;stico&#44; monitorizaci&#243;n y criterios de derivaci&#243;n en pacientes con psoriasis&#44; en caso de sospecha de esteatosis hep&#225;tica metab&#243;lica&#46;</p></span>"
      ]
      "en" => array:2 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abst0015" class="elsevierStyleSection elsevierViewall"><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Recent years have seen concerted efforts to understand the relation between psoriasis and metabolic-associated fatty liver disease &#40;MAFLD&#41;&#46; Not only is MALFD diagnosed more often in patients with psoriasis&#44; but its clinical course is also more aggressive&#46; A common approach is therefore needed to enable early detection of liver disease coincident with psoriasis&#46; Especially important is an analysis of risks and benefits of potentially hepatotoxic treatments&#46; This consensus paper presents the recommendations of a group of experts in dermatology and hepatology regarding screening for MALFD as well as criteria for monitoring patients and referring them to hepatologists when liver disease is suspected&#46;</p></span>"
      ]
    ]
    "NotaPie" => array:1 [
      0 => array:3 [
        "etiqueta" => "&#9674;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0025">Todos los componentes del Grupo de Trabajo para el Abordaje Com&#250;n de la Psoriasis y la EHmet &#40;GACPE&#41; est&#225;n relacionados en el <a class="elsevierStyleCrossRef" href="#sec0050">anexo</a>&#46;</p>"
        "identificador" => "fn0005"
      ]
    ]
    "apendice" => array:1 [
      0 => array:1 [
        "seccion" => array:1 [
          0 => array:5 [
            "apendice" => "<p id="par0250" class="elsevierStylePara elsevierViewall">El Grupo de Trabajo para el Abordaje Com&#250;n de la Psoriasis y la EHmet &#40;GACPE&#41; est&#225; constituido por siete dermat&#243;logos y cinco hepat&#243;logos&#44; especializados en el manejo de la psoriasis y la EHmet&#58;</p>"
            "etiqueta" => "Anexo"
            "titulo" => "Grupo de Trabajo para el Abordaje Com&#250;n de la Psoriasis y la EHmet &#40;GACPE&#41;&#58;"
            "identificador" => "sec0050"
            "apendiceSeccion" => array:2 [
              0 => array:3 [
                "apendice" => "<p id="par0260" class="elsevierStylePara elsevierViewall">Jorge Alonso Su&#225;rez-P&#233;rez&#46; Departamento de Dermatolog&#237;a&#44; Hospital Universitario Virgen de la Victoria&#44; M&#225;laga&#44; Espa&#241;a&#46;</p> <p id="par0265" class="elsevierStylePara elsevierViewall">Susana Armesto Alonso&#46; Departamento de Dermatolog&#237;a&#44; Hospital Universitario Marqu&#233;s de Valdecilla&#44; Santander&#44; Espa&#241;a&#46;</p> <p id="par0270" class="elsevierStylePara elsevierViewall">Isabel Belinch&#243;n Romero&#46; Departamento de Dermatolog&#237;a&#44; Hospital General Universitario de Alicante&#44; Instituto de Investigaci&#243;n Sanitaria y Biom&#233;dica &#40;ISABIAL&#41;&#44; Universidad Miguel Hern&#225;ndez de Elche&#44; Alicante&#44; Espa&#241;a&#46;</p> <p id="par0275" class="elsevierStylePara elsevierViewall">Jos&#233; Manuel Carrascosa Carrillo&#46; Departamento de Dermatolog&#237;a&#46; Hospital Universitario Germans Trias i Pujol&#46; Universitat Aut&#242;noma de Barcelona&#46; IGTP Badalona&#44; Espa&#241;a&#46;</p> <p id="par0280" class="elsevierStylePara elsevierViewall">Francisco Guimer&#225; Mart&#237;n-Neda&#46; Servicio de Dermatolog&#237;a y Patolog&#237;a&#44; Hospital Universitario de Canarias&#44; La Laguna&#44; Espa&#241;a&#46;</p> <p id="par0285" class="elsevierStylePara elsevierViewall">Pedro Herranz Pinto&#46; Departamento de Dermatolog&#237;a&#44; Hospital Universitario La Paz&#44; Madrid&#44; Espa&#241;a&#46;</p> <p id="par0290" class="elsevierStylePara elsevierViewall">Eva Vilarrasa Rull&#46; Departamento de Dermatolog&#237;a&#44; Hospital Santa Creu i Sant Pau&#44; Universitat Aut&#242;noma de Barcelona&#44; Barcelona&#44; Espa&#241;a&#46;</p>"
                "titulo" => "Dermat&#243;logos"
                "identificador" => "sec0055"
              ]
              1 => array:3 [
                "apendice" => "<p id="par0300" class="elsevierStylePara elsevierViewall">Javier Ampuero Herrojo&#46; Departamento de Enfermedades Digestivas&#44; Hospital Universitario Virgen del Roc&#237;o&#46; Laboratorio 213&#44; Instituto de Biomedicina de Sevilla &#40;IBIS&#41;&#46; Departamento de Medicina&#44; Universidad de Sevilla&#46; Centro Biom&#233;dico en Red de Enfermedades Hep&#225;ticas y Digestivas &#40;CIBERehd&#41;&#46; Sevilla&#44; Espa&#241;a&#46;</p> <p id="par0305" class="elsevierStylePara elsevierViewall">Salvador Benlloch P&#233;rez&#46; Servicio de Enfermedades Digestivas&#44; Hospital Arnau de Vilanova&#46; Valencia&#46; Centro Biom&#233;dico en Red de Enfermedades Hep&#225;ticas y Digestivas &#40;CIBERehd&#41;&#46; Valencia&#44; Espa&#241;a&#46;</p> <p id="par0310" class="elsevierStylePara elsevierViewall">Javier Crespo Garc&#237;a&#46; Servicio de Gastroenterolog&#237;a y Hepatolog&#237;a&#46; Hospital Universitario Marqu&#233;s de Valdecilla&#46; IDIVAL&#46; Escuela de Medicina&#46; Universidad de Cantabria&#46; Santander&#44; Espa&#241;a&#46;</p> <p id="par0315" class="elsevierStylePara elsevierViewall">Antonio Olveira Mart&#237;n&#46; Servicio de Aparato Digestivo&#44; Hospital Universitario La Paz&#44; Madrid&#44; Espa&#241;a&#46;</p>"
                "titulo" => "Hepat&#243;logos"
                "identificador" => "sec0060"
              ]
            ]
          ]
        ]
      ]
    ]
    "multimedia" => array:7 [
      0 => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figura 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 655
            "Ancho" => 2925
            "Tamanyo" => 121640
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Progresi&#243;n de la EHmet&#46; Desde la esteatosis hep&#225;tica &#40;estable&#44; con escaso riesgo de progresi&#243;n&#44; caracterizada por la acumulaci&#243;n de grasa intracelular en el hepatocito&#41;&#44; pasando por la evoluci&#243;n a esteatohepatitis no alcoh&#243;lica &#40;EHNA&#41; &#40;cuando la infiltraci&#243;n de grasa va acompa&#241;ada de cambios inflamatorios y da&#241;o celular&#41;&#44; y el desarrollo de fibrosis hep&#225;tica &#40;dep&#243;sito de col&#225;geno en forma de septos fibrosos que provocan una alteraci&#243;n arquitectural y disfunci&#243;n progresiva del hepatocito&#41;&#46; La fibrosis predispone al desarrollo de cirrosis &#40;septos fibr&#243;ticos y n&#243;dulos de regeneraci&#243;n&#41; y carcinoma hepatocelular &#40;CHC&#41; y&#47;o fallo hep&#225;tico<a class="elsevierStyleCrossRefs" href="#bib0495"><span class="elsevierStyleSup">6&#44;8&#44;10&#44;12&#8211;14</span></a>&#46;</p>"
        ]
      ]
      1 => array:7 [
        "identificador" => "fig0010"
        "etiqueta" => "Figura 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr2.jpeg"
            "Alto" => 1365
            "Ancho" => 2933
            "Tamanyo" => 218408
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Algoritmo de cribado del paciente de riesgo de EHmet&#46; Se debe tener en cuenta que en funci&#243;n de la realidad asistencial de cada hospital y la disponibilidad de elastometr&#237;a de transici&#243;n &#40;ET&#41;&#44; la ET se puede solicitar desde el Servicio de Dermatolog&#237;a o se debe derivar el paciente al Servicio de Aparato Digestivo&#46;</p> <p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">&#42;Se aconseja realizar ET para evaluar el riesgo de fibrosis a pacientes con FIB-4 bajo y con tratamiento hepatot&#243;xico&#46;</p>"
        ]
      ]
      2 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Tabla 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">AH&#58; &#225;cido hialur&#243;nico&#59; ALT&#58; alanina aminotransferasa&#59; APRI&#58; <span class="elsevierStyleItalic">AST to platelet ratio index</span>&#59; AST&#58; aspartato aminotransferasa&#59; DM&#58; diabetes mellitus&#59; ELF&#58; <span class="elsevierStyleItalic">enhanced liver fibrosis</span>&#59; FLI&#58; <span class="elsevierStyleItalic">fatty liver index</span>&#59; GGT&#58; gamma-glutamil transferasa&#59; HFS&#58; <span class="elsevierStyleItalic">Hepamet fibrosis score</span>&#59; HSI&#58; <span class="elsevierStyleItalic">hepatic steatosis index</span>&#59; IMC&#58; &#237;ndice de masa corporal&#59; NAFLD-FS&#58; <span class="elsevierStyleItalic">non-alcoholic fatty liver disease fibrosis score</span>&#59; PIIINP&#58; p&#233;ptido amino-terminal del procol&#225;geno III&#59; TIMP-1&#58; inhibidor tisular de la metaloproteinasa 1 de la matriz&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&#205;ndice&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Estadio&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Par&#225;metros&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " colspan="4" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Riesgo de fibrosis avanzada seg&#250;n valores de corte</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">HSI<a class="elsevierStyleCrossRef" href="#bib0670"><span class="elsevierStyleSup">41</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Esteatosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ALT&#47;AST&#44; IMC&#44; sexo&#44; diabetes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="4" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#60; 30&#58; bajo&#62; 36&#58; alto</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">FLI<a class="elsevierStyleCrossRef" href="#bib0675"><span class="elsevierStyleSup">42</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Esteatosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Per&#237;metro abdominal&#44; IMC&#44; triglic&#233;ridos&#44; GGT&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="4" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#60; 30&#58; bajo30-59&#58; intermedio&#8805; 60&#58; alto</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">NAFLD-FS <a class="elsevierStyleCrossRef" href="#bib0680"><span class="elsevierStyleSup">43</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Fibrosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hiperglucemia en ayunas&#47;DM&#44; edad&#44; IMC&#44; ALT&#44; AST&#44; plaquetas&#44; alb&#250;mina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="4" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#60; -1&#46;455&#58; F0-F2&#44; bajo-1&#46;455-0&#44;675&#58; indeterminado&#62; 0&#44;675&#58; F3-F4&#44; alto</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#205;ndice FIB-4<a class="elsevierStyleCrossRef" href="#bib0685"><span class="elsevierStyleSup">44</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Fibrosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Edad&#44; ALT&#44; AST&#44; plaquetas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="4" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#60; 1&#44;30&#58; F0-F2&#44; bajo&#62; 2&#44;67&#58; F3-F4&#44; alto</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">HFS<a class="elsevierStyleCrossRef" href="#bib0665"><span class="elsevierStyleSup">40</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Fibrosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Sexo&#44; edad&#44; DM&#44; glucosa&#44; insulina&#44; HOMA &#40;No DM&#41;&#44; AST&#44; alb&#250;mina&#44; plaquetas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Valor HFS&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">F2-F4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">F3-F4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">F4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#60; 0&#44;12&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">23&#44;6&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">8&#44;1&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#44;9&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#44;12-0&#44;47&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">57&#44;1&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">33&#44;7&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7&#44;4&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#62; 0&#44;47&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">86&#44;4&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">76&#44;3&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">35&#44;5&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">APRI<a class="elsevierStyleCrossRef" href="#bib0690"><span class="elsevierStyleSup">45</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Fibrosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">AST&#44; plaquetas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="4" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">F0-F2&#58; &#60; 0&#44;5&#59; 72&#44;7&#37;F3-F4&#58; &#62; 1&#44;5&#59; 54&#44;2&#37;</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#205;ndice BARD<a class="elsevierStyleCrossRef" href="#bib0695"><span class="elsevierStyleSup">46</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Fibrosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ALT&#44; AST&#44; DM&#44; IMC&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="4" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0-1&#58; bajo2-4&#58; alto</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#205;ndice ELF<a class="elsevierStyleCrossRef" href="#bib0700"><span class="elsevierStyleSup">47</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Fibrosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">AH&#44; PIIINP&#44; TIMP-1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="4" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#60; 7&#44;7&#58; nulo o bajo&#8805; 7&#44;7-9&#44;7&#58; moderado&#8805; 9&#44;8 alto</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3185341.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">&#205;ndices para el diagn&#243;stico no invasivo de la EHmet</p>"
        ]
      ]
      3 => array:8 [
        "identificador" => "tbl0010"
        "etiqueta" => "Tabla 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at2"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">ACC&#58; acetil-coenzima A carboxilasa&#59; ASK1&#58; cinasa reguladora de la se&#241;al de apoptosis 1&#59; CCR2&#47;5&#58; correceptor de quimiocinas 2&#47;5&#59; FGF21&#58; factor de crecimiento de fibroblastos 21&#59; FXR&#58; receptor X farnesoide&#59; GLP1&#58; p&#233;ptido similar al glucag&#243;n 1&#59; HSP47 siRNA&#58; &#225;cido ribonucleico peque&#241;o de interferencia de la prote&#237;na de choque t&#233;rmico 47&#59; PPAR&#945;&#47;&#948;&#58; receptores activados por proliferadores peroxisomales &#945;&#47;&#948;&#59; SCD&#58; estearoil-coenzima A desaturasa&#59; SGLT2&#58; cotransportador de sodio-glucosa tipo 2&#59; TLR4&#58; receptor tipo toll 4&#59; TR&#946;&#58; receptor &#946; de hormona tiroidea&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Diana&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">F&#225;rmaco&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Acci&#243;n&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Fase&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Ref&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Diabetes&#44; resistencia a la insulina</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Semaglutida&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">An&#225;logo del receptor GLP1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">II&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0735"><span class="elsevierStyleSup">54</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Canagliflozina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Inhibidor SGLT2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">piloto&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0740"><span class="elsevierStyleSup">55</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">BMS-986036&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">FGF21 recombinante&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">II&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0745"><span class="elsevierStyleSup">56</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Dislipemia</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Aramcol&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Inhibidor SCD&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">III&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0750"><span class="elsevierStyleSup">57</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Firsocostat &#40;GS-0976&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Inhibidor ACC&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">II&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0755"><span class="elsevierStyleSup">58</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Receptor nuclear</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#193;cido obetic&#243;lico&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Agonista FXR&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">III&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0760"><span class="elsevierStyleSup">59</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Elafibranor&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Agonista PPAR&#945;&#47;&#948;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">III&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0765"><span class="elsevierStyleSup">60</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Resmetirom &#40;MGL-3196&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Agonista TR&#946;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">III&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0770"><span class="elsevierStyleSup">61</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Apoptosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Emricasan&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Inhibidor caspasas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">II&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0775"><span class="elsevierStyleSup">62</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="5" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Inflamaci&#243;n&#44; fibrosis</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Selonsertib&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Inhibidor ASK1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">III&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0780"><span class="elsevierStyleSup">63</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Cenicriviroc&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Antagonista CCR2&#47;5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">III&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0785"><span class="elsevierStyleSup">64</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">GR-MD-02&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Inhibidor de galectina-3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">I&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0790"><span class="elsevierStyleSup">65</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">JKB-121&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Antagonista TLR4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">II&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0795"><span class="elsevierStyleSup">66</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ND-LO2-s0201&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">HSP47 siRNA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">II&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><a class="elsevierStyleCrossRef" href="#bib0805"><span class="elsevierStyleSup">67</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3185344.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Ensayos cl&#237;nicos de tratamientos para la EHmet &#40;adaptado de<a class="elsevierStyleCrossRef" href="#bib0730"><span class="elsevierStyleSup">53</span></a>&#41;</p>"
        ]
      ]
      4 => array:8 [
        "identificador" => "tbl0015"
        "etiqueta" => "Tabla 3"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at3"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">NA&#58; no aplicable &#40;no existen estudios al respecto&#41;&#59; BILt&#58; bilirrubina total&#46;</p><p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">El grupo de inhibidores de TNF incluye etanercept&#44; adalimumab e infliximab&#46; El grupo de anti-IL17A incluye brodalumab&#44; ixekizumab y secukinumab&#46; El grupo de anti-IL23 incluye tildrakizumab&#44; guselkumab&#44; risankizumab&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">F&#225;rmaco&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Toxicidad&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Tipo de da&#241;o&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">En insuficiencia hep&#225;tica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Riesgo incrementado de da&#241;o hep&#225;tico&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Metotrexato<a class="elsevierStyleCrossRefs" href="#bib0815"><span class="elsevierStyleSup">69&#8211;73</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#43;&#43;&#43;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Da&#241;o oxidativo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Uso con precauci&#243;nContraindicado si BILt &#62; 5 mg&#47;dL&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">EHmet&#47;obesidad&#44; leflunomida&#44; alcohol&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Acitretina<a class="elsevierStyleCrossRefs" href="#bib0855"><span class="elsevierStyleSup">74&#44;75</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#43;&#43;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Disfunci&#243;n mitocondrial&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Contraindicado&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hipertransaminemia de 15-30&#37;<a class="elsevierStyleCrossRef" href="#bib0860"><span class="elsevierStyleSup">75</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Inhibidores TNF<a class="elsevierStyleCrossRefs" href="#bib0865"><span class="elsevierStyleSup">76&#8211;78</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#43;&#43;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Fallo hep&#225;tico&#44; hepatitis no infecciosa&#44; insuficiencia hep&#225;tica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Aumento de riesgo de da&#241;o hep&#225;tico con adalimumab<a class="elsevierStyleCrossRef" href="#bib0880"><span class="elsevierStyleSup">79</span></a> y hepatitis autoinmune con infliximab<a class="elsevierStyleCrossRef" href="#bib0875"><span class="elsevierStyleSup">78</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ab IL-12&#47;23<a class="elsevierStyleCrossRef" href="#bib0880"><span class="elsevierStyleSup">79</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#43;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">N&#47;A&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ab IL-23<a class="elsevierStyleCrossRefs" href="#bib0925"><span class="elsevierStyleSup">80&#8211;82</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#43;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Aumento de las transaminasas<a class="elsevierStyleCrossRef" href="#tblfn0025">&#42;</a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ab IL-17<a class="elsevierStyleCrossRefs" href="#bib0890"><span class="elsevierStyleSup">83&#8211;85</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Posible efecto protector de la inhibici&#243;n de IL-17A en modelos animales<a class="elsevierStyleCrossRef" href="#bib0935"><span class="elsevierStyleSup">86</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Apremilast<a class="elsevierStyleCrossRef" href="#bib0940"><span class="elsevierStyleSup">87</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">NA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ciclosporina<a class="elsevierStyleCrossRef" href="#bib0945"><span class="elsevierStyleSup">88</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Rara&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Da&#241;o oxidativo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">SeguroRequiere reducci&#243;n de dosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Obesidad&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3185342.png"
              ]
            ]
          ]
          "notaPie" => array:1 [
            0 => array:3 [
              "identificador" => "tblfn0025"
              "etiqueta" => "&#42;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Solo guselkumab&#44; en estudios de artritis psori&#225;sica&#44; seg&#250;n ficha t&#233;cnica&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">F&#225;rmacos empleados en el tratamiento de la psoriasis y su impacto hep&#225;tico &#40;adaptada de<a class="elsevierStyleCrossRefs" href="#bib0590"><span class="elsevierStyleSup">25&#44;69&#8211;88</span></a>&#41;</p>"
        ]
      ]
      5 => array:8 [
        "identificador" => "tbl0020"
        "etiqueta" => "Tabla 4"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at4"
            "detalle" => "Tabla "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Escalas de gravedad de la psoriasis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">BSA<a class="elsevierStyleCrossRef" href="#tblfn0010">&#42;</a> 10&#37; o PASI<a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">&#42;&#42;</span></a> &#62; 10 o DLQI<a class="elsevierStyleCrossRef" href="#tblfn0020"><span class="elsevierStyleSup">&#42;&#42;&#42;</span></a> &#62; 10&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Localizaci&#243;n&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#193;reas expuestas &#40;regi&#243;n facial y dorso de manos&#41;&#44; palmas&#44; plantas&#44; genitales&#44; cuero cabelludo&#44; u&#241;as y placas recalcitrantes&#44; con impacto funcional o psicol&#243;gico para el paciente&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Fracaso de terapias previas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No controlable con tratamiento t&#243;pico o fototerapia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3185343.png"
              ]
            ]
          ]
          "notaPie" => array:3 [
            0 => array:3 [
              "identificador" => "tblfn0010"
              "etiqueta" => "&#42;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0010">La determinaci&#243;n de la superficie corporal afectada&#44; <span class="elsevierStyleItalic">body surface area</span> &#40;BSA&#41;&#44; es una de las escalas de medida m&#225;s empleadas en la evaluaci&#243;n de la gravedad de la psoriasis<a class="elsevierStyleCrossRef" href="#bib0950"><span class="elsevierStyleSup">91</span></a>&#46; El &#237;ndice BSA se calcula a partir de la media aritm&#233;tica de la superficie de la piel afectada ponderada seg&#250;n el &#225;rea total que ocupa cada parte del cuerpo evaluada&#58; la cabeza representa 10&#37;&#44; las extremidades superiores 20&#37;&#44; el tronco 30&#37; y las extremidades inferiores 40&#37; de la superficie corporal total<a class="elsevierStyleCrossRef" href="#bib0955"><span class="elsevierStyleSup">92</span></a>&#46;</p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0015"
              "etiqueta" => "&#42;&#42;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0015">El <span class="elsevierStyleItalic">Psoriasis Area Severity Index</span> &#40;PASI&#41; es la escala de medida m&#225;s utilizada para la valoraci&#243;n de la gravedad de la psoriasis y la toma de decisi&#243;n para la indicaci&#243;n de tratamiento&#46; Este &#237;ndice combina la valoraci&#243;n de cada lesi&#243;n de psoriasis del 0 al 4 &#40;0 &#61; ninguno&#44; 1 &#61; leve&#44; 2 &#61; moderado&#44; 3 &#61; marcado&#44; 4 &#61; muy marcado&#41; con base en tres par&#225;metros&#58; eritema&#44; infiltraci&#243;n y descamaci&#243;n&#44; en cuatro partes del cuerpo&#58; cabeza&#44; tronco&#44; extremidades superiores y extremidades inferiores<a class="elsevierStyleCrossRefs" href="#bib0955"><span class="elsevierStyleSup">92&#44;93</span></a>&#46;</p>"
            ]
            2 => array:3 [
              "identificador" => "tblfn0020"
              "etiqueta" => "&#42;&#42;&#42;"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0020">El <span class="elsevierStyleItalic">Dermatology Life Quality Index</span> &#40;DLQI&#41; se compone de 10 preguntas con cuatro respuestas &#40;0 &#61; nada&#44; 1 &#61; un poco&#44; 2 &#61; mucho&#44; 3 &#61; much&#237;simo&#41; y se calcula sumando la puntuaci&#243;n de cada pregunta&#46; A mayor puntuaci&#243;n&#44; mayor es el deterioro de la calidad de vida<a class="elsevierStyleCrossRef" href="#bib0965"><span class="elsevierStyleSup">94</span></a>&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">Definici&#243;n de la psoriasis &#171;moderada a grave&#187; candidata a terapia sist&#233;mica propuesta por el Grupo de Psoriasis &#40;GPS&#41; de la Academia Espa&#241;ola de Dermatolog&#237;a y Venereolog&#237;a &#40;AEDV&#41;<a class="elsevierStyleCrossRef" href="#bib0610"><span class="elsevierStyleSup">29</span></a></p>"
        ]
      ]
      6 => array:5 [
        "identificador" => "fig0015"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "fx1.jpeg"
            "Alto" => 300
            "Ancho" => 1333
            "Tamanyo" => 37221
          ]
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "Bibliograf&#237;a"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:94 [
            0 => array:3 [
              "identificador" => "bib0470"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "&#91;Prevalence of ten Immune-mediated inflammatory diseases &#40;IMID&#41; in Spain&#93;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Rev Esp Salud Publica&#46;"
                        "fecha" => "2019"
                        "volumen" => "93"
                        "paginaInicial" => "e201903013"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0475"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Psoriasis and comorbid diseases"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2016.07.064"
                      "Revista" => array:7 [
                        "tituloSerie" => "J Am Acad Dermatol&#46;"
                        "fecha" => "2017"
                        "volumen" => "76"
                        "paginaInicial" => "377"
                        "paginaFinal" => "390"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S0140673613624228"
                          "estado" => "S300"
                          "issn" => "01406736"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0480"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Relationship between non-alcoholic fatty liver disease and psoriasis&#58; A novel Hepato-Dermal axis&#63;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [ …4]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3390/ijms17020217"
                      "Revista" => array:5 [
                        "tituloSerie" => "Int J Mol Sci&#46;"
                        "fecha" => "2016"
                        "volumen" => "17"
                        "paginaInicial" => "217"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0485"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Looking for a new name for non-alcoholic fatty liver disease in Spanish&#58; esteatosis hep&#225;tica metab&#243;lica &#40;EHmet&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Rev Esp Enferm Dig&#46;"
                        "fecha" => "2021"
                        "volumen" => "113"
                        "paginaInicial" => "161"
                        "paginaFinal" => "163"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0490"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Non-alcoholic fatty liver disease&#58; Metabolic&#44; genetic&#44; epigenetic and environmental risk factors"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [ …4]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3390/ijerph18105227"
                      "Revista" => array:6 [
                        "tituloSerie" => "Int J Environ Res Public Health&#46;"
                        "fecha" => "2021"
                        "volumen" => "18"
                        "paginaInicial" => "5227"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S0090825809007240"
                          "estado" => "S300"
                          "issn" => "00908258"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0495"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Non-alcoholic fatty liver disease&#58; A sign of systemic disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.metabol.2017.04.011"
                      "Revista" => array:6 [
                        "tituloSerie" => "Metabolism&#46;"
                        "fecha" => "2017"
                        "volumen" => "72"
                        "paginaInicial" => "94"
                        "paginaFinal" => "108"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0500"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The Metabolic Syndrome and Its Influence on Nonalcoholic Steatohepatitis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.cld.2015.10.002"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Liver Dis&#46;"
                        "fecha" => "2016"
                        "volumen" => "20"
                        "paginaInicial" => "225"
                        "paginaFinal" => "243"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0505"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Global epidemiology of nonalcoholic fatty liver disease&#8212;Meta-analytic assessment of prevalence&#44; incidence&#44; and outcomes"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Hepatology&#46;"
                        "fecha" => "2016"
                        "volumen" => "64"
                        "paginaInicial" => "73"
                        "paginaFinal" => "84"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0510"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis&#58; Implications for Liver Transplantation"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [ …4]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1097/TP.0000000000002484"
                      "Revista" => array:6 [
                        "tituloSerie" => "Transplantation&#46;"
                        "fecha" => "2019"
                        "volumen" => "103"
                        "paginaInicial" => "22"
                        "paginaFinal" => "27"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0515"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Consensus document Management of non-alcoholic fatty liver disease &#40;NAFLD&#41;&#46; Clinical practice guideline"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.gastrohep.2017.12.003"
                      "Revista" => array:7 [
                        "tituloSerie" => "Gastroenterol Hepatol&#46;"
                        "fecha" => "2018"
                        "volumen" => "41"
                        "paginaInicial" => "328"
                        "paginaFinal" => "349"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S0140673618324875"
                          "estado" => "S300"
                          "issn" => "01406736"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0520"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/hep.30251"
                      "Revista" => array:6 [
                        "tituloSerie" => "Hepatology&#46;"
                        "fecha" => "2019"
                        "volumen" => "69"
                        "paginaInicial" => "2672"
                        "paginaFinal" => "2682"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0525"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Burden of liver diseases in the world"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [ …4]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jhep.2018.09.014"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Hepatol&#46;"
                        "fecha" => "2019"
                        "volumen" => "70"
                        "paginaInicial" => "151"
                        "paginaFinal" => "171"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0530"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Fourth&#44; the progression of liver disease in NASH is not linear and can be manifested by periods of progression&#44; regression and stability"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [ …1]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:4 [
                        "tituloSerie" => "Nature&#46;"
                        "fecha" => "2017"
                        "volumen" => "550"
                        "paginaInicial" => "S102"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0535"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1053/j.gastro.2014.11.039"
                      "Revista" => array:6 [
                        "tituloSerie" => "Gastroenterology&#46;"
                        "fecha" => "2015"
                        "volumen" => "148"
                        "paginaInicial" => "547"
                        "paginaFinal" => "555"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0540"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Relationship between psoriasis and non-alcoholic fatty liver disease &#8211; Updated systematic review and adjusted meta-analysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [ …4]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/ajd.13015"
                      "Revista" => array:6 [
                        "tituloSerie" => "Australas J Dermatol&#46;"
                        "fecha" => "2019"
                        "volumen" => "60"
                        "paginaInicial" => "e352"
                        "paginaFinal" => "e355"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0545"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [ …4]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "J Hepatol&#46;"
                        "fecha" => "2009"
                        "volumen" => "51"
                        "paginaInicial" => "758"
                        "paginaFinal" => "764"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0550"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The increased prevalence of non-alcoholic fatty liver disease in psoriatic patients&#58; A study from South India"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1440-0960.2012.00905.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "Australas J Dermatol&#46;"
                        "fecha" => "2012"
                        "volumen" => "53"
                        "paginaInicial" => "190"
                        "paginaFinal" => "197"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0555"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Risk of non-alcoholic fatty liver disease in patients with psoriasis&#58; A systematic review and meta-analysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Eur Acad Dermatology Venereol&#46;"
                        "fecha" => "2015"
                        "volumen" => "29"
                        "paginaInicial" => "656"
                        "paginaFinal" => "662"
                        "itemHostRev" => array:3 [
                          "pii" => "S1470204516306271"
                          "estado" => "S300"
                          "issn" => "14702045"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0560"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Non-alcoholic fatty liver disease is associated with bacterial translocation and a higher inflammation response in psoriatic patients"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1038/s41598-020-79139-8"
                      "Revista" => array:6 [
                        "tituloSerie" => "Sci Rep&#46;"
                        "fecha" => "2021"
                        "volumen" => "11"
                        "paginaInicial" => "1"
                        "paginaFinal" => "12"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib0565"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Psoriasis and fatty liver&#58; A harmful synergy"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Rev Esp Enfermedades Dig&#46;"
                        "fecha" => "2019"
                        "volumen" => "111"
                        "paginaInicial" => "314"
                        "paginaFinal" => "319"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib0570"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Eur Acad Dermatol Venereol&#46;"
                        "fecha" => "2016"
                        "volumen" => "30"
                        "paginaInicial" => "282"
                        "paginaFinal" => "287"
                        "itemHostRev" => array:3 [
                          "pii" => "S1470204517304692"
                          "estado" => "S300"
                          "issn" => "14702045"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib0575"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The diagnosis and management of nonalcoholic fatty liver disease&#58; Practice guidance from the American Association for the Study of Liver Diseases"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/hep.29367"
                      "Revista" => array:7 [
                        "tituloSerie" => "Hepatology&#46;"
                        "fecha" => "2018"
                        "volumen" => "67"
                        "paginaInicial" => "328"
                        "paginaFinal" => "357"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S0360301619340659"
                          "estado" => "S300"
                          "issn" => "03603016"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib0580"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Increased prevalence of advanced liver fibrosis in patients with psoriasis&#58; A cross-sectional analysis from the rotterdam study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Acta Derm Venereol&#46;"
                        "fecha" => "2016"
                        "volumen" => "96"
                        "paginaInicial" => "213"
                        "paginaFinal" => "217"
                        "itemHostRev" => array:3 [
                          "pii" => "S0090825809004636"
                          "estado" => "S300"
                          "issn" => "00908258"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib0585"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Nonalcoholic fatty liver disease in patients with psoriasis&#58; a consequence of systemic inflammatory burden&#63;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/bjd.16239"
                      "Revista" => array:7 [
                        "tituloSerie" => "Br J Dermatol&#46;"
                        "fecha" => "2018"
                        "volumen" => "179"
                        "paginaInicial" => "16"
                        "paginaFinal" => "29"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S0140673617324406"
                          "estado" => "S300"
                          "issn" => "01406736"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib0590"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Liver Illness and Psoriatic Patients"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [ …5]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Biomed Res Int&#46;"
                        "fecha" => "2018"
                        "volumen" => "2018"
                        "paginaInicial" => "1"
                        "paginaFinal" => "12"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib0595"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Consenso sobre M&#233;todos de Detecci&#243;n y Derivaci&#243;n de Enfermedades Hep&#225;ticas Prevalentes Ocultas&#46; Consenso AEEH"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:5 [ …5]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:2 [
                        "tituloSerie" => "Gastroenterol Hepatol&#46;"
                        "fecha" => "2022"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            26 => array:3 [
              "identificador" => "bib0600"
              "etiqueta" => "27"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "M&#233;todos de consenso Uso adecuado de la evidencia en la toma de decisiones&#46; &#171;M&#233;todo RAND&#47;UCLA&#187;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Rehabilitaci&#243;n"
                        "fecha" => "2001"
                        "volumen" => "35"
                        "paginaInicial" => "388"
                        "paginaFinal" => "392"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            27 => array:3 [
              "identificador" => "bib0605"
              "etiqueta" => "28"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Research methods for formal consensus development"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.7748/nr.22.6.35.e1342"
                      "Revista" => array:6 [
                        "tituloSerie" => "Nurse Res&#46;"
                        "fecha" => "2015"
                        "volumen" => "22"
                        "paginaInicial" => "35"
                        "paginaFinal" => "40"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            28 => array:3 [
              "identificador" => "bib0610"
              "etiqueta" => "29"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Practical update of the Recommendations Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology &#40;GPS&#41; on the Treatment of Psoriasis with Biologic Therapy Part 1&#46; Concepts and General Management of Psoriasis with Biologic Therapy"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ad.2021.10.003"
                      "Revista" => array:6 [
                        "tituloSerie" => "Actas Dermosifiliogr&#46;"
                        "fecha" => "2022"
                        "volumen" => "113"
                        "paginaInicial" => "261"
                        "paginaFinal" => "277"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            29 => array:3 [
              "identificador" => "bib0615"
              "etiqueta" => "30"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Practical Update of the Guidelines Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology &#40;GPs&#41; on the Treatment of Psoriasis With Biologic Agents&#58; Part 2 - Management of Special Populations Patients With Comorbid Conditions&#44; and Risk"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ad.2022.01.024"
                      "Revista" => array:6 [
                        "tituloSerie" => "Actas Dermosifiliogr&#46;"
                        "fecha" => "2022"
                        "volumen" => "113"
                        "paginaInicial" => "583"
                        "paginaFinal" => "609"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            30 => array:3 [
              "identificador" => "bib0620"
              "etiqueta" => "31"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Valoraci&#243;n bioqu&#237;mica en la enfermedad hep&#225;tica grasa asociada a la disfunci&#243;n metab&#243;lica"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Adv Lab Med&#46;"
                        "fecha" => "2021"
                        "volumen" => "2"
                        "paginaInicial" => "209"
                        "paginaFinal" => "219"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            31 => array:3 [
              "identificador" => "bib0625"
              "etiqueta" => "32"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "colaboracion" => "European Association for the Study of the Liver &#40;EASL&#41;&#46; European Association for the Study of Diabetes &#40;EASD&#41;&#46; European Association for the Study of Obesity &#40;EASO&#41;"
                          "etal" => false
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "J Hepatol&#46;"
                        "fecha" => "2016"
                        "volumen" => "64"
                        "paginaInicial" => "1388"
                        "paginaFinal" => "1402"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            32 => array:3 [
              "identificador" => "bib0630"
              "etiqueta" => "33"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1053/jhep.2003.50229"
                      "Revista" => array:6 [
                        "tituloSerie" => "Hepatology&#46;"
                        "fecha" => "2003"
                        "volumen" => "37"
                        "paginaInicial" => "1286"
                        "paginaFinal" => "1292"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            33 => array:3 [
              "identificador" => "bib0635"
              "etiqueta" => "34"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Utilidad pr&#225;ctica de los &#237;ndices no invasivos en la esteatosis hep&#225;tica metab&#243;lica"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.endinu.2021.08.001"
                      "Revista" => array:5 [
                        "tituloSerie" => "Endocrinol Diabetes Nutr&#46;"
                        "fecha" => "2022"
                        "volumen" => "69"
                        "paginaInicial" => "418"
                        "paginaFinal" => "425"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            34 => array:3 [
              "identificador" => "bib0640"
              "etiqueta" => "35"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Current guidelines for the management of non-alcoholic fatty liver disease&#58; A systematic review with comparative analysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3748/wjg.v24.i30.3361"
                      "Revista" => array:6 [
                        "tituloSerie" => "World J Gastroenterol&#46;"
                        "fecha" => "2018"
                        "volumen" => "24"
                        "paginaInicial" => "3361"
                        "paginaFinal" => "3373"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            35 => array:3 [
              "identificador" => "bib0645"
              "etiqueta" => "36"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Development of a simple noninvasive index to predict significant fibrosis in patients with HIV&#47;HCV coinfection"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/hep.21178"
                      "Revista" => array:6 [
                        "tituloSerie" => "Hepatology&#46;"
                        "fecha" => "2006"
                        "volumen" => "43"
                        "paginaInicial" => "1317"
                        "paginaFinal" => "1325"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            36 => array:3 [
              "identificador" => "bib0650"
              "etiqueta" => "37"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [ …5]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/gut.2010.216077"
                      "Revista" => array:6 [
                        "tituloSerie" => "Gut&#46;"
                        "fecha" => "2010"
                        "volumen" => "59"
                        "paginaInicial" => "1265"
                        "paginaFinal" => "1269"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            37 => array:3 [
              "identificador" => "bib0655"
              "etiqueta" => "38"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/apt.14219"
                      "Revista" => array:6 [
                        "tituloSerie" => "Aliment Pharmacol Ther&#46;"
                        "fecha" => "2017"
                        "volumen" => "46"
                        "paginaInicial" => "617"
                        "paginaFinal" => "627"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            38 => array:3 [
              "identificador" => "bib0660"
              "etiqueta" => "39"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis &#8211; 2021 update"
                      "autores" => array:1 [
                        0 => array:2 [
                          "colaboracion" => "European Association for the Study of the Liver&#46; Clinical Practice Guideline Panel&#46; EASL Governing Board representative"
                          "etal" => false
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jhep.2021.05.025"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Hepatol&#46;"
                        "fecha" => "2021"
                        "volumen" => "75"
                        "paginaInicial" => "659"
                        "paginaFinal" => "689"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            39 => array:3 [
              "identificador" => "bib0665"
              "etiqueta" => "40"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1038/ajg.2016.453"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Gastroenterol&#46;"
                        "fecha" => "2017"
                        "volumen" => "112"
                        "paginaInicial" => "740"
                        "paginaFinal" => "751"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            40 => array:3 [
              "identificador" => "bib0670"
              "etiqueta" => "41"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Development and Validation of Hepamet Fibrosis Scoring System&#8211;A Simple Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Clin Gastroenterol Hepatol&#46;"
                        "fecha" => "2020"
                        "volumen" => "18"
                        "paginaInicial" => "216"
                        "paginaFinal" => "225&#46;e5"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            41 => array:3 [
              "identificador" => "bib0675"
              "etiqueta" => "42"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Hepatic steatosis index&#58; a simple screening tool reflecting nonalcoholic fatty liver disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.dld.2009.08.002"
                      "Revista" => array:6 [
                        "tituloSerie" => "Dig Liver Dis&#46;"
                        "fecha" => "2010"
                        "volumen" => "42"
                        "paginaInicial" => "503"
                        "paginaFinal" => "508"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            42 => array:3 [
              "identificador" => "bib0680"
              "etiqueta" => "43"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The Fatty Liver Index&#58; a simple and accurate predictor of hepatic steatosis in the general population"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1186/1471-230X-6-33"
                      "Revista" => array:5 [
                        "tituloSerie" => "BMC Gastroenterol&#46;"
                        "fecha" => "2006"
                        "volumen" => "6"
                        "paginaInicial" => "33"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            43 => array:3 [
              "identificador" => "bib0685"
              "etiqueta" => "44"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The NAFLD fibrosis score&#58; a noninvasive system that identifies liver fibrosis in patients with NAFLD"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/hep.21496"
                      "Revista" => array:6 [
                        "tituloSerie" => "Hepatology&#46;"
                        "fecha" => "2007"
                        "volumen" => "45"
                        "paginaInicial" => "846"
                        "paginaFinal" => "854"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            44 => array:3 [
              "identificador" => "bib0690"
              "etiqueta" => "45"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1186/1471-230X-12-2"
                      "Revista" => array:5 [
                        "tituloSerie" => "BMC Gastroenterol&#46;"
                        "fecha" => "2012"
                        "volumen" => "12"
                        "paginaInicial" => "2"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            45 => array:3 [
              "identificador" => "bib0695"
              "etiqueta" => "46"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "AST to Platelet Ratio Index and fibrosis 4 calculator scores for non-invasive assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [ …4]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.dld.2017.05.002"
                      "Revista" => array:6 [
                        "tituloSerie" => "Dig Liver Dis&#46;"
                        "fecha" => "2017"
                        "volumen" => "49"
                        "paginaInicial" => "1133"
                        "paginaFinal" => "1138"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            46 => array:3 [
              "identificador" => "bib0700"
              "etiqueta" => "47"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [ …5]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/gut.2007.146019"
                      "Revista" => array:6 [
                        "tituloSerie" => "Gut&#46;"
                        "fecha" => "2008"
                        "volumen" => "57"
                        "paginaInicial" => "1441"
                        "paginaFinal" => "1447"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            47 => array:3 [
              "identificador" => "bib0705"
              "etiqueta" => "48"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Noninvasive markers of fibrosis in nonalcoholic fatty liver disease&#58; Validating the European Liver Fibrosis Panel and exploring simple markers"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/hep.21984"
                      "Revista" => array:6 [
                        "tituloSerie" => "Hepatology&#46;"
                        "fecha" => "2008"
                        "volumen" => "47"
                        "paginaInicial" => "455"
                        "paginaFinal" => "460"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            48 => array:3 [
              "identificador" => "bib0710"
              "etiqueta" => "49"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Transient elastography&#58; A new noninvasive method for assessment of hepatic fibrosis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ultrasmedbio.2003.07.001"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ultrasound Med Biol&#46;"
                        "fecha" => "2003"
                        "volumen" => "29"
                        "paginaInicial" => "1705"
                        "paginaFinal" => "1713"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            49 => array:3 [
              "identificador" => "bib0715"
              "etiqueta" => "50"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Liver elastography&#58; what it is&#44; how it is done&#44; and how it is interpreted"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.rx.2017.11.002"
                      "Revista" => array:6 [
                        "tituloSerie" => "Radiologia&#46;"
                        "fecha" => "2018"
                        "volumen" => "60"
                        "paginaInicial" => "183"
                        "paginaFinal" => "189"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            50 => array:3 [
              "identificador" => "bib0720"
              "etiqueta" => "51"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/hep.23312"
                      "Revista" => array:6 [
                        "tituloSerie" => "Hepatology&#46;"
                        "fecha" => "2010"
                        "volumen" => "51"
                        "paginaInicial" => "454"
                        "paginaFinal" => "462"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            51 => array:3 [
              "identificador" => "bib0725"
              "etiqueta" => "52"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of NAFLD with diet physical activity and exercise"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jhep.2017.05.016"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Hepatol&#46;"
                        "fecha" => "2017"
                        "volumen" => "67"
                        "paginaInicial" => "829"
                        "paginaFinal" => "846"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            52 => array:3 [
              "identificador" => "bib0730"
              "etiqueta" => "53"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Current status&#44; problems&#44; and perspectives of non-alcoholic fatty liver disease research"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3748/wjg.v25.i2.163"
                      "Revista" => array:7 [
                        "tituloSerie" => "World J Gastroenterol&#46;"
                        "fecha" => "2019"
                        "volumen" => "25"
                        "paginaInicial" => "163"
                        "paginaFinal" => "177"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S0090825820339676"
                          "estado" => "S300"
                          "issn" => "00908258"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            53 => array:3 [
              "identificador" => "bib0735"
              "etiqueta" => "54"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med&#46;"
                        "fecha" => "2021"
                        "volumen" => "384"
                        "paginaInicial" => "1113"
                        "paginaFinal" => "1124"
                        "itemHostRev" => array:3 [
                          "pii" => "S0360301620341146"
                          "estado" => "S300"
                          "issn" => "03603016"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            54 => array:3 [
              "identificador" => "bib0740"
              "etiqueta" => "55"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus&#58; Preliminary prospective study based on serial liver biopsies"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/hep4.1019"
                      "Revista" => array:6 [
                        "tituloSerie" => "Hepatol Commun&#46;"
                        "fecha" => "2017"
                        "volumen" => "1"
                        "paginaInicial" => "46"
                        "paginaFinal" => "52"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            55 => array:3 [
              "identificador" => "bib0745"
              "etiqueta" => "56"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Pegbelfermin &#40;BMS-986036&#41;&#44; a PEGylated fibroblast growth factor 21 analogue&#44; in patients with non-alcoholic steatohepatitis&#58; a randomised&#44; double-blind&#44; placebo-controlled&#44; phase 2<span class="elsevierStyleHsp" style=""></span>a trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(18)31785-9"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet&#46;"
                        "fecha" => "2019"
                        "volumen" => "392"
                        "paginaInicial" => "2705"
                        "paginaFinal" => "2717"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            56 => array:3 [
              "identificador" => "bib0750"
              "etiqueta" => "57"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "ClinicalTrials&#46;gov&#46; A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH &#40;ARMOR&#41; &#91;consultado 1 Jul 2022&#93;&#46; Disponible en&#58; <a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT04104321">https&#58;&#47;&#47;clinicaltrials&#46;gov&#47;ct2&#47;show&#47;NCT04104321</a>&#46;"
                ]
              ]
            ]
            57 => array:3 [
              "identificador" => "bib0755"
              "etiqueta" => "58"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "GS-0976 &#40;Firsocostat&#41;&#58; an investigational liver-directed acetyl-CoA carboxylase &#40;ACC&#41; inhibitor for the treatment of non-alcoholic steatohepatitis &#40;NASH&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [ …5]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1080/13543784.2020.1668374"
                      "Revista" => array:6 [
                        "tituloSerie" => "Expert Opin Investig Drugs&#46;"
                        "fecha" => "2020"
                        "volumen" => "29"
                        "paginaInicial" => "135"
                        "paginaFinal" => "141"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            58 => array:3 [
              "identificador" => "bib0760"
              "etiqueta" => "59"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic&#44; non-alcoholic steatohepatitis &#40;FLINT&#41;&#58; a multicentre&#44; randomised&#44; placebo-controlled trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(14)61933-4"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet&#46;"
                        "fecha" => "2015"
                        "volumen" => "385"
                        "paginaInicial" => "956"
                        "paginaFinal" => "965"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            59 => array:3 [
              "identificador" => "bib0765"
              "etiqueta" => "60"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Elafibranor&#44; an Agonist of the Peroxisome Proliferator-Activated Receptor-alpha and -delta&#44; Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1053/j.gastro.2016.01.038"
                      "Revista" => array:6 [
                        "tituloSerie" => "Gastroenterology&#46;"
                        "fecha" => "2016"
                        "volumen" => "150"
                        "paginaInicial" => "1147"
                        "paginaFinal" => "1159&#46;e5"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            60 => array:3 [
              "identificador" => "bib0770"
              "etiqueta" => "61"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Hepatol Commun&#46;"
                        "fecha" => "2021"
                        "volumen" => "5"
                        "paginaInicial" => "573"
                        "paginaFinal" => "588"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            61 => array:3 [
              "identificador" => "bib0775"
              "etiqueta" => "62"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The pan-caspase inhibitor Emricasan &#40;IDN-6556&#41; decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Liver Int&#46;"
                        "fecha" => "2015"
                        "volumen" => "35"
                        "paginaInicial" => "953"
                        "paginaFinal" => "966"
                        "itemHostRev" => array:3 [
                          "pii" => "S0360301619339665"
                          "estado" => "S300"
                          "issn" => "03603016"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            62 => array:3 [
              "identificador" => "bib0780"
              "etiqueta" => "63"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "NASH&#58; Novel therapeutic strategies targeting ASK1 in NASH"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1038/nrgastro.2017.42"
                      "Revista" => array:6 [
                        "tituloSerie" => "Nat Rev Gastroenterol Hepatol&#46;"
                        "fecha" => "2017"
                        "volumen" => "14"
                        "paginaInicial" => "329"
                        "paginaFinal" => "330"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            63 => array:3 [
              "identificador" => "bib0785"
              "etiqueta" => "64"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A randomized&#44; placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/hep.29477"
                      "Revista" => array:7 [
                        "tituloSerie" => "Hepatology&#46;"
                        "fecha" => "2018"
                        "volumen" => "67"
                        "paginaInicial" => "1754"
                        "paginaFinal" => "1767"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S147020451630626X"
                          "estado" => "S300"
                          "issn" => "14702045"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            64 => array:3 [
              "identificador" => "bib0790"
              "etiqueta" => "65"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Randomised clinical study&#58; GR-MD-02&#44; a galectin-3 inhibitor&#44; vs&#46; placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/apt.13816"
                      "Revista" => array:6 [
                        "tituloSerie" => "Aliment Pharmacol Ther&#46;"
                        "fecha" => "2016"
                        "volumen" => "44"
                        "paginaInicial" => "1183"
                        "paginaFinal" => "1198"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            65 => array:3 [
              "identificador" => "bib0795"
              "etiqueta" => "66"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "JKB-121 in patients with nonalcoholic steatohepatitis&#58; A phase 2 double blind randomized placebo control study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "J Hepatol&#46;"
                        "fecha" => "2018"
                        "volumen" => "68"
                        "paginaInicial" => "S103"
                        "itemHostRev" => array:3 [
                          "pii" => "S2352302620303604"
                          "estado" => "S300"
                          "issn" => "23523026"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            66 => array:3 [
              "identificador" => "bib0805"
              "etiqueta" => "67"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "ClinicalTrials&#46;gov&#46; JUNIPER&#58; A Phase 2 Study to Evaluate the Safety&#44; Biological Activity&#44; and PK of ND-L02-s0201 in Subjects With IPF &#91;consultado 1 Jul 2022&#93;&#46; Disponible en&#58; <a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT03538301">https&#58;&#47;&#47;clinicaltrials&#46;gov&#47;ct2&#47;show&#47;NCT03538301</a>&#46;"
                ]
              ]
            ]
            67 => array:3 [
              "identificador" => "bib0810"
              "etiqueta" => "68"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Systemic psoriasis therapies and comorbid disease in patients with psoriasis&#58; A review of potential risks and benefits"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [ …4]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Aesthet Dermatol&#46;"
                        "fecha" => "2019"
                        "volumen" => "12"
                        "paginaInicial" => "46"
                        "paginaFinal" => "54"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            68 => array:3 [
              "identificador" => "bib0815"
              "etiqueta" => "69"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Methotrexate and liver fibrosis in people with psoriasis&#58; A systematic review of observational studies"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Br J Dermatol&#46;"
                        "fecha" => "2014"
                        "volumen" => "171"
                        "paginaInicial" => "17"
                        "paginaFinal" => "29"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            69 => array:3 [
              "identificador" => "bib0820"
              "etiqueta" => "70"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "NICE&#46; Psoriasis&#58; assessment and management &#40;CG153&#41;&#46; Clinical Guideline 84&#44; no pagination&#44; 2015&#46;"
                ]
              ]
            ]
            70 => array:3 [
              "identificador" => "bib0825"
              "etiqueta" => "71"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Methotrexate Hepatotoxicity and the Impact of Nonalcoholic Fatty Liver Disease"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [ …4]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.amjms.2017.03.014"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Med Sci&#46;"
                        "fecha" => "2017"
                        "volumen" => "354"
                        "paginaInicial" => "172"
                        "paginaFinal" => "181"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            71 => array:3 [
              "identificador" => "bib0830"
              "etiqueta" => "72"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Unmet needs in patients with moderate-to-severe plaque psoriasis treated with methotrexate in real world practice&#58; FirST study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1080/09546634.2020.1801977"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Dermatolog Treat&#46;"
                        "fecha" => "2022"
                        "volumen" => "33"
                        "paginaInicial" => "1329"
                        "paginaFinal" => "1338"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            72 => array:3 [
              "identificador" => "bib0850"
              "etiqueta" => "73"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Agencia Espa&#241;ola de Medicamentos y Productos Sanitarios&#46; Ficha T&#233;cnica de Metotrexato&#46;"
                ]
              ]
            ]
            73 => array:3 [
              "identificador" => "bib0855"
              "etiqueta" => "74"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Ficha t&#233;cnica de Acitretina&#46; Agencia Europea de Medicamentos&#44; 2020&#46;"
                ]
              ]
            ]
            74 => array:3 [
              "identificador" => "bib0860"
              "etiqueta" => "75"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Acitretin affects bioenergetics of liver mitochondria and promotes mitochondrial permeability transition&#58; potential mechanisms of hepatotoxicity"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.tox.2013.01.020"
                      "Revista" => array:6 [
                        "tituloSerie" => "Toxicology&#46;"
                        "fecha" => "2013"
                        "volumen" => "306"
                        "paginaInicial" => "93"
                        "paginaFinal" => "100"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            75 => array:3 [
              "identificador" => "bib0865"
              "etiqueta" => "76"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Ficha t&#233;cnica de Humira&#46; Agencia Europea de Medicamentos&#44; 2009&#46;"
                ]
              ]
            ]
            76 => array:3 [
              "identificador" => "bib0870"
              "etiqueta" => "77"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Ficha t&#233;cnica de Cimzia&#46; Agencia Europea de Medicamentos&#44; 2019&#46;"
                ]
              ]
            ]
            77 => array:3 [
              "identificador" => "bib0875"
              "etiqueta" => "78"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Ficha t&#233;cnica de Remicade&#46; Agencia Europea de Medicamentos&#44; 2014&#46;"
                ]
              ]
            ]
            78 => array:3 [
              "identificador" => "bib0880"
              "etiqueta" => "79"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Agencia Espa&#241;ola de Medicamentos y Productos Sanitarios&#46; Ficha T&#233;cnica de Ustekinumab&#44; Stelara&#174;&#44; 2013&#46;"
                ]
              ]
            ]
            79 => array:3 [
              "identificador" => "bib0925"
              "etiqueta" => "80"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:1 [
                      "autores" => array:1 [
                        0 => array:2 [
                          "colaboracion" => "European Medicines Agency Tremfya &#40;Guselkumab&#41;&#58; summary of product characteristics"
                          "etal" => false
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:4 [
                        "tituloSerie" => "Agencia Eur Medicam&#46;"
                        "fecha" => "2019"
                        "paginaInicial" => "1"
                        "paginaFinal" => "71"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            80 => array:3 [
              "identificador" => "bib0930"
              "etiqueta" => "81"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Ficha t&#233;cnica de Skyrizi&#46; Agencia Europea de Medicamentos&#44; 2014&#46;"
                ]
              ]
            ]
            81 => array:3 [
              "identificador" => "bib0885"
              "etiqueta" => "82"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Ficha t&#233;cnica de Tremfya&#46; Agencia Europea de Medicamentos&#44; 2009&#46;"
                ]
              ]
            ]
            82 => array:3 [
              "identificador" => "bib0890"
              "etiqueta" => "83"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Ficha t&#233;cnica de Cosentyx&#46; Agencia Europea de Medicamentos&#44; 2019&#46;"
                ]
              ]
            ]
            83 => array:3 [
              "identificador" => "bib0895"
              "etiqueta" => "84"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Ficha t&#233;cnica de Kyntheum&#46; Agencia Europea de Medicamentos&#44; 2014&#46;"
                ]
              ]
            ]
            84 => array:3 [
              "identificador" => "bib0900"
              "etiqueta" => "85"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Ficha t&#233;cnica de Taltz&#46; Agencia Europea de Medicamentos&#44; 2019&#46; doi&#58;10&#46;2307&#47;j&#46;ctvdf0dxq&#46;12&#46;"
                ]
              ]
            ]
            85 => array:3 [
              "identificador" => "bib0935"
              "etiqueta" => "86"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Metabolic Inflammation-Associated IL-17A Causes Non-alcoholic Steatohepatitis and Hepatocellular Carcinoma"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ccell.2016.05.020"
                      "Revista" => array:6 [
                        "tituloSerie" => "Cancer Cell&#46;"
                        "fecha" => "2016"
                        "volumen" => "30"
                        "paginaInicial" => "161"
                        "paginaFinal" => "175"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            86 => array:3 [
              "identificador" => "bib0940"
              "etiqueta" => "87"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Agencia Espa&#241;ola de Medicamentos y Productos Sanitarios&#46; Ficha T&#233;cnica de Apremilast&#46;"
                ]
              ]
            ]
            87 => array:3 [
              "identificador" => "bib0945"
              "etiqueta" => "88"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Agencia Espa&#241;ola de Medicamentos y Productos Sanitarios&#46; Ficha T&#233;cnica Ciclosporina&#44; 2020&#46;"
                ]
              ]
            ]
            88 => array:3 [
              "identificador" => "bib0915"
              "etiqueta" => "89"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "EASL Clinical Practice Guidelines&#58; Drug-induced liver injury"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jhep.2019.02.014"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Hepatol&#46;"
                        "fecha" => "2019"
                        "volumen" => "70"
                        "paginaInicial" => "1222"
                        "paginaFinal" => "1261"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            89 => array:3 [
              "identificador" => "bib0920"
              "etiqueta" => "90"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Drug use and toxicity in psoriatic disease&#58; Focus on methotrexate"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Rheumatol&#46;"
                        "fecha" => "2008"
                        "volumen" => "35"
                        "paginaInicial" => "1454"
                        "paginaFinal" => "1457"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            90 => array:3 [
              "identificador" => "bib0950"
              "etiqueta" => "91"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Validaci&#243;n del m&#233;todo de cuantificaci&#243;n del &#225;rea corporal afectada por la psoriasis mediante l&#225;piz &#243;ptico"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ad.2019.07.002"
                      "Revista" => array:6 [
                        "tituloSerie" => "Actas Dermosifiliogr&#46;"
                        "fecha" => "2020"
                        "volumen" => "111"
                        "paginaInicial" => "143"
                        "paginaFinal" => "148"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            91 => array:3 [
              "identificador" => "bib0955"
              "etiqueta" => "92"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A comparison between BSA&#44; PASI"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "PLASI and SAPASI as measures of disease severity and improvement by therapy in patients with psoriasis&#46;"
                        "fecha" => "2008"
                        "paginaInicial" => "1019"
                        "paginaFinal" => "1023"
                        "itemHostRev" => array:3 [
                          "pii" => "S0090825820338087"
                           …2
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            92 => array:3 [
              "identificador" => "bib0960"
              "etiqueta" => "93"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Assessing Psoriasis Severity and Outcomes for Clinical Trials and Routine Clinical Practice"
                      "autores" => array:1 [
                        0 => array:2 [ …2]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.det.2014.09.005"
                      "Revista" => array:6 [
                        "tituloSerie" => "Dermatol Clin&#46;"
                        "fecha" => "2015"
                        "volumen" => "33"
                        "paginaInicial" => "57"
                        "paginaFinal" => "71"
                        "link" => array:1 [ …1]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            93 => array:3 [
              "identificador" => "bib0965"
              "etiqueta" => "94"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Adaptaci&#243;n transcultural al espa&#241;ol del cuestionario Dermatology Life Quality Index &#40;DLQI&#41;&#58; El &#205;ndice de Calidad de Vida en Dermatolog&#237;a &#124; Actas Dermo-Sifiliogr&#225;ficas &#91;consultado 1 Jul 2022&#93;&#46; Disponible en&#58; <a target="_blank" href="https://www.actasdermo.org/es-adaptacion-transcultural-al-espanol-del-articulo-13003408">https&#58;&#47;&#47;www&#46;actasdermo&#46;org&#47;es-adaptacion-transcultural-al-espanol-del-articulo-13003408</a>&#46;"
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "es"
  "url" => "/00017310/0000011400000005/v2_202306061222/S000173102300056X/v2_202306061222/es/main.assets"
  "Apartado" => array:4 [
    "identificador" => "6238"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Documento de consenso"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/00017310/0000011400000005/v2_202306061222/S000173102300056X/v2_202306061222/es/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S000173102300056X?idApp=UINPBA000044"
]
Información del artículo
ISSN: 00017310
Idioma original: Español
Datos actualizados diariamente
año/Mes Html Pdf Total
2024 Noviembre 6 3 9
2024 Octubre 197 100 297
2024 Septiembre 214 66 280
2024 Agosto 217 81 298
2024 Julio 179 75 254
2024 Junio 197 87 284
2024 Mayo 467 77 544
2024 Abril 167 56 223
2024 Marzo 167 71 238
2024 Febrero 121 55 176
2024 Enero 125 46 171
2023 Diciembre 113 34 147
2023 Noviembre 143 66 209
2023 Octubre 132 51 183
2023 Septiembre 135 62 197
2023 Agosto 163 60 223
2023 Julio 184 54 238
2023 Junio 192 80 272
2023 Mayo 262 96 358
2023 Abril 101 39 140
2023 Marzo 152 128 280
2023 Febrero 106 134 240
2023 Enero 1 3 4
Mostrar todo

Siga este enlace para acceder al texto completo del artículo

Idiomas
Actas Dermo-Sifiliográficas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?